| Symbol | NONOF |
|---|---|
| Name | NOVO-NORDISK A/S |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 10179 United States NY 383 Madison Avenue Floor 11 |
| Telephone | 4544448888 |
| Fax | — |
| — | |
| Website | https://www.novonordisk.com/ |
| Incorporation | DK |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Victor Mokuolu, CPA PLLC;DeVisser Gray LLP, Chartered Accountants;Smythe LLP;Dale Matheson Carr-Hilton Labonte LLP;Grant Thornton - Halifax, NS (Canada);Interactive Edgar Corp.;Davidson & Company LLP;DeVisser Gray LLP, Chartered Accountants;Charlton & Co.;Deloitte Touche Tohmatsu;PKF OConnor Davies, LLP;RSM Partners;Grassi & Co., CPAs, P.C.;Main Street Consulting and Accounting;Haynie & Company, CPA;YHB;Patrick D. Heyn, CPA, P.A.;Mary B. George;Shim & Associates LLP - Vancouver, British Columbia (Canada);Grant Thornton UK LLP;WWC, Professional Corporation;Harish Belwal, CPA;Dylan Floyd Accounting & Consulting;BDO AG;Prager Metis CPAs LLC;RBSM LLP;Dale Matheson Carr-Hilton Labonte LLP;Sam S. Mah Inc.;Thomas Tran;Turner Stone & Co.;MNP LLP;Fruci & Associates II, PLLC;Jones & OConnell LLP.;Victor Mokuolu, CPA PLLC;KPMG LLP.;Grant Thornton LLP;Davidson & Company LLP;Rachel Boulds, CPA;KPMG LLP.;MNP LLP;Elliott Davis;Davidson & Company LLP;Whitley Penn;Hay & Watson;Weinberg & Company;Bolko & Associates, LLC;Integritat Audit, Accounting & Advisory, LLC;PricewaterhouseCoopers LLP;Salberg & Company, P.A.;Mayer Hoffman McCann P.C.;CohnReznick LLP;TPS THAYER, LLC;Deloitte & Touche LLP;KCCW Accountancy Corp;Kesselman & Kesselman C.P.A.s;Jackson & Company, Chartered Accountants;NoFire Technologies;Olayinka Oyebola & Co;Torres Obregon y Asociados, SC;Rotenberg Meril Solomon Bertiger & Guttilla, P.C.;DBB McKennon;KPMG LLP.;Marcum LLP;UHY LLP;WithumSmith+Brown;Whitley Penn - Fort Worth, Texas (USA);PricewaterhouseCoopers LLP;Dale Matheson Carr-Hilton Labonte LLP;SRCO Professional Corporation, Charted Accountant;Deloitte Touche Tohmatsu, LLC;Ronald R. Chadwick, P.C.;Manning Elliott LLP;Bulloch, Brown, DuPertuis, Seger & Company, PC;BDO;Baker Tilly US, LLP;KPMG LLP - New York, New York, (USA);Pipara & Co LLP;Pitcher Partners Queensland;Marcum LLP;MNP LLP;Fresh Notion Financial Services;HTL CPAs & Business Advisors;S.R. Snodgrass, P.C.;Dalby, Wendland & Co., PC;PricewaterhouseCoopers LLP;Baker Tilly US, LLP;Lynda R. Keeton CPA, LLC;Chuck Ragland CPA;KPMG LLP.;McGovern Hurley LLP;Davidson & Company LLP;PricewaterhouseCoopers LLP;Yount, Hyde & Barbour, P.C.;EY - Perth, WA (Australia);Ernst & Young LLP;MNP LLP;Deloitte & Touche LLP;Charlton & Co.;CBIZ CPAs P.C.;BDO Audit Pty Ltd;Dale Matheson Carr-Hilton Labonte LLP;MNP LLP;Deloitte & Touche LLP;Smith Elliott Kearns & Company, LLC;TPS THAYER, LLC;Bauer and Company;MNP LLP;Ernst & Young LLP;MNP LLP;Latiff Chagpar CPA;RBSM LLP;PricewaterhouseCoopers LLP;BF Borgers CPA PC;MaloneBailey, LLP;KPMG Accountants N.V.;Eide Bailly LLP;MNP LLP;D&H Group LLP;PricewaterhouseCoopers LLP;PricewaterhouseCoopers LLP;Baker Tilly WM LLP;Ernst & Young LLP;Yount, Hyde & Barbour, P.C.;Green & Company CPAs;Macias Gini & OConnell LLP;BDO USA, LLP;Hacker, Johnson & Smith PA;PricewaterhouseCoopers LLP;Deloitte LLP;DBB McKennon;Deloitte LLP;Ernst & Young LLP;Mercurius & Associates LLP;Baker Tilly US, LLP;Saturna Group Chartered Professional Accountants LLP;HTL CPAs & Business Advisors;MaloneBailey, LLP;Crowe MacKay LLP;PricewaterhouseCoopers LLP;Shibu Abraham Professional Corporation;Ernst & Young LLP;Baker Tilly US, LLP;Crowe MacKay LLP;GreenGrowth CPAs;Nanuk Warman, CPA Inc.;MoneyMinds Management LLC;UHY LLP;Manning Elliott LLP;Ernst & Young LLP;Cox CPA Services, Inc.;DMCL Chartered Accountants;Pitcher Partners Queensland;FORVIS, LLP;Deloitte LLP;Baker Tilly WM LLP;Manning Elliott LLP;MNP LLP;Carl Ford Associates;Canas, CPA LLC;Astra Audit & Advisory, LLC;Davidson & Company LLP;RSM US LLP;Lakeport Business Services;Q Accountancy Corporation;Fruci & Associates II, PLLC;Ernst & Young LLP;Davidson & Company LLP;Victor Mokuolu, CPA PLLC;WithumSmith + Brown PC;Astra Audit & Advisory, LLC;Mao & Ying LLP;Davidson & Company LLP;DeVisser Gray LLP, Chartered Accountants;TAAD LLP;Dale Matheson Carr-Hilton Labonte LLP;Harish Belwal, CPA;Davidson & Company LLP;PricewaterhouseCoopers LLP;Grant Thornton, LLP;Daszkal Bolton LLP;BDO Audit (WA) Pty Ltd - Subiaco, Western Australia (Australia);RBSM LLP;McGovern Hurley LLP;Baker Tilly US, LLP;Ernst & Young LLP;Wipfli LLP;Kronick Kalada Berdy & Co, PC;Deloitte LLP;Tanner LLC;B F Borgers CPA PC;Crowe MacKay LLP;Brightman Almagor & Co.;Zakai CPA;Weinberg & Company;YCM CPA INC.;D&H Group LLP;Kost Forer Gabbay & Kasierer;Crowe Horwath, LLP;Bluechip Accounting LLC;Grassi & Co., CPAs, P.C.;MNP LLP;PricewaterhouseCoopers LLP;Ernst & Young LLP;Baker Tilly US, LLP;Shandong Haoxin Certified Public Accountants Co., Ltd.;Patterson CPAs, LLC;Assure CPA, LLC;Dale Matheson Carr-Hilton Labonte LLP;BDO Espana;PricewaterhouseCoopers LLP;Clearline Chartered Accountants;Meyers Norris Penny, LLP;FRUCI & ASSOCIATES, P.S.;Hongxin CPA Ltd;Crowe MacKay LLP;Crowe MacKay LLP;Marcum LLP;Manning Elliott LLP;KCCW Accountancy Corp;PricewaterhouseCoopers LLP;Marcum LLP;PricewaterhouseCoopers LLP;Baks & Co;Morgan & Company, Chartered Accountants;Grant Thorton LLP;Hall Chadwick;DeVisser Gray LLP, Chartered Accountants;A Chan & Company LLP;Smythe LLP.;Marcum LLP;JDDA CPA, LLC;KPMG LLP - New York, New York, (USA);Davidson & Company LLP;Cross Davis & Co. LLP;Ziv Haft Certified Public Accountants (Isr.);PricewaterhouseCoopers LLP;Kingery & Crouse, P.A.;Audirevi S.P.A.;GBQ Partners LLC;Audacie;MaloneBailey, LLP;Grassi & Co., CPAs, P.C.;BDO USA, LLP;Fruci & Associates II, PLLC;Marcum LLP;RJI International CPAs;Centurion ZD CPA Limited;Deloitte & Touche LLP;Marcum LLP;Crowe, LLP;Warren Averett, LLC;Clearhouse LLP;Michael Gillespie & Associates, PLLC;FORVIS, LLP;Davidson & Company LLP;Friedman LLP;Yount, Hyde & Barbour, P.C.;BF Borgers CPA PC;K.K. Mehta CPA Associates PPLC;BDO Canada LLP;McGovern Hurley LLP;Baker Tilly WM LLP;RSM Australia Partners - Perth, WA (Australia);KPMG;RSM US LLP;Baker Tilly WM LLP;KPMG Accountants N.V.;LAO Professionals;Ernst & Young LLP;PricewaterhouseCoopers LLP;M&K CPAS, PLLC;Kauffman Kim LLP;BDO USA, LLP;Adeptus Partners, LLC;M&K CPAS, PLLC;Mr. Yusuke MORIKUBO;BDO Seidman, LLP;MNP LLP;James Stafford Chartered Accountants;William Buck Audit and Assurance;Brown, Edwards & Company L.L.P;Deloitte LLP;Keens Accounting LLC;Marcum LLP;Grant Thornton LLP;Marcum LLP;Manning Elliott LLP;GreenGrowth CPAs;M&K CPAS, PLLC;Ernst & Young LLP;KPMG LLP.;Grant Thornton UK LLP;PricewaterhouseCoopers LLP;Hudgens CPA, LLC;Turner, Stone & Company, L.L.P.;Victor Mokuolu, CPA PLLC;Davidson & Company LLP;Boulay Group P.L.L.P.;Dale Matheson Carr-Hilton Labonte LLP;M&K CPAS, PLLC;Ernst & Young LLP - Toronto, Ontario (Canada);PKF OConnor Davies, LLP;Synergia CPA, LLC;Goff Backa Alfera & Company, LLC;Manning Elliott LLP;L J Soldinger Associates, LLC;Slappey Financial & Tax Services, LLC;Deloitte Touche Tohmatsu;Dale Matheson Carr-Hilton Labonte LLP;Astra Audit & Advisory, LLC;Crowe MacKay LLP;Hall Chadwick;Grant Thornton LLP;Baker Tilly WM LLP;PKF Littlejohn;UHY McGovern Hurley LLP;BDO USA, LLP;RSM Norge AS - Oslo;Dale Matheson Carr-Hilton Labonte LLP;Saturna Group Chartered Professional Accountants LLP;Kreit & Chiu;RBSM LLP;MNP LLP;Davidson & Company LLP;BDO Audit Pty Ltd;PricewaterhouseCoopers LLP;PKF OConnor Davies, LLP;S.R. Snodgrass, P.C.;Elkana Amitai CPA;Quality Financial Services LLC;Aloba, Awomolo & Partners;BF Borgers CPA PC;UHY McGovern Hurley LLP;ND Design, Inc;Clark, Schaefer, Hackett & Co.;Weaver and Tidwell, L.L.P.;BPM LLP;MNP LLP;Saturna Group Chartered Professional Accountants LLP;Meyers Norris Penny, LLP;MNP LLP;Baker Tilly WM LLP;Marcum LLP;Fruci & Associates II, PLLC;Haskell & White LLP;Weinberg & Company;J&S Associate;MNP LLP;CFO Oncall, Inc.;Dale Matheson Carr-Hilton Labonte LLP;BF Borgers CPA PC;Kenway Mack Slusarchuk Stewart LLP Charted Accountants;CDA/CPA Group;Davidson & Company LLP;Eric Gurr CPA, LLC Accountants;Marincovich & Co.;Baker Tilly US, LLP;BDO USA, LLP;J&S Associate;Turner, Stone & Company, L.L.P.;Weinberg & Company;MNP LLP;De Joya Griffith & Company, LLC;Dale Matheson Carr-Hilton Labonte LLP;DMCL Chartered Accountants;Bush & Associates CPA;Victor Mokuolu, CPA PLLC;Marcum LLP;Onestop Assurance PAC - (Singapore);Dale Matheson Carr-Hilton Labonte LLP;UHY LLP;PricewaterhouseCoopers LLP;The Bonadio Group;Stovall, Grandey & Allen, LLP;Davidson & Company LLP;Ernst & Young LLP;Fruci & Associates II, PLLC;Baker Tilly WM LLP;Dale Matheson Carr-Hilton Labonte LLP;Elliott Davis;Hall Chadwick;Cutler & Co.;RBSM LLP;MNP LLP;PricewaterhouseCoopers LLP;Saturna Group Chartered Professional Accountants LLP;DMCL Chartered Accountants;Manning Elliott LLP;BDO Canada LLP;NVS Chartered Accountants Professional Corp;TPS THAYER, LLC;Grant Thornton LLP;PricewaterhouseCoopers LLP;T. E. Lott and Company;Crowe MacKay LLP;JLKZ CPA LLP;J&S Associate;RBSM LLP;Hall Chadwick;BDO;Consultia LLC;DeVisser Gray LLP, Chartered Accountants;BDO Canada LLP;Boladale Lawal & Co (Chartered Accountants);RBSM LLP;Crowe LLP;Deloitte AS;HLB Mann Judd;Fruci & Associates II, PLLC;RSM Canada LLP;Saturna Group Chartered Professional Accountants LLP;BDO Audit Pty Ltd;Bush & Associates CPA;Buckley Dodds Parker LLP;Gregory, Sharer & Stuart, P.A.;Wei Wei & Co., LLP;DeVisser Gray LLP, Chartered Accountants;RBSM LLP;RSM Canada LLP;Get OTC Current;EisnerAmper LLP;DMCL Chartered Accountants;Demetrius Berkower LLC;Kingston Ross Pasnak LLP;Frazier & Deeter, LLC;Simon & Edward, LLP;Deloitte Accountants B.V.;M&K CPAS, PLLC;BDO USA, LLP;Hall Chadwick;EY - Perth, WA (Australia);De Joya Griffith & Company, LLC;Scarrow & Donald LLP;Pinaki & Associates LLC;K.Brice Toussaint;Eide Bailly LLP;Yount, Hyde & Barbour, P.C.;Deloitte LLP;PricewaterhouseCoopers LLP;FRUCI & ASSOCIATES, P.S.;Baker Tilly WM LLP;Crowe MacKay LLP;Dallas Consulting Services;Horne LLP;RSM Australia - Sydney, NSW (Australia);BF Borgers CPA PC;Aloba, Awomolo & Partners;Grassi & Co., CPAs, P.C.;Davidson & Company LLP;B F Borgers CPA PC;The Hall Group, CPAs;Hay & Watson;UHY McGovern Hurley LLP;Marcum LLP;Deloitte LLP;Astra Audit & Advisory, LLC;M&K CPAS, PLLC;Haynie & Company, CPA;MNP LLP;Smythe LLP;BDO USA, LLP;Hicks & Co. LLC;Davidson & Company LLP;KPMG;PricewaterhouseCoopers LLP - Ottawa, Ontario (Canada);Manning Elliott LLP;FRUCI & ASSOCIATES, P.S.;Michael T. Studer CPA P.C.;Anton & Chia LLP;Davidson & Company LLP;PricewaterhouseCoopers LLP - Edmonton, Alberta (Canada);Raymond Chabot Grant Thornton;Dale Matheson Carr-Hilton Labonte LLP;Assurance Dimensions Inc;S.R. Snodgrass, P.C.;Manning Elliott LLP;KPMG LLP - New York, New York, (USA);D&H Group LLP;Frazier & Deeter, LLC;De Visser Gray Chartered Accountants;KPMG LLP.;Davidson & Company LLP;Richter LLC.;Carr, Riggs & Ingram LLC;Mercurius & Associates LLP;M&K CPAS, PLLC;BDO Canada LLP;Griffith, Delaney, Hillman & Lett;DMCL Chartered Accountants;Davidson & Company LLP;Haynie & Company, CPA;EKS&H;FAR out Numbered, LLC;Marcum LLP;Astra Audit & Advisory, LLC;Nexia Sab & T;Astra Audit & Advisory, LLC;PricewaterhouseCoopers LLP;Grassi & Co., CPAs, P.C.;CBIZ CPAs P.C.;Pinnacle Tax Services;McGovern Hurley Cunningham, LLP;M&K CPAS, PLLC;B F Borgers CPA PC;Davidson & Company LLP;BDO LLP (UK);Elliott Davis;Davidson & Company LLP;Wolf & Company, P.C.;Simon & Edward, LLP;Audacie;Davidson & Company LLP;FORVIS, LLP;Frazier & Deeter, LLC;SingerLewak LLP;CliftonLarsonAllen LLP;Marcum LLP;Elliott Davis;Davidson & Company LLP;Schulman Wolfson & Abruzzo, LLP;Cupit, Milligan, Ogden & Williams;RSM Corporate Australia Pty Ltd;Baker Tilly WM LLP;Bush & Associates CPA;Fahn Kanne & Co.;Malone Bailey - Houstone, TX (USA);Marcum Bernstein & Pinchuk LLP;PricewaterhouseCoopers LLP;Beckles & Co;Niagara Financial Services;Equity Search Inc.;LBB & Associates Ltd., LLP;M&K CPAS, PLLC;Fruci & Associates II, PLLC;Ernst & Young LLP;Michael Gillespie & Associates, PLLC;DeVisser Gray LLP, Chartered Accountants;BDO USA, LLP;Ernst & Young LLP;Plante Moran;Main Street Consulting and Accounting;Grant Thornton UK LLP;KPMG LLP.;UHY LLP;Reeves and Co;Paris, Kreit & Chiu CPA LLP - Santa Ana, California (USA);Victor Mokuolu, CPA PLLC;PricewaterhouseCoopers LLP;H-Squared Performance Financial;Plante Moran;Manning Elliott LLP;Asesoria Global CPA;PKF Littlejohn;One Advisory Group Ltd;Friedman LLP;Grant Thornton LLP - Mississauga, Ontario (Canada);TAAD LLP;Boladale Lawal & Co (Chartered Accountants);Fruci & Associates II, PLLC;FRUCI & ASSOCIATES, P.S.;Vic Devlaeminck PC;Davidson & Company LLP;Fruci & Associates II, PLLC;McGovern Hurley Cunningham, LLP;PEEL CPA;Baker Tilly US, LLP;CFO-NOW;De Visser Gray Chartered Accountants;Mantyla McReynolds, LLC;Schulman Wolfson & Abruzzo, LLP;Moss Adams LLP;KPMG LLP.;PricewaterhouseCoopers AB;Pinnacle Accountancy Group of Utah;Barton CPA PLLC;RSM US LLP;Ernst & Young LLP;MGO CPA;KPMG LLP.;Natan & Associates, LLC;Davidson & Company LLP;Sadler, Gibb & Associates, LLC;Scott Chichester;Clearhouse LLP;M&K CPAS, PLLC;Gries & Associates, LLC;Crowe MacKay LLP;Manning Elliott LLP;Ernst & Young LLP;Whitley Penn;Accell Audit & Compliance, P.A;De Visser Gray Chartered Accountants;Ernst & Young LLP;Sadler, Gibb & Associates, LLC;MNP LLP;Sadler, Gibb & Associates, LLC;Aprio;HLB Mann Judd;Burr, Pilger & Mayer;Ernst & Young - Perth, Western Australia (Australia);KPMG LLP.;Mayer Hoffman McCann P.C.;Ernst & Young LLP;Bush & Associates CPA;Michael Gillespie & Associates, PLLC;Baker Tilly US, LLP;Raymond Chabot Grant Thornton;Frazier & Deeter, LLC;Mao & Ying LLP;Demetrius Berkower LLC;BDO USA, LLP;Forvis Mazars, LLP;Fruci & Associates II, PLLC;AJ Robbins CPA LLC;PBO Advisory Group;Dale Matheson Carr-Hilton Labonte LLP;Michael Gillespie & Associates, PLLC;S.R. Snodgrass, P.C.;WeiserMazars LLP;Smythe LLP.;CBIZ CPAs P.C.;Grant Thorton Audity Pty Ltd;Crowe MacKay LLP;SR Snodgrass, PC;Astra Audit & Advisory, LLC;Forvis Mazars, LLP;PKF Littlejohn;Silvertree Partners;Rodefer Moss & Co, PLLC;PricewaterhouseCoopers LLP;Ernst & Young LLP;WDM Chartered Accountants;Eide Bailly LLP;La Posta and Associates;Davidson & Company LLP;Moss Adams LLP;UHY LLP;Rose, Snyder & Jacobs;PAN-CHINA SINGAPORE PAC;Michael Gillespie & Associates, PLLC;McGovern Hurley LLP;Integritat Audit, Accounting & Advisory, LLC;M&K CPAS, PLLC;PKF Littlejohn;McGovern Hurley Cunningham, LLP;MNP LLP;PricewaterhouseCoopers LLP;WSRP, LLC;Coulter & Justus, P.C.;Marcum LLP;Olayinka Oyebola & Co;De Visser Gray Chartered Accountants;Lee Schlussel & Company;S.R. Snodgrass, P.C.;BF Borgers CPA PC;Factsco, LLC;M&K CPAS, PLLC;Davidson & Company LLP;Davidson & Company LLP;Davidson & Company LLP;Shim & Associates LLP - Vancouver, British Columbia (Canada);DeVisser Gray LLP, Chartered Accountants;M&K CPAS, PLLC;M&K CPAS, PLLC;HLB Mann Judd;Green Stone Group Holdings LLC;Ernst & Young LLP;Dale Matheson Carr-Hilton Labonte LLP;KPMG LLP.;Raymond Chabot Grant Thornton;Yevgeniy Grinberg CPA;DeVisser Gray LLP, Chartered Accountants;Total CFO, LLC;Ernst & Young LLP;Davidson & Company LLP;Moss Adams LLP;De Visser Gray Chartered Accountants;Marcum LLP;Fruci & Associates II, PLLC;Metcalf & Scott, Accountancy Corp.;MNP LLP;Dale Matheson Carr-Hilton Labonte LLP;Burr, Pilger & Mayer;M&K CPAS, PLLC;Boladale Lawal & Co (Chartered Accountants);PricewaterhouseCoopers LLP;GAAP Genies;Hudgens CPA, LLC;LKS & Associates, Ltd;Baker Tilly US, LLP;PricewaterhouseCoopers LLP;Deloitte LLP;Rosenberg Rich Baker Berman & Company;L J Soldinger Associates, LLC;Forvis Mazars, LLP;Lipton LLP;Scarrow & Company;Mendoza Berger & Company, LLP;Rothstein, Kass & Company, P.C.;BDO Canada LLP;Paris, Kreit & Chiu CPA LLP - Santa Ana, California (USA);Michael Gillespie & Associates, PLLC;Barton CPA PLLC;KCCW Accountancy Corp;PricewaterhouseCoopers LLP;M&K CPAS, PLLC;DeVisser Gray LLP, Chartered Accountants;Kingston Ross Pasnak LLP;BDO East Coast Partnership;Hall Chadwick;KPMG LLP.;Astra Audit & Advisory, LLC;Dale Matheson Carr-Hilton Labonte LLP;M&K CPAS, PLLC;Sadler, Gibb & Associates, LLC;M&K CPAS, PLLC;PKF Littlejohn;Davidson & Company LLP;GreenGrowth CPAs;Alexander & Williams, LLC;Ernst & Young LLP;Ernst & Young LLP;Seymour J. Weinberg, CPA;KPMG LLP - New York, New York, (USA);Kingston Ross Pasnak LLP;Plante & Moran, PLLC;Moss Adams LLP;Elliott Davis;Raymond Chabot Grant Thornton;RBSM LLP;BDO Audit Pty Ltd;Ernst & Young LLP;RBSM LLP;Partiz & Company;Rehmann Robson LLC;Smythe LLP.;Shim & Associates LLP - Vancouver, British Columbia (Canada);Heaton & Company, PLLC;Davidson & Company LLP;KWCO, P.C;Kost Forer Gabbay & Kasierer;KPMG LLP.;Manning Elliott LLP;Plante Moran;RSM Australia Partners;Hacker, Johnson & Smith PA;Stowe & Degon;Michael Gillespie & Associates, PLLC;Ernst & Young LLP;Salberg & Company, P.A.;CFO Oncall, Inc.;PricewaterhouseCoopers LLP;Crowe U.K. LLP;TPS THAYER, LLC;KPMG LLP - New York, New York, (USA);CBIZ CPAs P.C.;Hannis T. Bourgeois, LLP;Sadler, Gibb & Associates, LLC;MacKay LLP;Grant Thornton;PricewaterhouseCoopers LLP;PKF;WithumSmith + Brown PC;Vic Devlaeminck PC;Harish Belwal, CPA;DeVisser Gray LLP, Chartered Accountants;UHY LLP;The Accounting Connection;Hanul LLC;Davidson & Company LLP;Ernst & Young Bedrijfsrevisoren BVBA;Forvis Mazars, LLP;Mao & Ying LLP;BDO USA, LLP;Saturna Group Chartered Professional Accountants LLP;Interactive Edgar Corp.;MNP LLP;HDCPA Professional Corporation;Macias Gini & OConnell LLP;DeVisser Gray LLP, Chartered Accountants;Slack & Company LLC;TAAD LLP;Green Stone Group Holdings LLC;McGovern Hurley LLP;MaloneBailey, LLP;Davison & Company;Dale Matheson Carr-Hilton Labonte LLP;Moss Adams LLP;Marcum LLP;MNP LLP;MNP LLP;Davidson & Company LLP;WDM Chartered Accountants;Hall Chadwick;Coulter & Justus, P.C.;Victor Mokuolu, CPA PLLC;Seligson & Giannattasio, LLP;Baker Tilly US, LLP;MNP LLP;David Hexter, CPA, PA;Deloitte & Touche LLP;Davidson & Company LLP;MNP LLP;LBB & Associates Ltd., LLP;Eide Bailly LLP;Saturna Group Chartered Professional Accountants LLP;MNP LLP;RBSM LLP;MacKay LLP;Meyers Norris Penny, LLP;Eide Bailly LLP;M&K CPAS, PLLC;DNTW Chartered Accountants, LLP;PKF Antares;KAP Jamaludin, Ardi, Sukimto & Rekan;BDO USA, LLP;DeVisser Gray LLP, Chartered Accountants;Vandelanotte Bedrijfsrevisoren CVBA;GreenGrowth CPAs;WithumSmith+Brown;Dale Matheson Carr-Hilton Labonte LLP;PricewaterhouseCoopers LLP;Wong Johnson and Associates;Mac Accounting Group, LLP - Midvale, Utah (USA);On Point Accounting Services;Marcum LLP;Executive Industries;KPMG LLP.;Dale Matheson Carr-Hilton Labonte LLP;KPMG LLP.;CohnReznick LLP;Crowe MacKay LLP;PricewaterhouseCoopers LLP;Manning Elliott LLP;Weinberg & Company;Forvis Mazars, LLP;Smythe LLP;Dale Matheson Carr-Hilton Labonte LLP;Buckley Dodds Parker LLP;Horizon Assurance LLP;Davidson & Company LLP;Ernst & Young LLP - Toronto, Ontario (Canada);Quality Financial Services LLC;Asesoria Global CPA;RBSM LLP;T. E. Lott and Company;GreenGrowth CPAs;Richter LLC.;Frank, Rimerman & Co. LLP;GreenGrowth CPAs;Assure CPA, LLC;Mun & Associates;LAO Professionals;FRUCI & ASSOCIATES, P.S.;Rachel Boulds, CPA;KPMG LLP.;Dixon, Davis, Bagent and Company;Smythe LLP;BDO USA, LLP;PricewaterhouseCoopers LLP;Crowe MacKay LLP;Deloitte & Touche LLP;Smythe LLP.;Deloitte LLP - Calgary, Alberta (Canada);MNP LLP;Green Growth CPAs;CBIZ CPAs P.C.;Davidson & Company LLP;Cross Davis & Co. LLP;Tanner LLC;Crowe Chizek LLP;Davidson & Company LLP;Elkana Amitai CPA;Kenway Mack Slusarchuk Stewart LLP Charted Accountants;Bhamji Taxation Services Inc. CPA, CMA;Baker Tilly WM LLP;Baker Tilly US, LLP;DeVisser Gray LLP, Chartered Accountants;Davidson & Company LLP;Elderton Audit UK;McGovern Hurley Cunningham, LLP;PKF Littlejohn;WDM Chartered Accountants;Weaver and Tidwell, L.L.P.;BDO USA, LLP;NMS Inc.;MNP LLP;Dale Matheson Carr-Hilton Labonte LLP;Mahoney Sabol & Company, LLP;Urish Popeck & Co.;KPMG LLP.;RSM Australia Pty Ltd - Deakin, ACT (Australia);GreenGrowth CPAs;PwC - Southbank, Victoria (Australia);Rosenberg Rich Baker Berman & Company;Clearhouse LLP;KPMG LLP - New York, New York, (USA);Rose, Snyder & Jacobs;Smc International Tax & Accounting Services;Hall Chadwick;MNP LLP;TAAD LLP;Davidson & Company LLP;Baker Tilly WM LLP;Horne LLP;Ernst & Young LLP;M&K CPAS, PLLC;HHC;Ryanne Consulting Services Inc;Jack Runke CPA;Grant Thornton;McGovern Hurley Cunningham, LLP;EisnerAmper LLP;Heard, McElroy & Vestal, LLP;M&K CPAS, PLLC;MNP LLP;Novogradac & Company LLP;KPMG LLP.;RSM US LLP;Vogel CPAs, PC;Horne LLP;Hogan Taylor LLP;Morrison CPA Limited;Rosenfield & Co, PLC - Orlando, Florida (USA);DeVisser Gray LLP, Chartered Accountants;Forvis Mazars, LLP;Kingston Ross Pasnak LLP;KPMG LLP.;MNP LLP;MNP LLP;PKF Littlejohn;Benjamin & Ko;PKF Littlejohn;Manning Elliott LLP;RBSM LLP;Park Avenue Accounting;Natan & Associates, LLC;GZTY CPA Group LLC;GBH CPAs, PC;Pannell Kerr Forster of Texas;SRCO Professional Corporation, Charted Accountant;BDO Canada LLP;Davidson & Company LLP;Davidson & Company LLP;De Visser Gray Chartered Accountants;Fruci & Associates II, PLLC;Assurance Dimensions Inc;Davidson & Company LLP;LJ Soldinger Assoc, LLC;Windes, Inc.;MNP LLP;Mauldin & Jenkins, LLC;Cherry Bekaert LLP;Yu Certified Public Accountant PC;YWL & Company LLC;Deloitte LLP - Calgary, Alberta (Canada);PricewaterhouseCoopers LLP;PricewaterhouseCoopers LLP;Dale Matheson Carr-Hilton Labonte LLP;Reliant, CPA PC Certified Public Accountants;Deloitte Touche Tohmatsu;CohnReznick LLP;Dale Matheson Carr-Hilton Labonte LLP;Clearhouse LLP;Davidson & Company LLP;Davidson & Company LLP;BF Borgers CPA PC;Kreit & Chiu;KPMG LLP - New York, New York, (USA);DMCL Chartered Accountants;Dale Matheson Carr-Hilton Labonte LLP;Chisholm, Bierwolf, Nilson & Morrill, LLC;PricewaterhouseCoopers LLP;KBL, LLP;Brad Hacker and Company;CBIZ CPAs P.C.;Macias Gini & OConnell LLP;M&K CPAS, PLLC;Manning Elliott LLP;McConnell & Jones, LLP;MNP LLP;Thomas Leger & Co., LLP;Urish Popeck & Co.;Davidson & Company LLP;Interactive Edgar Corp.;PKF OConnor Davies, LLP;Crowe MacKay LLP;Yount, Hyde & Barbour, P.C.;Zeifmans LLP Chartered Accountants;M.N. Vijay Kumar;ATO Professionals;Davidson & Company LLP;Astra Audit & Advisory, LLC;KPMG LLP.;Manning Elliott LLP;Smythe LLP.;Davidson & Company LLP;M&K CPAS, PLLC;Haynie & Company, CPA;Wipfli LLP;Saturna Group Chartered Professional Accountants LLP;M.N. Vijay Kumar;Chang Park CPA;Brad Hacker and Company;Assurance Dimensions;Farber Hass Hurley LLP;Moore Stephens DHCL LLP;KPMG LLP.;PricewaterhouseCoopers LLP;Kost Forer Gabbay & Kasierer;Mayer Hoffman McCann P.C.;RJI International CPAs;Ernst & Young LLP.;Haynie & Company, CPA;Manning Elliott LLP;The Mercadien Group;Crowe, LLP;De Visser Gray Chartered Accountants;WithumSmith + Brown PC;MNP LLP;PricewaterhouseCoopers LLP;Sadler, Gibb & Associates, LLC;TKM Accounting Services;LKS & Associates, Ltd;Boladale Lawal & Co (Chartered Accountants);Friedman LLP;Mac Accounting Group, LLP - Midvale, Utah (USA);Crowe Horwath (HK) CPA Limited;Moore Audit S.A.;DeVisser Gray LLP, Chartered Accountants;Ernst & Young LLP;KPMG LLP - New York, New York, (USA);DMCL Chartered Accountants;PWC - Oslo, Norway;BDO Audit Pty Ltd;Shanghai Li Tong CPAs Co., LTD.;Barzily&Co Certified Public Accountants;Haynie & Company, CPA;Stephano Slack LLC;Tait, Weller & Baker;PricewaterhouseCoopers LLP;KPMG LLP.;MaloneBailey, LLP;Jewett, Schwartz, Wolfe and Associates;Thomas Howell Ferguson, P.A.;Ernst & Young LLP.;Wipfli LLP;Reliant, CPA PC Certified Public Accountants;Crowe MacKay LLP;CrossDavis & Company LLP - Vancouver, British Columbia (Canada);Davidson & Company LLP;FORVIS, LLP;Carl Kruse;Mancera SC;Victor Mokuolu, CPA PLLC;Ernst & Young LLP;Hudgens CPA, LLC;Patterson CPAs, LLC;Turner, Stone & Company, L.L.P.;WithumSmith + Brown PC;Rogoff & Company, P.C.;Tait, Weller & Baker;Davidson & Company LLP;Moss Adams LLP;Davidson & Company LLP;BDO USA, LLP;Cohen & Company, Ltd.;KBL, LLP;Forvis Mazars, LLP;J & J Consultants;BDO Australia Ltd.;Fruci & Associates II, PLLC;EisnerAmper LLP;Hacker, Johnson & Smith PA;Crowe U.K. LLP;De Visser Gray Chartered Accountants;Davidson & Company LLP;Robison, Hill & Co., APC;D&H Group LLP;Greystone Reporting, Ltd.;Ward Tax LLC;JP Centurion & Partners PLT;Hexcellence Consulting Sdn. Bhd.;Michael Gillespie & Associates, PLLC;Clearhouse LLP;RJI International CPAs;Haynie & Company, CPA;PKF Antares;PKF Antares;Crowe LLP;Hall Chadwick Melbourne Audit - Melbourne, Victoria (Australia);PKF Littlejohn;Grassi & Co., CPAs, P.C.;KPMG LLP.;MNP LLP;KPMG LLP - New York, New York, (USA);Simon & Edward, LLP;DBB McKennon;Grassi & Co., CPAs, P.C.;Yichien Yeh, CPA;Fruci & Associates II, PLLC;Yount, Hyde & Barbour, P.C.;Moore Australia Audit (WA);Dale Matheson Carr-Hilton Labonte LLP;Victor Mokuolu, CPA PLLC;Shim & Associates LLP - Vancouver, British Columbia (Canada);Exchange Group Chartered Accountants LLP;Baker Tilly HMW LLP - Winnipeg, Manitoba (Canada);JLKZ CPA LLP;Davidson & Company LLP;Clearhouse LLP;Crowe LLP;Reliant, CPA PC Certified Public Accountants;Charlton & Co.;KBL, LLP;Crowe MacKay LLP;S.R. Snodgrass, P.C.;McGovern Hurley LLP;Saturna Group Chartered Professional Accountants LLP;Dale Matheson Carr-Hilton Labonte LLP;HJ & Associates, LLC;Clearhouse LLP;EisnerAmper LLP;Baker Tilly WM LLP;M&K CPAS, PLLC;WithumSmith + Brown PC;Mercurius & Associates LLP;Ernst & Young LLP;Lake & Associates;GreenGrowth CPAs;KPMG;Shine Wing Certified Public Accountants;Dale Matheson Carr-Hilton Labonte LLP;Michael Gillespie & Associates, PLLC;Cherry Bekaert LLP;Barton CPA PLLC;Clearhouse LLP;PricewaterhouseCoopers LLP;Schulman Wolfson & Abruzzo, LLP;PricewaterhouseCoopers LLP;DFK Laurence Varnay Auditors Pty Ltd;Ernst & Young LLP;Haynie & Company, CPA;Crowe LLP;Fortune CPA Inc;DeVisser Gray LLP, Chartered Accountants;Mercurius & Associates LLP;McGovern Hurley Cunningham, LLP;Galaz, Yamazaki, Ruiz Urquiza S.C.;Plante & Moran, PLLC;Jones Simkins, P.C.;Weaver and Tidwell, L.L.P.;CF Audits LLC;M&K CPAS, PLLC;Berman & Company, P.A.;WithumSmith + Brown PC;B F Borgers CPA PC;Ernst & Young LLP;Mazars;Ernst & Young LLP;KCCW Accountancy Corp;PKF Littlejohn;PricewaterhouseCoopers LLP;Kreston GTA LLP;Michael T. Studer CPA P.C.;Consultia LLC;Davidson & Company LLP;KPMG LLP.;BPM LLP;BDO Ziv Haft;Roger Yeh, CPA;PricewaterhouseCoopers LLP - Ottawa, Ontario (Canada);Adler Shine LLP;DMCL Chartered Accountants;Manning Elliott LLP;Forvis Mazars, LLP;L&L CPAs, PA;DeVisser Gray LLP, Chartered Accountants;Baker Tilly US, LLP;PricewaterhouseCoopers LLP;Ernst & Young LLP - Toronto, Ontario (Canada);Davidson & Company LLP;Davidson & Company LLP;KB Park CPA;Smythe LLP;Turner, Stone & Company, L.L.P.;Berry, Dunn, McNeil & Parker;MaloneBailey, LLP;Raymond Chabot Grant Thornton;Deloitte GmbH - Germany;CBIZ CPAs P.C.;GBQ Partners LLC;Richard Blickstein Accounting and Taxes, Inc;BDO Canada LLP;Davidson & Company LLP;Manning Elliott LLP;The Griggs Group;Crowe LLP;Marcum LLP;Ernst & Young LLP;Moss Adams LLP;Exchange Group Chartered Accountants LLP;Smythe LLP;Kreston GTA LLP;Grant Thornton, LLP;Strohm Ballweg, LLP;Welch LLP;Deloitte AB;Elliott Davis;RSM Australia Partners;Systems Services - Mesa, Arizona (USA);MNP LLP;DFK Laurence Varnay Auditors Pty Ltd;Dale Matheson Carr-Hilton Labonte LLP;RJM Consulting, LLC;ACCOUNTING & MANAGEMENT SERVICES;PKF Littlejohn;James DiPrima;Stephano Slack LLC;Marcum LLP;KPMG LLC;CDL Consultants;Deloitte & Touche LLP;Davidson & Company LLP;HDCPA Professional Corporation;Deloitte & Touche LLP;Kenway Mack Slusarchuk Stewart LLP Charted Accountants;Wei Wei & Co., LLP;MNP LLP;Marcum LLP;CBIZ CPAs P.C.;Michael Gillespie & Associates, PLLC;Hutchins Clenney Rumsey Huckaby, PC;Carlos J. Valdes & Associates;MaloneBailey, LLP;Grant Thorton LLP;PricewaterhouseCoopers LLP;Davidson & Company LLP;James Moore & Co.;Weinberg & Company;JV CPA INC.;Victor Mokuolu, CPA PLLC;Accell Audit & Compliance, P.A;Clearhouse LLP;PricewaterhouseCoopers LLP;DMCL Chartered Accountants;Horizon Assurance LLP;Manning Elliott LLP;Smythe LLP.;McGovern Hurley Cunningham, LLP;BF Borgers CPA PC;J&S Associate;Reliant, CPA PC Certified Public Accountants;Bush & Associates CPA;Moss Adams LLP;BakerTillyVirchow;MNP LLP;KPMG LLP.;K. R. Margetson Ltd.;KPMG Accountants N.V.;Robert Adams, CPA;Factsco, LLC;Davidson & Company LLP;PricewaterhouseCoopers LLP;Deloitte LLP;Rose, Snyder & Jacobs;UHY McGovern Hurley LLP;KPMG Accountants N.V.;Yount, Hyde & Barbour, P.C.;Victor Mokuolu, CPA PLLC;Kreston GTA LLP;Deloitte Touche Tohmatsu;Fruci & Associates II, PLLC;MNP LLP;Goldstein Franklin, Inc.;KPMG Accountants N.V.;Crowe MacKay LLP;Astra Audit & Advisory, LLC;Davidson & Company LLP;Cooper Parry Group;Rowbotham & Company LLP;Olayinka Oyebola & Co;BDO USA, LLP;Smythe LLP.;Kreit & Chiu;Grassi & Co., CPAs, P.C.;Dale Matheson Carr-Hilton Labonte LLP;Raymond Chabot Grant Thornton;UHY McGovern Hurley LLP;BPM LLP;DBB McKennon;Burr Pilger Mayer, Inc.;JP Centurion & Partners PLT;DMCL Chartered Accountants;MNP LLP;Ernst & Young LLP;Siskos & Associates - CPA Tax & Accounting Services;M&K CPAS, PLLC;McGovern Hurley LLP;Fruci & Associates II, PLLC;M&K CPAS, PLLC;BDO USA, LLP;Anton & Chia LLP;Haynie & Company, CPA;CohnReznick LLP;Shim & Associates LLP - Vancouver, British Columbia (Canada);Remote Books Online;Ernst & Young LLP;Deloitte & Touche LLP;Davidson & Company LLP;Davidson & Company LLP;MNP LLP;CohnReznick LLP;Davidson & Company LLP;Meyers Norris Penny, LLP;KPMG LLP.;UHY LLP;CS&S Enterprises;Mauldin & Jenkins, LLC;Saturna Group Chartered Professional Accountants LLP;McGovern Hurley Cunningham, LLP;PricewaterhouseCoopers LLP;Marcum LLP;Barzily&Co Certified Public Accountants;McGovern Hurley Cunningham, LLP;Imowitz Koenig & Co.,LLP;Kurt Streams;Li & Company, PC;Stephano Slack LLC;BDO Audit (WA) Pty Ltd - Subiaco, Western Australia (Australia);Crowe MacKay LLP;Paul Gibbons & Associates, LLC;Whitley Penn;Davidson & Company LLP;Don D Meyers, Associates;RSM US LLP;Liggett & Webb, P.A.;Mallett & Barnes Tax Service;Davidson & Company LLP;Accounting Business Solutions Pty Ltd;D&H Group LLP;Marcum LLP;YCM CPA INC.;TAAD LLP;Davidson & Company LLP;Kingston Ross Pasnak LLP;Buckley Dodds Parker LLP;Bonadio & Co., LLP;MacKay LLP;Interactive Edgar Corp.;FRUCI & ASSOCIATES, P.S.;CFGI;Grant Thornton LLP - Mississauga, Ontario (Canada);Salberg & Company, P.A.;BDO Audit (WA) Pty Ltd - Subiaco, Western Australia (Australia);Clearhouse LLP;Accell Audit & Compliance, P.A;Freed Maxick CPAs, P.C.;Davidson & Company LLP;Grassi & Co., CPAs, P.C.;Smythe LLP;GZTY CPA Group LLC;Aventure Consultancy, LLC.;MNP LLP;Yount, Hyde & Barbour, P.C.;UHY LLP;MNP LLP;MNP LLP;JP Centurion & Partners PLT;GreenGrowth CPAs;Rosenberg Rich Baker Berman & Company;MGO CPA;CBIZ CPAs P.C.;KPMG;Ernst & Young LLP;LBB & Associates Ltd., LLP;TPS THAYER, LLC;Smythe LLP.;DeVisser Gray LLP, Chartered Accountants;Marcum LLP;Haynie & Company, CPA;Ernst & Young LLP;KMJ Corbin & Company LLP;WithumSmith+Brown;Plymale & Gillespie CPAs, PLLC;MaloneBailey, LLP;PricewaterhouseCoopers LLP;Mao & Ying LLP;Benjamine Leung & Co.,Ltd.;KPMG Accountants N.V.;MNP LLP;PricewaterhouseCoopers LLP;RSM US LLP;De Joya Griffith & Company, LLC;Deloitte LLP;MNP LLP;Accell Audit & Compliance, P.A;Liggett & Webb, P.A.;KPMG AB;Factsco, LLC;Astra Audit & Advisory, LLC;Victor Mokuolu, CPA PLLC;Natan & Associates, LLC.;Urish Popeck & Co.;Manning Elliott LLP;PricewaterhouseCoopers LLP;M&K CPAS, PLLC;Saturna Group Chartered Professional Accountants LLP;RBSM LLP;BDO USA, LLP;Abu-Farah Professional Corporation;BDO Canada LLP;PricewaterhouseCoopers LLP;Viele Solimano Swagler & Chapman;BF Borgers CPA PC;PKF Littlejohn;Plante & Moran, PLLC;M&K CPAS, PLLC;Eide Bailly LLP;Elkana Amitai CPA;Fruci & Associates II, PLLC;Stephano Slack LLC;Sadler, Gibb & Associates, LLC;Ernst & Young LLP;BCRG Group Inc.;MNP LLP;The Accounting Connection;Strothman+CO;Vic Devlaeminck PC;DBB McKennon;Cohen & Company, Ltd.;DMCL Chartered Accountants;Crowe MacKay LLP;DeVisser Gray LLP, Chartered Accountants;McGovern Hurley Cunningham, LLP;Michael T. Studer CPA P.C.;Maggart & Associates, P.C.;Dale Matheson Carr-Hilton Labonte LLP;Dale Matheson Carr-Hilton Labonte LLP;Plante Moran;Turner Stone & Co.;RBSM LLP;CFO-NOW;KLJ & Associates, LLP;Davidson & Company LLP;Davidson & Company LLP;BDO Australia Ltd.;M&K CPAS, PLLC;L & L CPAs PA;Davidson & Company LLP;EY GLOBAL;Dale Matheson Carr-Hilton Labonte LLP;BCRG Group Inc.;Raymond Chabot Grant Thornton;PricewaterhouseCoopers LLP;Deloitte GmbH - Germany;Deloitte LLP;Sutton Robinson Freeman & Co., P.C.;Russell, Craft & Schulz;Interactive Edgar Corp.;Freed Maxick CPAs, P.C.;Davidson & Company LLP;Vic Devlaeminck PC;Davidson & Company LLP;Eide Bailly LLP;MaloneBailey, LLP;WWC, Professional Corporation;Pubco Reporting Services Inc;EC Barrett, LLC;HJ & Associates, LLC;Assentsure PAC.;Fruci & Associates II, PLLC;BDO USA, LLP;Simon & Edward, LLP;DILIGENCY ACCOUNTANCY CORPORATION;Semple, Marchal & Cooper, LLP;RBSM LLP;Marcum LLP;PMB Helin Donovan, LLP;Dale Matheson Carr-Hilton Labonte LLP;Schechter Dokken Kanter Andrews & Selcer Ltd;TWC Consulting, LLC.;Fruci & Associates II, PLLC;DBB McKennon;Trust Net CPA Firm;PricewaterhouseCoopers LLP;Stephano Slack LLC;Armanino LLP - Woodland Hills, California (USA);Hogan Taylor LLP;Langley, Williams & Company, LLC;Ankit Consulting Services, Inc.;KPMG LLP.;Simon & Edward, LLP;Duncan Lee, CPA;Assentsure PAC.;RBSM LLP;Freed Maxick CPAs, P.C.;Forvis Mazars, LLP;Smythe LLP.;Abu-Farah Professional Corporation;Total Asia Associates;MNP LLP;PricewaterhouseCoopers LLP;Ovadia Kriheli & Co.;WithumSmith+Brown;Crowe LLP;CBIZ CPAs P.C.;Shim & Associates LLP - Vancouver, British Columbia (Canada);Jones Simkins, P.C.;Wipfli LLP;GBH CPAs, PC;RSM US LLP;Madsen & Associates CPAs, Inc.;PricewaterhouseCoopers LLP;Grant Thornton LLP;Elliott Davis;Dale Matheson Carr-Hilton Labonte LLP;Ernst & Young LLP.;CBIZ CPAs P.C.;DMCL Chartered Accountants;JP Centurion & Partners PLT;KPMG LLP - New York, New York, (USA);Bush & Associates CPA;KPMG LLP.;Bush & Associates CPA;Clark, Schaefer, Hackett & Co.;Scarrow & Donald LLP;Mayer Hoffman McCann P.C.;Paritz & Company, P.A.;Mayer Hoffman McCann P.C.;Will Stephenson Advisory LLC;Laquerre Audi;Smythe LLP.;Campbell & Lineberry;Plante Moran;Rehmann Robson LLC;Ernst & Young LLP;DMCL Chartered Accountants;MNP LLP;Davidson & Company LLP;KPMG Accountants N.V.;Barton CPA PLLC;Yu Certified Public Accountant PC;Davidson & Company LLP;HJ & Associates, LLC;BDJ Partners - Sydney, NSW (Australia);M&K CPAS, PLLC;BF Borgers CPA PC;BDO Canada LLP;Smythe LLP.;KCoe Isom, LLP;Grant Thornton LLP;KPMG LLP.;BDO Australia Ltd.;Deloitte Touche Tohmatsu;McGovern Hurley LLP;Fruci & Associates II, PLLC;RSM Canada LLP - Calgary, Alberta (Canada);MNP LLP;MNP LLP;De Visser Gray Chartered Accountants;Guimond Lavallee;Ernst & Young LLP;Davidson & Company LLP;McGovern Hurley LLP;Baker Tilly WM LLP;Dale Matheson Carr-Hilton Labonte LLP;Deloitte LLP;Michael T. Studer CPA P.C.;Ernst & Young LLP;MNP LLP;Baker Tilly WM LLP;Beckles & Co;FRUCI & ASSOCIATES, P.S.;BDO Australia Ltd.;EMS Consulting Services, LLC.;PricewaterhouseCoopers LLP;Brunet Roy Dube - Montreal, Quebec (Canada);RJM Consulting, LLC;S.R. Snodgrass, P.C.;Simon & Edward, LLP;Shim & Associates LLP - Vancouver, British Columbia (Canada);Ernst & Young LLP.;Mclean Delmo Bentleys Audit Pty Ltd;Kost Forer Gabbay & Kasierer;Hein & Associates LLP;Ernst & Young LLP;Victor Mokuolu, CPA PLLC;Centurion ZD CPA Limited;Haynie & Company, CPA;Wipfli LLP;Deloitte LLP;PricewaterhouseCoopers LLP;McGovern Hurley Cunningham, LLP;Auxilium Financial Services;Grant Thornton;Dale Matheson Carr-Hilton Labonte LLP;B F Borgers CPA PC;PricewaterhouseCoopers LLP;Friedman LLP;Dale Matheson Carr-Hilton Labonte LLP;Yarel + Partners, CPAs;Brightman Almagor & Co.;MaloneBailey, LLP;Liggett & Webb, P.A.;Michael Gillespie & Associates, PLLC;BDO Ziv Haft;Smythe LLP;Lancaster & David, Chartered Accountants;MNP LLP;J & J Consultants;Rose, Snyder & Jacobs;Crowe MacKay LLP;Kingston Ross Pasnak LLP;Kost Forer Gabbay & Kasierer;Haskell & White LLP;Clearhouse LLP;Yount, Hyde & Barbour, P.C.;WDM Chartered Accountants;Galaz, Yamazaki, Ruiz Urquiza S.C.;Crowe Horwath, LLP;Smythe LLP.;BF Borgers CPA PC;Pubco Reporting Services Inc;JP Centurion & Partners PLT;Eide Bailly LLP;Davidson & Company LLP;KBL, LLP;Lake & Associates CPAS LLC;Vic Devlaeminck PC;Mac Accounting Group, LLP - Midvale, Utah (USA);KPMG LLP.;Boladale Lawal & Co (Chartered Accountants);John Scholz CA;Watson Dauphinee & Musuch;Baker Tilly WM LLP;Julie Siska CPA;Mayer Hoffman McCann P.C.;McGovern Hurley LLP;MaloneBailey, LLP;Berkowitz Pollack Brant Advisors and Accountants, LLP;Hecker and Associates;Brooks Mitchell, CPA;Saltmarsh, Cleaveland & Gund;Hays Macintyre - London, England (United Kingdom);KPMG AZSA LLC;BDO Audit Pty Ltd;Davidson & Company LLP;MNP LLP;MNP LLP;Hannis T. Bourgeois, LLP;Saturna Group Chartered Professional Accountants LLP;HLB Mann Judd;Craig Ainge;FORVIS, LLP;Forvis Mazars, LLP;Don D Meyers, Associates;Mark Shelly International LLC;Audirevi S.P.A.;Davidson & Company LLP;RBSM LLP;PricewaterhouseCoopers AS;MNP LLP;Davidson & Company LLP;DeVisser Gray LLP, Chartered Accountants;M&K CPAS, PLLC;Crowe MacKay LLP;DBB McKennon;HJ & Associates, LLC;Deloitte LLP;The Accounting Connection;Baker Tilly US, LLP;PricewaterhouseCoopers LLP;Fruci & Associates II, PLLC;Centri Business Consulting, LLC;Haynie & Company, CPA;M&K CPAS, PLLC;Wipfli LLP;KPMG Accountants N.V.;T. St. Denis, Inc.;Baker Tilly WM LLP;SRCO Professional Corporation, Charted Accountant;MNP LLP;Vavrinek, Trine, Day & Co., LLP;WithumSmith + Brown PC;M.S. Mahava Rao;DMCL Chartered Accountants;PricewaterhouseCoopers LLP;RSM UK Audit LLP - Leeds, England (United Kingdom);MaloneBailey, LLP;Baker Tilly US, LLP;Boladale Lawal & Co (Chartered Accountants);Simon & Edward, LLP;Davidson & Company LLP;Forvis Mazars, LLP;Albin, Randall & Bennett, CPAs;Marcum LLP;PWC LLP - Vancouver, British Columbia (Canada);HLB Mann Judd;Dale Matheson Carr-Hilton Labonte LLP;DMCL Chartered Accountants;MGO CPA;Dale Matheson Carr-Hilton Labonte LLP;MNP LLP;McConnell & Jones, LLP;Kyle and Company, PC;Marcum LLP;KPMG LLP.;Simon & Edward, LLP;Manning Elliott LLP;WWC, Professional Corporation;McGovern Hurley Cunningham, LLP;WWC, Professional Corporation;Michael T. Studer CPA P.C.;Pablo Malana & Co.;KPMG LLP.;Davidson & Company LLP;Yvonne Lai;Salberg & Company, P.A.;MICHAEL K FISH CPA PA;BDO Audit Pty Ltd;Hacker, Johnson & Smith PA;Reliant, CPA PC Certified Public Accountants;Victor Mokuolu, CPA PLLC;Crowe LLP;AMN Professionals;Boladale Lawal & Co (Chartered Accountants);Davidson & Company LLP;Davidson & Company LLP;Grant Thorton Audity Pty Ltd;Haskell & White LLP;Comprehensive Accounting;Anderson Bradshaw PLLC;Marcum LLP;Smythe LLP.;S.R. Snodgrass, P.C.;Davidson & Company LLP;Mercurius & Associates LLP;Davidson & Company LLP;KPMG Accountants N.V.;DeVisser Gray LLP, Chartered Accountants;KPMG LLP.;TAAD LLP;EisnerAmper LLP;PricewaterhouseCoopers LLP;Grant Thornton, LLP;BPM LLP;McGovern Hurley LLP;Goldstein Franklin, Inc.;Fruci & Associates II, PLLC;AOGB CPA Limited;Rachel Boulds, CPA;Manning Elliott LLP;PKF;Wipfli LLP;MNP LLP;RSM Canada LLP;Enterprise CPAs, Ltd.;Dale Matheson Carr-Hilton Labonte LLP;Heaton & Company, PLLC;Pinnacle Accountancy Group of Utah;Wipfli LLP;Davidson & Company LLP;PKF Littlejohn;Davidson & Company LLP;Saturna Group Chartered Professional Accountants LLP;SmartBooks;Reconta, Ernst & Young S.p.A.;Davidson & Company LLP;Blue Chip Accounting, LLC;Beckles & Company;The Accounting Connection;HKCMCPA Company Limited;Shim & Associates LLP - Vancouver, British Columbia (Canada);Davidson & Company LLP;Davidson & Company LLP;Ankit Consulting Services, Inc.;GreenGrowth CPAs;KPMG;Ronald R. Chadwick, P.C.;Ruth Abady-Soltanovici , CPA;Pinnacle Accountancy Group of Utah;MNP LLP;My CPA, PA;DMCL Chartered Accountants;Solutions Group Accounting Firm;Fahn Kanne & Co.;Manning Elliott LLP;L J Soldinger Associates, LLC;MNP LLP;Baker Tilly US, LLP;CBIZ CPAs P.C.;A Chan & Company LLP;Kreston GTA LLP;M&K CPAS, PLLC;CliftonLarsonAllen LLP;RBSM LLP;Frank Artz Tax & Accounting;Euro-American Finance Network, Inc.;Cherry Bekaert LLP;The Accounting Connection;Boladale Lawal & Co (Chartered Accountants);Milhouse Neal LLP;PKF Littlejohn;Crowe LLP;Davidson & Company LLP;Whitley Penn;WWC, Professional Corporation;Citrin Cooperman & Company LLC;BDO London - London, England (United Kingdom);TAAD LLP;CBIZ CPAs P.C.;Pitcher Partners Queensland;BDO USA, LLP;McGovern Hurley LLP;M&K CPAS, PLLC;NOW CFO;McGovern Hurley LLP;Sadler, Gibb & Associates, LLC;SaxBST LLP;CBIZ CPAs P.C.;Assurance Dimensions Inc;MNP LLP;William Buck Audit and Assurance;A-Frame Accounting & Advisory, Inc>CPA,CA;MNP LLP;Davidson & Company LLP;Wolf & Company, P.C.;steuerbord Steuerberatungges. mbH;DLA, LLC;EMS Consulting Services, LLC.;Integritat Audit, Accounting & Advisory, LLC;Moore & Associates, Chartered;Fruci & Associates II, PLLC;Turner, Stone & Company, L.L.P.;Charles E. Heath CPA, P.A.;Davidson & Company LLP;L Damora CGA;M&K CPAS, PLLC;Deloitte LLP;Harbourside CPA LLP;DNTW Chartered Accountants, LLP;Integritat Audit, Accounting & Advisory, LLC;PricewaterhouseCoopers LLP;EisnerAmper LLP;Pasternack & Company, LLP;Malone Bailey LLP;Marcum LLP;HJ & Associates, LLC;Greentree Financial Group, Inc.;McGovern Hurley LLP;McGladrey LLP;Semple, Marchal & Cooper, LLP;PricewaterhouseCoopers LLP;Boladale Lawal & Co (Chartered Accountants);KCCW Accountancy Corp;CL Partners CPA Limited;Wolf & Company, P.C.;UHY McGovern Hurley LLP;MS PARTNERS LLP;Tait, Weller & Baker;MaloneBailey, LLP;Ernst & Young LLP;MNP LLP;KPMG LLP.;Grant Thornton UK LLP;NOW CFO;Grant Thornton LLP;BDO Audit Pty Ltd;PricewaterhouseCoopers LLP;Marcum LLP;CBIZ CPAs P.C.;Davidson & Company LLP;BF Borgers CPA PC;PricewaterhouseCoopers LLP;MNP LLP;David E. Severson, CPA;McGovern Hurley LLP;DBB McKennon;Sadler, Gibb & Associates, LLC;PricewaterhouseCoopers LLP;PricewaterhouseCoopers LLP - Ottawa, Ontario (Canada);Hacker, Johnson & Smith PA;Hein & Associates LLP;Dale Matheson Carr-Hilton Labonte LLP;UHY LLP;Pannell Kerr Forster of Texas;Weaver Martin & Samyn;LL Bradford LLC;MNP LLP;HLB Mann Judd;Dale Matheson Carr-Hilton Labonte LLP;D&H Group LLP;Forvis Mazars, LLP;PricewaterhouseCoopers AB;Assurance Dimensions;Grassi & Co., CPAs, P.C.;Davidson & Company LLP;Friedman LLP;Fruci & Associates II, PLLC;PKF Littlejohn;Elliott Davis;Yount, Hyde & Barbour, P.C.;D. Brooks and Associates CPAs, P.A.;MICHAEL K FISH CPA PA;Davidson & Company LLP;RSM US LLP;Alexander & Williams, LLC;RBSM LLP;McGovern Hurley LLP;Meyers Norris Penny, LLP;Payne & Smith, LLC;KPMG LLP.;Grossman St. Amour CPAs;PricewaterhouseCoopers LLP;Astra Audit & Advisory, LLC;KPMG AZSA LLC;MNP LLP;Salberg & Company, P.A.;Smythe LLP.;BCRG Group Inc.;Davidson & Company LLP;UHY LLP;L J Soldinger Associates, LLC;Yount, Hyde & Barbour, P.C.;Crowe LLP;DBB McKennon;Davidson & Company LLP;Freed Maxick CPAs, P.C.;CBIZ CPAs P.C.; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0000353278 |
| Description | Novo-Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems; vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products (OAD). Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management (NovoSeven(R) RT), growth hormone therapy, hormone replacement therapy and other products. Additional info from NASDAQ: Additional info from OTC: |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| NNC0497-0040 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| NNC0497-0040 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| NNC0497-0040 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| NNC0497-0040 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| NNC0497-0040 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| NNC0497-0040 | Other | Phase PHASE1 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07578584 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| sodium chloride 0.9% w/v | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01730014 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01730014 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01730014 |
| 148-0287-A-4.2mM-cartridge | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01730014 |
| placebo | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01848002 |
| catridecacog | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01848002 |
| placebo | Other | Phase PHASE1 | Inflammation | TERMINATED | NCT01689025 |
| NNC0114-0006 | Other | Phase PHASE1 | Inflammation | TERMINATED | NCT01689025 |
| placebo | Other | Phase PHASE1 | Acquired Bleeding Disorder | COMPLETED | NCT01153997 |
| catridecacog | Other | Phase PHASE1 | Acquired Bleeding Disorder | COMPLETED | NCT01153997 |
| Norditropin NordiFlex® | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01327924 |
| gastric bypass | Other | Preclinical | Obesity | COMPLETED | NCT01463449 |
| Genotropin Pen® | Other | Phase PHASE1 | Growth Disorder | COMPLETED | NCT01943084 |
| Norditropin® FlexPro® pen | Other | Phase PHASE1 | Growth Disorder | COMPLETED | NCT01943084 |
| placebo | Other | Approved | Hyperglycemia | COMPLETED | NCT01472640 |
| liraglutide | Other | Approved | Hyperglycemia | COMPLETED | NCT01472640 |
| Placebo semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Placebo semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Placebo cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07527195 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| NNC1679-0001 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07570992 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07415954 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07571005 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| NNC0113-5840 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07566390 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07503210 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT05689372 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Placebo | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07567001 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | COMPLETED | NCT06805539 |
| Semaglutide | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| Cagrisema | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07564414 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868581 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868581 |
| NNC 0128-0000-2011 | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01288391 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01530048 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01498939 |
| repaglinide | Other | Preclinical | Diabetes | COMPLETED | NCT01498900 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01490112 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT01789086 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT01789086 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02100475 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02100475 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01880736 |
| turoctocog alfa | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01692925 |
| somatropin | Other | Phase PHASE4 | Growth Hormone Disorder | TERMINATED | NCT01698944 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01611688 |
| NNC0215-0384 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01611688 |
| eptacog alfa (activated) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01586936 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01572753 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | TERMINATED | NCT01564563 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | TERMINATED | NCT01564563 |
| standard therapy | Drug | Phase PHASE2 | Acquired Bleeding Disorder | TERMINATED | NCT01564563 |
| somatropin | Other | Phase PHASE4 | Genetic Disorder | COMPLETED | NCT01734486 |
| somatropin | Other | Phase PHASE4 | Foetal Growth Problem | COMPLETED | NCT01734447 |
| 17-beta estradiol | Other | Phase PHASE3 | Genetic Disorder | COMPLETED | NCT01710696 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01836523 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01836523 |
| turoctocog alfa | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01138501 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01814137 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01814137 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01814137 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02060266 |
| Early intervention | Other | Approved | Health Behavior | COMPLETED | NCT01799447 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02235961 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02235961 |
| NNC9204-0530 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02235961 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT02321878 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02300844 |
| NNC0174-0833 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02300844 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02054897 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02054897 |
| basal insulin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01850615 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01850615 |
| Liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03191396 |
| Semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03191396 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02906917 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02906917 |
| Insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02906917 |
| Placebo (NNC0113-2023) | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03617081 |
| NNC0113-2023 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03617081 |
| somatropin | Other | Phase PHASE3 | Genetic Disorder | COMPLETED | NCT01927861 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02773381 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02773381 |
| somatropin | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01973244 |
| somapacitan | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01973244 |
| Insulin glargine | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03687827 |
| Insulin degludec | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03687827 |
| Liraglutide or Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Non-Insulin-Dependent | COMPLETED | NCT02299388 |
| MEDI5117 Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT01559103 |
| MEDI5117 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT01559103 |
| Placebo (NNC0165-1562) | Other | Phase PHASE1 | Metabolism and Nutrition Disorders | COMPLETED | NCT03574584 |
| Semaglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorders | COMPLETED | NCT03574584 |
| NNC0165-1562 | Other | Phase PHASE1 | Metabolism and Nutrition Disorders | COMPLETED | NCT03574584 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03648281 |
| Placebo | Other | Phase PHASE4 | Obesity, Visceral | COMPLETED | NCT03038620 |
| Liraglutide | Other | Phase PHASE4 | Obesity, Visceral | COMPLETED | NCT03038620 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT04287179 |
| Fiasp® | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT03895515 |
| Cross-over study | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT05375656 |
| Cross-over study | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT05375656 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02692716 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02692716 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02607865 |
| sitagliptin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02607865 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02607865 |
| DV3395 C1 | Other | Phase PHASE1 | Healthy Volunteers, Medical Device | COMPLETED | NCT05314283 |
| Long BPL RYGB | Other | Approved | Obesity | UNKNOWN | NCT04196348 |
| Short BPL RYGB | Other | Approved | Obesity | UNKNOWN | NCT04196348 |
| Long BPL RYGB | Other | Approved | Obesity | UNKNOWN | NCT04196348 |
| Short BPL RYGB | Other | Approved | Obesity | UNKNOWN | NCT04196348 |
| LANTUS® SOLOSTAR® INSULIN PEN | Other | Phase PHASE4 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03668808 |
| TRESIBA® FLEXTOUCH® | Other | Phase PHASE4 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03668808 |
| Insulin Glargine | Other | Phase PHASE4 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03668808 |
| Insulin Degludec | Other | Phase PHASE4 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03668808 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05317845 |
| HM-PRO | Other | Approved | Hematologic Malignancy | COMPLETED | NCT04757545 |
| NNC0385-0434 B | Other | Phase PHASE1 | Healthy Volunteers; High Cholesterol | COMPLETED | NCT05333107 |
| NNC0385-0434 F | Other | Phase PHASE1 | Healthy Volunteers; High Cholesterol | COMPLETED | NCT05333107 |
| NNC0385-0434 G | Other | Phase PHASE1 | Healthy Volunteers; High Cholesterol | COMPLETED | NCT05333107 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Primary Hyperoxaluria Type 3 | COMPLETED | NCT04555486 |
| DCR-PHXC | Other | Phase PHASE1 | Primary Hyperoxaluria Type 3 | COMPLETED | NCT04555486 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05087342 |
| Semaglutide 2.4mg | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05087342 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05804162 |
| Moxifloxacin | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05804162 |
| Cagrilintide Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05804162 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05804162 |
| NNC0148-0287 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03789578 |
| Semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03789578 |
| NNC0148-0287sema | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03789578 |
| No tretament given | Other | Preclinical | Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD) | COMPLETED | NCT06769646 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT04889183 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT04889183 |
| No treatment given | Drug | Preclinical | Overweight | COMPLETED | NCT06874751 |
| Placebo A (NNC0174 1213 A) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06719011 |
| Cagrilintide B | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06719011 |
| NNC0174-1213 A | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06719011 |
| Semaglutide | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06097390 |
| Placebo (NNC0560-0004) | Other | Phase PHASE1 | Healthy Volunteers - Liver Diseases | COMPLETED | NCT06133270 |
| NNC0560-0004 | Other | Phase PHASE1 | Healthy Volunteers - Liver Diseases | COMPLETED | NCT06133270 |
| recombinant factor XIII | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT02670213 |
| Semaglutide | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05533632 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05443334 |
| Placebo GIP | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07411560 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07411560 |
| Glucose-dependent Insulinotropic Polypeptide (GIP) | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07411560 |
| Carbohydrate | Other | Approved | Type 1 Diabetes | COMPLETED | NCT01223560 |
| Exercise | Other | Approved | Type 1 Diabetes | COMPLETED | NCT01223560 |
| Insulin Aspart | Other | Approved | Type 1 Diabetes | COMPLETED | NCT01223560 |
| neutral protamine insulin | Other | Approved | Type 2 Diabetes Mellitus | UNKNOWN | NCT01310452 |
| insulin detemir | Other | Approved | Type 2 Diabetes Mellitus | UNKNOWN | NCT01310452 |
| Victoza® | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01208012 |
| administration of autologous stored platelets | Other | Phase PHASE2 | Bleeding | COMPLETED | NCT01248351 |
| autologous stored platelets | Other | Phase PHASE2 | Bleeding | COMPLETED | NCT01248351 |
| DexCom CGM | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| SenseWear Pro3® armband | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Insulin-Levemir and Exenatide-Bayetta | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Exenatide-Bayetta | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Insulin-Levemir | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Insulin detemir | Other | Phase PHASE4 | Diabetes Mellitus, Type 1 | UNKNOWN | NCT01440439 |
| Insulin glargine | Other | Phase PHASE4 | Diabetes Mellitus, Type 1 | UNKNOWN | NCT01440439 |
| Isotone NaCl | Other | Approved | Kidney Functional | COMPLETED | NCT01333163 |
| Human GLP-1 (7-36) amide | Other | Approved | Kidney Functional | COMPLETED | NCT01333163 |
| Health counseling and exercise | Other | Phase EARLY_PHASE1 | Acute Leukemia | COMPLETED | NCT01557686 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01542060 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01649570 |
| Blast Traumatic Brain Injury | Other | Preclinical | Traumatic Brain Injury | UNKNOWN | NCT01666964 |
| counseling and behavioral therapy for weight loss | Drug | Approved | Obesity | COMPLETED | NCT01312090 |
| Whole body cryotherapy | Drug | Approved | Obesity | COMPLETED | NCT01312090 |
| Open-loop control | Other | Approved | Type 1 Diabetes | COMPLETED | NCT01444443 |
| Closed-loop control | Other | Approved | Type 1 Diabetes | COMPLETED | NCT01444443 |
| Atenolol | Other | Approved | Healthy | UNKNOWN | NCT01795235 |
| Placebo | Other | Approved | Healthy | UNKNOWN | NCT01795235 |
| Glucagon | Other | Approved | Healthy | UNKNOWN | NCT01795235 |
| Saline | Other | Approved | Healthy | UNKNOWN | NCT01795235 |
| Basal-bolus detemir-aspart insulin regimen | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT01828970 |
| Personal instruction | Other | Approved | Musculoskeletal Disorders | COMPLETED | NCT01543893 |
| Video instruction | Other | Approved | Musculoskeletal Disorders | COMPLETED | NCT01543893 |
| Glimepiride | Other | Phase PHASE2 | Maturity-onset Diabetes of the Young | COMPLETED | NCT01610934 |
| liraglutide | Other | Phase PHASE2 | Maturity-onset Diabetes of the Young | COMPLETED | NCT01610934 |
| somatropin | Other | Phase PHASE1 | Growth Disorder | WITHDRAWN | NCT01512095 |
| Liraglutide | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT01394341 |
| insulin degludec/liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01916174 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | TERMINATED | NCT01467414 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01193387 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01173926 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01173926 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01173926 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01134224 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01134224 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00992537 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00992537 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00992537 |
| oral placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01405261 |
| I.v. NNC 0113-0987 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01405261 |
| oral NNC 0113-0987 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01405261 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01121289 |
| NN1218 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01121289 |
| insulin 338 (GIPET I) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01931137 |
| Norditropin SimpleXx (growth hormone) | Other | Phase PHASE2 | Growth Hormone Deficiency | COMPLETED | NCT01090778 |
| activated recombinant human factor VII | Other | Preclinical | Acquired Bleeding Disorder | COMPLETED | NCT01285089 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01550653 |
| liraglutide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01550653 |
| Placebo-liraglutide | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT01664676 |
| Liraglutide | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT01664676 |
| eptacog alfa (activated) | Other | Phase PHASE1 | Congenital Bleeding Disorder | WITHDRAWN | NCT02084810 |
| activated recombinant human factor VII | Other | Phase PHASE1 | Congenital Bleeding Disorder | WITHDRAWN | NCT02084810 |
| Soccer training | Other | Approved | Prostatic Neoplasms | COMPLETED | NCT01711892 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01866748 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01866748 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01934686 |
| human soluble insulin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02162407 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02162407 |
| insulin human | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01269606 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01269606 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01967589 |
| NNC0113-0987 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01967589 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01487421 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01487421 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01766245 |
| estradiol, 25 mcg | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01085877 |
| repaglinide | Other | Preclinical | Diabetes | COMPLETED | NCT01077570 |
| No treatment given | Drug | Preclinical | Growth Hormone Disorder | WITHDRAWN | NCT01068639 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01978613 |
| NNC0113-0987 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01978613 |
| gliclazide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01022762 |
| repaglinide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01022762 |
| repaglinide | Other | Preclinical | Diabetes | COMPLETED | NCT01355718 |
| placebo | Other | Phase PHASE2 | Inflammation | WITHDRAWN | NCT02097264 |
| Adalimumab | Other | Phase PHASE2 | Inflammation | WITHDRAWN | NCT02097264 |
| NNC0109-0012 | Other | Phase PHASE2 | Inflammation | WITHDRAWN | NCT02097264 |
| placebo | Other | Phase PHASE1 | Inflammation | WITHDRAWN | NCT01018238 |
| NNC 0151-0000-0000 | Other | Phase PHASE1 | Inflammation | WITHDRAWN | NCT01018238 |
| NNC 0128-0000-2021 | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01272206 |
| NNC 0128-0000-2011 | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01272206 |
| placebo | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT01270789 |
| Liraglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT01270789 |
| IVGTT | Other | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| OGTT | Other | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| TNF-alfa | Other | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| Placebo (Saline) | Other | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| GLP-1 | Other | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| No treatment given | Drug | Preclinical | Diabetes | WITHDRAWN | NCT01957592 |
| placebo | Other | Phase PHASE2 | Inflammation | TERMINATED | NCT01706159 |
| catridecacog | Other | Phase PHASE2 | Inflammation | TERMINATED | NCT01706159 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01955603 |
| NNC0215-0384 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01955603 |
| activated recombinant human factor VII | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01312636 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02172313 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01278160 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01278160 |
| 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) | Other | Preclinical | Menopause | COMPLETED | NCT01076621 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01215435 |
| eptacog alfa (activated) | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01949792 |
| activated recombinant human factor VII | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01234545 |
| observational study | Other | Preclinical | Hemorrhage | COMPLETED | NCT01532661 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01934673 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02161588 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02161588 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507389 |
| activated recombinant human factor VII | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01476423 |
| somatropin | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01109017 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01515553 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01498926 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01877200 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02231684 |
| NNC0113-0987 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02094521 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01515579 |
| liraglutide | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01499108 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02113332 |
| Liraglutide | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02113332 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01623375 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01619345 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01469143 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01469143 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01455142 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01296438 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01296438 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01272973 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01272973 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01773798 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01773798 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01773798 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01773798 |
| insulin degludec/insulin aspart 15 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01773798 |
| insulin human | Other | Preclinical | Diabetes | TERMINATED | NCT02382757 |
| 2 mg estradiol / 1 mg norethisterone acetate (NETA) | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01596010 |
| biphasic human insulin 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01486888 |
| Placebo | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01755572 |
| Liraglutide | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01755572 |
| insulin human | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511159 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511159 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511159 |
| somatropin | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01543867 |
| Placebo | Other | Phase PHASE4 | Partial Corticotrope Insufficiency | TERMINATED | NCT01089075 |
| Hydrocortisone | Other | Phase PHASE4 | Partial Corticotrope Insufficiency | TERMINATED | NCT01089075 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT02230631 |
| activated recombinant human factor VII | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01220141 |
| isophane human insulin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01486901 |
| somatropin | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01543880 |
| Other: 4. Usual care | Other | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| Experimental: 3. Experimental | Other | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| Experimental: 2. Experimental | Other | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| Experimental: 1. Experimental | Other | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01890993 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01597713 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01597713 |
| NNC 0148-0000-0362 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01597713 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01242826 |
| NovoPen® 3 | Other | Preclinical | Diabetes | COMPLETED | NCT01454024 |
| FlexPen® | Other | Preclinical | Diabetes | COMPLETED | NCT01454024 |
| somatropin | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01604161 |
| biphasic human insulin 50 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01892020 |
| biphasic insulin aspart 50 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01892020 |
| No treatment given | Drug | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT02241694 |
| Remote ischemic conditioning | Other | Approved | Kidney Transplantation | UNKNOWN | NCT01395719 |
| Subcutaneous insertions of needles | Other | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT02531776 |
| Placebo | Other | Phase PHASE2 | Kidney Failure, Chronic | WITHDRAWN | NCT02284230 |
| Liraglutide | Other | Phase PHASE2 | Kidney Failure, Chronic | WITHDRAWN | NCT02284230 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01846312 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01125553 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868529 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868529 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00966368 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01319240 |
| insulin degludec/liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01319240 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01319240 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865292 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865292 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 55 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 45 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 40 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868555 |
| insulin degludec/insulin aspart 45 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868555 |
| insulin degludec/insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868555 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01868555 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865318 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865305 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865305 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865305 |
| insulin degludec/insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865305 |
| insulin degludec/insulin aspart 40 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865305 |
| insulin degludec/insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865305 |
| isophane human insulin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865279 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865279 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865279 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT02608853 |
| No treatment given | Drug | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01959555 |
| Exercise based multimodal intervention | Other | Approved | Acute Leukemia | COMPLETED | NCT01404520 |
| Liraglutide | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | TERMINATED | NCT01542242 |
| No treatment given | Drug | Preclinical | Haemostasis | COMPLETED | NCT02568202 |
| insulin degludec/insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865331 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865331 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01865331 |
| 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01477632 |
| 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01477632 |
| 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01477632 |
| placebo injection | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01628445 |
| liraglutide | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01628445 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01135992 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01135992 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01490099 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01569841 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01569841 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01709929 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01542476 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01542463 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01487408 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01487382 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01487369 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01538589 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01538576 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01536652 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01536613 |
| Physical activity intervention | Other | Approved | Type 2 Diabetes | COMPLETED | NCT02371239 |
| Liraglutide-placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT01237119 |
| Liraglutide | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT01237119 |
| Liraglutide - Placebo | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT01761318 |
| Liraglutide | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT01761318 |
| activated recombinant human factor VII | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01562457 |
| catridecacog | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01253811 |
| None, observational study | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT02486237 |
| Meal Test | Other | Preclinical | Bone Remodeling | COMPLETED | NCT02518737 |
| Meal Test | Other | Preclinical | Bone Remodeling | COMPLETED | NCT02518737 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02479022 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02479022 |
| Insulin 320 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02479022 |
| Outdoor weather | Other | Preclinical | Nonshivering Thermogenisis | COMPLETED | NCT02486419 |
| placebo | Other | Phase PHASE4 | Diabetic Kidney Disease | COMPLETED | NCT02545738 |
| Liraglutide | Other | Phase PHASE4 | Diabetic Kidney Disease | COMPLETED | NCT02545738 |
| Mixed Meal Tolerance Test with paracetamol | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT02408705 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT02408705 |
| Liraglutide | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT02408705 |
| recombinant factor XIII | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01082406 |
| catridecacog | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01082406 |
| Insulin detemir and pre-meal insulin aspart. | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00998335 |
| Long-acting bedtime insulin detemir (Levemir) | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00998335 |
| Neutral drinking-water | Other | Approved | Healthy Participants | COMPLETED | NCT02917616 |
| Alkaline drinking-water | Other | Approved | Healthy Participants | COMPLETED | NCT02917616 |
| Neutral drinking-water | Other | Approved | Healthy Participants | COMPLETED | NCT02917616 |
| Alkaline drinking-water | Other | Approved | Healthy Participants | COMPLETED | NCT02917616 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01900834 |
| insulin human | Other | Preclinical | Diabetes | COMPLETED | NCT01492205 |
| Marketed low dose hormone replacement therapy | Drug | Preclinical | Menopause | COMPLETED | NCT01487304 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01545791 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01464099 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01565733 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01516242 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01992588 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01992588 |
| NordiFlex PenMate™ | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01500486 |
| placebo | Other | Phase PHASE1 | Haemostasis | TERMINATED | NCT01561950 |
| clopidogrel | Other | Phase PHASE1 | Haemostasis | TERMINATED | NCT01561950 |
| eptacog alfa (activated) | Other | Phase PHASE1 | Haemostasis | TERMINATED | NCT01561950 |
| eptacog alfa (activated) | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01561924 |
| placebo | Other | Phase PHASE1 | Haemostasis | COMPLETED | NCT01603342 |
| clopidogrel | Other | Phase PHASE1 | Haemostasis | COMPLETED | NCT01603342 |
| placebo | Other | Phase PHASE1 | Haemostasis | COMPLETED | NCT01561937 |
| eptacog alfa (activated) | Other | Phase PHASE1 | Haemostasis | COMPLETED | NCT01561937 |
| warfarin | Other | Phase PHASE1 | Haemostasis | COMPLETED | NCT01561937 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01045707 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01045707 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02207348 |
| biphasic human insulin 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01492166 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01704417 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01704417 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01212133 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02557620 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02557620 |
| biphasic human insulin 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01707160 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01707160 |
| insulin NPH | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01707134 |
| human soluble insulin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01707134 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01707134 |
| biphasic human insulin 30 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01697618 |
| biphasic insulin aspart 30 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01697618 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01520831 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01520831 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01520831 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01520831 |
| biphasic human insulin 30 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01520818 |
| biphasic insulin aspart 70 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01520818 |
| biphasic insulin aspart 50 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01520818 |
| biphasic insulin aspart 50 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01520753 |
| biphasic insulin aspart 70 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01520753 |
| biphasic human insulin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01467323 |
| biphasic insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01467323 |
| No treatment given | Drug | Preclinical | Growth Hormone Disorder | COMPLETED | NCT02005198 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620424 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620424 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620333 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620333 |
| biphasic human insulin 30 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01526980 |
| biphasic insulin aspart 70 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01526980 |
| biphasic insulin aspart 30 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01526980 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01526941 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01526941 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01524809 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01524809 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01548235 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01536600 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01536028 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01536028 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01536028 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01536028 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01527656 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01487811 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01487798 |
| biphasic human insulin 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01487798 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01486875 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01682902 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01682902 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01536639 |
| placebo | Other | Phase PHASE1 | Acquired Bleeding Disorder | COMPLETED | NCT02239146 |
| catridecacog | Other | Phase PHASE1 | Acquired Bleeding Disorder | COMPLETED | NCT02239146 |
| placebo | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01847989 |
| catridecacog | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01847989 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01601613 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01601613 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01562158 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01562158 |
| standard therapy | Drug | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01562158 |
| Plasma-derived FVII conc. (pdFVII PFL) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Plasma-derived FVII conc. (pdFVII Baxter) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Prothrombin Complex conc. (PCC) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Plasma-derived FVII (LFB) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Fresh frozen plasma (Source unspecified) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| activated recombinant human factor VII | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01566786 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01566786 |
| activated recombinant human factor VII | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01562587 |
| placebo | Other | Phase PHASE3 | Acquired Bleeding Disorder | COMPLETED | NCT01562574 |
| activated recombinant human factor VII | Other | Phase PHASE3 | Acquired Bleeding Disorder | COMPLETED | NCT01562574 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Other Haemostasis Disorder | COMPLETED | NCT01561352 |
| survey | Other | Preclinical | Diabetes | COMPLETED | NCT01950637 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01950637 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01601457 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01601457 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01563523 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01563523 |
| placebo | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01563471 |
| activated recombinant human factor VII | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01563471 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01563458 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01563458 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01563445 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01563445 |
| placebo | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01562821 |
| activated recombinant human factor VII | Other | Phase PHASE2 | Acquired Bleeding Disorder | COMPLETED | NCT01562821 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01068652 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01068652 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01068652 |
| insulin detemir | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01068652 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02131246 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02131246 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02033239 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02033239 |
| No treatment given | Drug | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01988532 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01924637 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01924637 |
| somatropin | Other | Phase PHASE4 | Foetal Growth Problem | COMPLETED | NCT01697644 |
| somatropin | Other | Phase PHASE3 | Genetic Disorder | COMPLETED | NCT01529840 |
| oestrogen | Other | Phase PHASE4 | Genetic Disorder | COMPLETED | NCT01518062 |
| somatropin | Other | Phase PHASE4 | Genetic Disorder | COMPLETED | NCT01518062 |
| No treatment given | Drug | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01503567 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01121276 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01121276 |
| insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01628341 |
| activated recombinant human factor VII | Other | Phase PHASE1 | Acquired Bleeding Disorder | COMPLETED | NCT01561417 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01507116 |
| insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01493388 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01437072 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01351922 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01435642 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01154881 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01151072 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01135927 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01135927 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01030926 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01030926 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01006057 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01002768 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01002768 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00976326 |
| glucose clamp | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01780272 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01076634 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01043510 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01043510 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620463 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620463 |
| glimepiride | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01509755 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01509755 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01509755 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01508923 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01508923 |
| levonorgestrel / ethinylestradiol | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01508858 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01508858 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01508858 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01508806 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507337 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507311 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507311 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507272 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507272 |
| somatropin | Other | Phase PHASE1 | Chronic Kidney Disease | COMPLETED | NCT01502137 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620476 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620476 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01615978 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01615978 |
| digoxin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| griseofulvin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| lisinopril | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| atorvastatin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| electrocardiogram (ECG) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01516255 |
| moxifloxacin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01516255 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01516255 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01516255 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01515592 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01515592 |
| glimepiride | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511692 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511692 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511692 |
| glimepiride | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01511172 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01511172 |
| metformin | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01511172 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01511172 |
| liraglutide [3H] | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01517568 |
| paracetamol | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01517555 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01517555 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01517555 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01513525 |
| metformin | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01511198 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01511198 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511185 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01511185 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01288326 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00993304 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00993304 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01697657 |
| insulin NPH | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01697657 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01697657 |
| insulin NPH | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01542450 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01542450 |
| insulin NPH | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497600 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497600 |
| insulin NPH | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497561 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497561 |
| human soluble insulin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01486940 |
| insulin NPH | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01486940 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01486940 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01486940 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497574 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497574 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01548248 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01548248 |
| human soluble insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01542489 |
| insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT01542489 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01542489 |
| insulin detemir | Other | Preclinical | Diabetes | COMPLETED | NCT01542424 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01542424 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497587 |
| placebo | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01647451 |
| NNC0114-0006 | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01647451 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01565408 |
| NNC0114-0006 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01565408 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01536665 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01536665 |
| estradiol, 25 mcg | Other | Preclinical | Menopause | COMPLETED | NCT01507454 |
| estradiol, 25 mcg | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01486979 |
| estradiol, 10 mcg | Other | Phase PHASE1 | Menopause | COMPLETED | NCT01486979 |
| Microgyn® | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01324505 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01324505 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01324505 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01208506 |
| NNC0114-0000-0005 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01208506 |
| NovoPen Echo® | Other | Preclinical | Diabetes | COMPLETED | NCT01180530 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00983021 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00983021 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00983021 |
| insulin degludec/liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00983021 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT02151409 |
| NNC 0151-0000-0000 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT02151409 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02098395 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02098395 |
| lixisenatide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01973231 |
| liraglutide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01973231 |
| placebo | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01282255 |
| NNC109-0012 | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01282255 |
| placebo | Other | Phase PHASE1 | Inflammation | TERMINATED | NCT01261767 |
| anti-IL-20 | Other | Phase PHASE1 | Inflammation | TERMINATED | NCT01261767 |
| placebo | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01223911 |
| NNC 0151-0000-0000 | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01223911 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01079234 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01079234 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01079234 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01038674 |
| anti-IL-20 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01038674 |
| placebo | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01034202 |
| Norditropin® SimpleXx® | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01034202 |
| NNC126-0083 | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01034202 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01006291 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01006291 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00982644 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00982644 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01590836 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01590836 |
| repaglinide and metformin combination tablet | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01490658 |
| metformin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01490658 |
| repaglinide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01490658 |
| repaglinide and metformin combination tablet | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01489644 |
| metformin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01489644 |
| repaglinide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01489644 |
| turoctocog alfa | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01365520 |
| turoctocog alfa | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01238367 |
| turoctocog alfa pegol | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01205724 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01174303 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01174303 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01138488 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01051102 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01051102 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00993096 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT00993096 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01226966 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02089451 |
| insulin detemir | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01165684 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01165684 |
| insulin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01720303 |
| isophane human insulin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01720303 |
| repaglinide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01720303 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01720290 |
| repaglinide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01720290 |
| placebo | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01698931 |
| glyburide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01698931 |
| repaglinide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01698931 |
| glyburide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01605773 |
| repaglinide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01605773 |
| insulin NPH | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01562561 |
| repaglinide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01562561 |
| repaglinide | Other | Preclinical | Diabetes | COMPLETED | NCT01498913 |
| repaglinide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01465152 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01465152 |
| isophane human insulin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01467141 |
| human insulin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01467141 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01467141 |
| No treatment given | Drug | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01322620 |
| biphasic insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01704378 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01697631 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01697631 |
| biphasic human insulin 50 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01650129 |
| biphasic insulin aspart 50 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01650129 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620437 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01618214 |
| eptacog alfa (activated) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01579968 |
| eptacog alfa (activated) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01579955 |
| biphasic insulin aspart 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01536626 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01527643 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01527630 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01527565 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01527552 |
| biphasic insulin aspart 30 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01527539 |
| biphasic insulin aspart 50 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01523041 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01523041 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01519674 |
| sitagliptin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01519674 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01519674 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497535 |
| insulin detemir | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01497535 |
| biphasic insulin aspart 30 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01486381 |
| biphasic human insulin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01467401 |
| biphasic insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01467401 |
| biphasic insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01467375 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01427920 |
| somatropin | Other | Phase PHASE1 | Genetic Disorder | COMPLETED | NCT01401244 |
| catridecacog | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01230021 |
| insulin glargine | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01123980 |
| glimepiride | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01123980 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01123980 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01123980 |
| autocover needle | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01024218 |
| NovoFine® needle 8 mm | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01024218 |
| somatropin | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT01563926 |
| placebo | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01555749 |
| NNC172-2021 | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01555749 |
| somatropin | Other | Preclinical | Genetic Disorder | COMPLETED | NCT01516229 |
| human insulin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01448070 |
| Norditropin NordiFlex® | Other | Phase PHASE4 | Growth Hormone Disorder | COMPLETED | NCT01245374 |
| 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) | Other | Phase PHASE4 | Menopause | COMPLETED | NCT01705249 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01690169 |
| NNC0113-0987 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01690169 |
| somatropin | Other | Phase PHASE3 | Genetic Disorder | COMPLETED | NCT01518036 |
| somatropin | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT01502124 |
| insulin human | Other | Preclinical | Diabetes | COMPLETED | NCT01492959 |
| biphasic human insulin 30 | Other | Preclinical | Diabetes | COMPLETED | NCT01492218 |
| human soluble insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01492153 |
| isophane human insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01492153 |
| biphasic human insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01492153 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01087645 |
| NN9925 (i.v.) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01087645 |
| NN9925 (oral) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01087645 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01809184 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01809184 |
| insulin 287 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01809184 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01796366 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01796366 |
| insulin 338 (GIPET I) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01796366 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01698697 |
| biphasic human insulin 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01620450 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01514487 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01486914 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01334034 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01334034 |
| NNC 0123-0000-0338 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01334034 |
| insulin detemir | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01868542 |
| sodium chloride 0.9% solution | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01680328 |
| 19 injections | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01680328 |
| sitagliptin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01046110 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01046110 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01388361 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01388361 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01388361 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01364428 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01326026 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01076647 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01076647 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01074268 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01074268 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01074268 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01068678 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01068678 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01068665 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01068665 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01570751 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01570751 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01617434 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01617434 |
| sitagliptin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02008682 |
| liraglutide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02008682 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02035371 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02035371 |
| metformin | Other | Phase PHASE4 | Diabetes | TERMINATED | NCT01486966 |
| human soluble insulin | Other | Phase PHASE4 | Diabetes | TERMINATED | NCT01486966 |
| insulin NPH | Other | Phase PHASE4 | Diabetes | TERMINATED | NCT01486966 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | TERMINATED | NCT01486966 |
| insulin detemir | Other | Phase PHASE4 | Diabetes | TERMINATED | NCT01486966 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01365507 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01272193 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01272193 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01045447 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01045447 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00978627 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00978627 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00978627 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01473953 |
| liraglutide-depot | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01473953 |
| placebo | Other | Phase PHASE2 | Diabetes | TERMINATED | NCT01206101 |
| liraglutide | Other | Phase PHASE2 | Diabetes | TERMINATED | NCT01206101 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01059799 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01059799 |
| placebo | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01751152 |
| NNC0114-0006 | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT01751152 |
| atorvastatin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02243098 |
| digoxin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02243098 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02243098 |
| warfarin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02022254 |
| metformin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02022254 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02022254 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02022254 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00982228 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00982228 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00982228 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00972283 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00972283 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT00972283 |
| Insulin Glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01849289 |
| Insulin Degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01849289 |
| somatropin | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01009905 |
| survey | Other | Preclinical | Diabetes | COMPLETED | NCT01950650 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01950650 |
| Dietary regimen | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01232491 |
| Insulin detemir | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01232491 |
| somatropin | Other | Preclinical | Genetic Disorder | COMPLETED | NCT01435629 |
| Placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03144271 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03144271 |
| eptacog alfa (activated) | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01392547 |
| vatreptacog alfa (activated) | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01392547 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02298192 |
| sitagliptin | Other | Preclinical | Diabetes | COMPLETED | NCT02077946 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT02077946 |
| somatropin | Other | Phase PHASE3 | Growth Disorder | COMPLETED | NCT01778023 |
| somapacitan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02962440 |
| Microgynon® | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02845219 |
| SNAC | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02845219 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02845219 |
| eptacog alfa (activated) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01876745 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01589653 |
| Placebo | Other | Phase PHASE2 | Psoriatic Arthritis | WITHDRAWN | NCT02472717 |
| liraglutide | Other | Phase PHASE2 | Psoriatic Arthritis | WITHDRAWN | NCT02472717 |
| NPH insulin | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03220425 |
| Insulin detemir | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03220425 |
| placebo | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT02490787 |
| Concizumab | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT02490787 |
| Epidemiological intervention | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT01117831 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01028404 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01028404 |
| NN1952 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01028404 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | TERMINATED | NCT01044108 |
| '2-0453 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | TERMINATED | NCT01044108 |
| NNC 0070-0002-0453 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | TERMINATED | NCT01044108 |
| turoctocog alfa | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT00984126 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT00978393 |
| nonacog beta pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01333111 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02594033 |
| insulin degludec | Other | Preclinical | Diabetes | COMPLETED | NCT02117622 |
| Insulin Degludec 100 UNT/ML [Tresiba] | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT03244241 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01821846 |
| nonacog beta pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01386528 |
| sulphonylurea | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01917656 |
| metformin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01917656 |
| liraglutide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01917656 |
| insulin degludec/liraglutide | Other | Preclinical | Diabetes | WITHDRAWN | NCT03070704 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01664247 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01664247 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01664247 |
| biphasic insulin aspart 30 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01538511 |
| biphasic insulin aspart 70 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01538511 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01114542 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01114542 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT02647944 |
| Liraglutide | Other | Phase PHASE2 | Obesity | COMPLETED | NCT02647944 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01618162 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01618162 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01999322 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01999322 |
| placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT01557166 |
| liraglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT01557166 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02079870 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02079870 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02612844 |
| NNC0143-0406 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02612844 |
| insulin glargine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02220296 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02220296 |
| Insulin 338 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02220296 |
| Placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02920385 |
| Levothyroxine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02920385 |
| SNAC | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02920385 |
| Semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02920385 |
| turoctocog alfa pegol | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT02920398 |
| oral anti-diabetic drug | Drug | Phase PHASE3 | Diabetes | COMPLETED | NCT01512108 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01512108 |
| Semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03010475 |
| SNAC | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03010475 |
| Rosuvastatin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03010475 |
| Furosemide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03010475 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02210871 |
| placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT01272232 |
| liraglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT01272232 |
| Placebos | Other | Phase PHASE4 | Type 1 Diabetes | COMPLETED | NCT01787916 |
| Liraglutide | Other | Phase PHASE4 | Type 1 Diabetes | COMPLETED | NCT01787916 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02835235 |
| NNC9204-0530 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02835235 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02911870 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02911870 |
| SNAC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02911870 |
| insulin degludec/liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT02754817 |
| glucose clamp | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01789593 |
| Saline | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT01505673 |
| Liraglutide | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT01505673 |
| placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT01272219 |
| liraglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT01272219 |
| catridecacog | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT00978380 |
| Aspart flexible dose | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01101867 |
| Aspart fixed dose | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01101867 |
| Placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02958085 |
| NNC0174-0833 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02958085 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02627287 |
| DV3316 pen-injector | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02627287 |
| FlexPen® | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02627287 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01585506 |
| insulin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01572740 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01572740 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01572740 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01403025 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01336023 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01336023 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01336023 |
| Insulin Aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02938572 |
| NNC0143-0406 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02938572 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02212067 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02212067 |
| insulin degludec/insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT02230618 |
| Liraglutide - Placebo | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT02660047 |
| Liraglutide | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT02660047 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02420262 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02420262 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02420262 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01713530 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01713530 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01713530 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01680341 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT02255266 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02146079 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02146079 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02014259 |
| Cardiac CT | Other | Approved | Diabetes | UNKNOWN | NCT03022344 |
| Cardiac CT | Other | Approved | Diabetes | UNKNOWN | NCT03022344 |
| Cardiac CT | Other | Approved | Diabetes | UNKNOWN | NCT03022344 |
| nonacog beta pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01395810 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02016911 |
| moxifloxacin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02064348 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02064348 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02064348 |
| Indocyanine Green (ICG) | Other | Approved | Secondary Lymphedema | UNKNOWN | NCT03572998 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02717858 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02717858 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02568306 |
| NNC0165-1562 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02568306 |
| Omeprazole | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02249871 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02249871 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02147431 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02147431 |
| BIAsp 30 | Other | Preclinical | Diabetes | COMPLETED | NCT03374774 |
| Placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03444467 |
| Glucagon | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03444467 |
| NNC9204-1513 | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03444467 |
| No treatment given | Drug | Preclinical | Haemophilia A, Haemophilia B, Obesity | COMPLETED | NCT03430154 |
| Placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03015207 |
| NNC0194-0499 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03015207 |
| Placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02941042 |
| NNC9204-1177 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02941042 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02870231 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02870231 |
| NNC9204-0530 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02870231 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02505334 |
| placebo | Other | Phase PHASE2 | Inflammation | TERMINATED | NCT01636843 |
| NNC0109-0012 | Other | Phase PHASE2 | Inflammation | TERMINATED | NCT01636843 |
| placebo | Other | Phase PHASE2 | Inflammation | TERMINATED | NCT01636817 |
| NNC0109-0012 | Other | Phase PHASE2 | Inflammation | TERMINATED | NCT01636817 |
| Diet/exercise | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT02131272 |
| Insulin NPH | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT02131272 |
| Insulin detemir | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT02131272 |
| biphasic insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02648217 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02648217 |
| sitagliptin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02254291 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02254291 |
| N-acetylcysteine | Other | Phase PHASE1 | Drug-Induced Acute Liver Injury | COMPLETED | NCT03679442 |
| Placebo | Other | Phase PHASE4 | Diabetes Complications | COMPLETED | NCT02473809 |
| Liraglutide | Other | Phase PHASE4 | Diabetes Complications | COMPLETED | NCT02473809 |
| placebo | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01907854 |
| sitagliptin | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01907854 |
| liraglutide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01907854 |
| Placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03095807 |
| NNC9204-1706 A | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03095807 |
| insulin | Other | Preclinical | Diabetes | COMPLETED | NCT01484262 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01484262 |
| Pancreatic clamp | Other | Approved | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT02337660 |
| Liver biopsy | Other | Approved | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT02337660 |
| Pancreatic clamp | Other | Approved | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT02337660 |
| Liver biopsy | Other | Approved | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT02337660 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02568280 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02568280 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02003677 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02003677 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01934712 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01934712 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT01696266 |
| insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01618188 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01618188 |
| liraglutide | Other | Preclinical | Diabetes | COMPLETED | NCT01345734 |
| biphasic insulin aspart 30 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01009580 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01009580 |
| biphasic insulin aspart 30 | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01059812 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01059812 |
| Control Group | Other | Approved | Type 1 Diabetes | TERMINATED | NCT02617160 |
| MD-Logic Pump Advisor | Other | Approved | Type 1 Diabetes | TERMINATED | NCT02617160 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02034513 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02034513 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02034513 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01952145 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01952145 |
| exenatide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01676116 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01676116 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01676116 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01392573 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01392573 |
| NN9924 (i.v.) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| NN9924 (s.c.) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| NN9924 (oral) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| No treatment given | Drug | Phase PHASE2 | Congenital Bleeding Disorder | COMPLETED | NCT02541942 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01686945 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01686945 |
| DPP-4 inhibitor | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02207374 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02207374 |
| somatropin | Other | Preclinical | Foetal Growth Problem | COMPLETED | NCT01110928 |
| turoctocog alfa | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT02941354 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01819129 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01819129 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01819129 |
| insulin aspart | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02453685 |
| insulin glargine | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02453685 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02453685 |
| standard antenatal care | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02617693 |
| lifestyle intervention | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02617693 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT02306681 |
| placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02696148 |
| liraglutide | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02696148 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02470039 |
| insulin glargine | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02470039 |
| insulin 338 (GIPET I) | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02470039 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01620489 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01620489 |
| Liraglutide 3 mg placebo | Other | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT02905864 |
| Liraglutide 3 mg (Saxenda) | Other | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT02905864 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01513590 |
| Insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03215498 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03215498 |
| biphasic insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02762578 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02762578 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02877355 |
| insulin glargine | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02536859 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02536859 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT02662114 |
| Extension Study CMS-recommended lifestyle counseling | Other | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Phentermine 15 MG | Other | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Placebo Oral Tablet | Other | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Portion-Controlled Diet | Other | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Liraglutide 3.0mg | Other | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| CMS-recommended lifestyle counseling | Other | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02030600 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02030600 |
| NNC172-2021 | Other | Phase PHASE1 | Congenital Bleeding Disorder | TERMINATED | NCT01631942 |
| placebo | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01228669 |
| NNC 0172-0000-2021 | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01228669 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT03584191 |
| Somapacitan | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT03212131 |
| Insulin Aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02933853 |
| Faster-acting insulin aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02933853 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01437592 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02670915 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02670915 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02670915 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02582242 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02305381 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02305381 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01835431 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01835431 |
| insulin degludec/insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01835431 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02500706 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02500706 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02500706 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01831765 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01831765 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01831765 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02128932 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02128932 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01930188 |
| sitagliptin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01930188 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01930188 |
| exenatide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01885208 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01885208 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01513473 |
| insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01513473 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01513473 |
| Ciclosporin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03466567 |
| Probenecid | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03466567 |
| Semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03466567 |
| Insulin aspart (NovoRapid®) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03407599 |
| Faster aspart | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03407599 |
| Placebo (NNC0174-0833) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03787225 |
| NNC0174-0833 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03787225 |
| Placebo | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03479892 |
| NNC0194-0499 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03479892 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01720446 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01720446 |
| insulin 338 (GIPET I) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02304627 |
| catridecacog | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01862367 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01179048 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01179048 |
| Insulin detemir | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03960814 |
| No treatment given | Drug | Preclinical | Metabolism and Nutrition Disorder | COMPLETED | NCT03235102 |
| No treatment given | Drug | Preclinical | Metabolism and Nutrition Disorder | COMPLETED | NCT03223493 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01959529 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01959529 |
| Metformin XR plus liraglutide | Other | Phase PHASE3 | Gestational Diabetes Mellitus | COMPLETED | NCT01234649 |
| Metformin XR plus placebo | Other | Phase PHASE3 | Gestational Diabetes Mellitus | COMPLETED | NCT01234649 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02461589 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02461589 |
| semaglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02461589 |
| somapacitan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03905850 |
| liraglutide plus insulin detemir | Other | Approved | Type 2 Diabetes | COMPLETED | NCT01232946 |
| insulin detemir | Other | Approved | Type 2 Diabetes | COMPLETED | NCT01232946 |
| liraglutide | Other | Approved | Type 2 Diabetes | COMPLETED | NCT01232946 |
| placebo | Other | Phase PHASE4 | Gestational Diabetes Mellitus | UNKNOWN | NCT02394158 |
| Metformin | Other | Phase PHASE4 | Gestational Diabetes Mellitus | UNKNOWN | NCT02394158 |
| placebo | Other | Phase PHASE4 | Gestational Diabetes Mellitus | UNKNOWN | NCT02394158 |
| Metformin | Other | Phase PHASE4 | Gestational Diabetes Mellitus | UNKNOWN | NCT02394158 |
| Empagliflozin 25 MG | Other | Phase PHASE4 | Type 2 Diabetes With Renal Manifestations | UNKNOWN | NCT04061200 |
| Placebo, 1,34 mg/mL | Other | Phase PHASE4 | Type 2 Diabetes With Renal Manifestations | UNKNOWN | NCT04061200 |
| Semaglutide, 1.34 mg/mL | Other | Phase PHASE4 | Type 2 Diabetes With Renal Manifestations | UNKNOWN | NCT04061200 |
| Semaglutide | Other | Phase PHASE1 | Obesity and Overweight | COMPLETED | NCT03707990 |
| Placebo (NNC0165-1875) | Other | Phase PHASE1 | Obesity and Overweight | COMPLETED | NCT03707990 |
| NNC0165-1875 | Other | Phase PHASE1 | Obesity and Overweight | COMPLETED | NCT03707990 |
| Normal physical activity | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT02982408 |
| Exercise | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT02982408 |
| High carbohydrate overfeeding | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT02982408 |
| No treatment given | Drug | Preclinical | Growth Hormone Deficiency in Children | COMPLETED | NCT03672617 |
| insulin degludec | Other | Preclinical | Diabetes | COMPLETED | NCT02392117 |
| insulin degludec/insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT02821052 |
| Dulaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02648204 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02648204 |
| Placebo (NNC9204-1706) | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03661879 |
| NNC9204-1706 | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03661879 |
| Semaglutide (administered by PDS290 pen) | Other | Phase PHASE1 | Overweight | TERMINATED | NCT04012255 |
| Semaglutide (administered by DV3396 pen) | Other | Phase PHASE1 | Overweight | TERMINATED | NCT04012255 |
| No treatment given | Drug | Preclinical | Diabetes | COMPLETED | NCT02066766 |
| somatropin | Other | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01580605 |
| Semaglutide D 7 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide D 3 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide C 7 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide C 3 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide B 7 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide B 3 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide 7 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide 3 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03292185 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03292185 |
| insulin degludec/liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03292185 |
| other injectable antidiabetic treatment regimens | Drug | Preclinical | Diabetes Mellitus | COMPLETED | NCT01892319 |
| insulin detemir | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT01892319 |
| insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02825251 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02825251 |
| No treatment given | Drug | Preclinical | Haemophilia A | COMPLETED | NCT03660774 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02501161 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02501161 |
| Insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT03674866 |
| Insulin Degludec/Insulin Aspart | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03745157 |
| PDS290 pen-injector | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| DV3372 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Semaglutide, 1.0 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Semaglutide, 0.5 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Semaglutide, 0.25 mg | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| NovoPen®4 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| PDS290 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| DV3372, 1.0 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| DV3372, 0.5 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 2.0 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 1.34 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 1.0 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 0.5 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Synthetic mesh | Other | Approved | Abdominal Donor-site | COMPLETED | NCT02076724 |
| Biological mesh | Other | Approved | Abdominal Donor-site | COMPLETED | NCT02076724 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03136484 |
| Placebo (canagliflozin) | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03136484 |
| Canagliflozin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03136484 |
| Semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03136484 |
| Cocktail of 5 already approved drugs | Drug | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04059367 |
| NNC9204-1177 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04059367 |
| Sitagliptin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02043054 |
| Liraglutide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02043054 |
| turoctocog alfa pegol | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT02994407 |
| Starter Kit Algorithm | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03365180 |
| insulin degludec/insulin aspart | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02844790 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02827708 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02827708 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02249910 |
| digoxin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02249910 |
| metformin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02249910 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02249910 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02070510 |
| warfarin | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02070510 |
| lisinopril | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02070510 |
| semaglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02070510 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03021187 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03021187 |
| CMS Intensive Behavior Therapy | Drug | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02963935 |
| placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02963935 |
| liraglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02963935 |
| Faster aspart 100 U/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723759 |
| Faster Aspart 200 U/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723759 |
| Fast-acting insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT03450863 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03175120 |
| Insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03175120 |
| Placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02963922 |
| Liraglutide 3.0 mg | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02963922 |
| turoctocog alfa | Other | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT03449342 |
| Somapacitan | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT03186495 |
| placebo | Other | Phase PHASE2 | Metabolism and Nutrition Disorder | COMPLETED | NCT02453711 |
| liraglutide | Other | Phase PHASE2 | Metabolism and Nutrition Disorder | COMPLETED | NCT02453711 |
| semaglutide | Other | Phase PHASE2 | Metabolism and Nutrition Disorder | COMPLETED | NCT02453711 |
| insulin degludec | Other | Preclinical | Diabetes | COMPLETED | NCT02779413 |
| Placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02918279 |
| Liraglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02918279 |
| turoctocog alfa | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT02035384 |
| no treatment | Drug | Preclinical | Quality of Life | COMPLETED | NCT02965144 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03811288 |
| Insulin Glargine | Other | Phase PHASE4 | Type2 Diabetes | TERMINATED | NCT03349840 |
| Insulin Degludec U100 | Other | Phase PHASE4 | Type2 Diabetes | TERMINATED | NCT03349840 |
| iLet™ | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03816761 |
| Fast-acting insulin aspart | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03816761 |
| Turoctocog alfa | Other | Phase PHASE3 | Haemophilia A | TERMINATED | NCT03588741 |
| thiazolidinediones | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| sulphonylurea | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| SGLT-2 inhibitors | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| meglitinides | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| DPP-4 inhibitors | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| alpha-glucosidase inhibitors | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| liraglutide | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| somatropin | Other | Phase PHASE3 | Adult Growth Hormone Deficiency | COMPLETED | NCT02382939 |
| somapacitan | Other | Phase PHASE3 | Adult Growth Hormone Deficiency | COMPLETED | NCT02382939 |
| BIAsp 30 | Other | Preclinical | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT03862690 |
| NNC0090-2746 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02205528 |
| Placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02205528 |
| Metformin | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02205528 |
| Liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02205528 |
| turoctocog alfa | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT02938585 |
| Semaglutide (administered by PDS290 pen) | Other | Phase PHASE2 | Healthy Volunteers Diabetes Mellitus, Type 2 | COMPLETED | NCT04007107 |
| Semaglutide (administered by DV3396 pen) | Other | Phase PHASE2 | Healthy Volunteers Diabetes Mellitus, Type 2 | COMPLETED | NCT04007107 |
| insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT01984372 |
| turoctocog alfa pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01489111 |
| insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02773368 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02773368 |
| No treatment given | Drug | Preclinical | Growth Disorder | COMPLETED | NCT02580032 |
| Needs assesment tool integrated in nursing consultation. | Other | Approved | Head and Neck Neoplasms | COMPLETED | NCT03443258 |
| Placebo | Other | Phase PHASE4 | Gestational Diabetes Mellitus | COMPLETED | NCT01795248 |
| Liraglutide | Other | Phase PHASE4 | Gestational Diabetes Mellitus | COMPLETED | NCT01795248 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02964247 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02964247 |
| Semaglutide (administered by PDS290 pen-injector) | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04238962 |
| Semaglutide (administered by DV3396 pen-injector) | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04238962 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03797885 |
| Norditropin | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT03075644 |
| somapacitan | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT03075644 |
| placebo | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT02229851 |
| somatropin | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT02229851 |
| somapacitan | Other | Phase PHASE3 | Growth Hormone Disorder | COMPLETED | NCT02229851 |
| turoctocog alfa pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01731600 |
| turoctocog alfa pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01480180 |
| Placebo | Other | Phase PHASE3 | Binge-Eating Disorder | TERMINATED | NCT03279731 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml | Other | Phase PHASE3 | Binge-Eating Disorder | TERMINATED | NCT03279731 |
| Cross-over study | Other | Approved | T2D | COMPLETED | NCT04011904 |
| turoctocog alfa | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01493778 |
| Placebo | Other | Phase PHASE1 | Overweight | COMPLETED | NCT03842202 |
| Semaglutide | Other | Phase PHASE1 | Overweight | COMPLETED | NCT03842202 |
| Norditropin NordiFlex® | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01706783 |
| somapacitan | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01706783 |
| placebo (somapacitan) | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01514500 |
| somapacitan | Other | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01514500 |
| 3D-Transit after Malone appendicostomy | Other | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| 3D-Transit during treatment with Pyridostigmine | Drug | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| 3D-Transit | Other | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| 11C Donepezil PET/CT scan | Other | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| insulin glargine | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03965013 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03965013 |
| NNC0268-0965 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03965013 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT02655770 |
| Liraglutide | Other | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT02655770 |
| Liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03018028 |
| Placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03018028 |
| Semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03018028 |
| oral placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01923181 |
| semaglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01923181 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03876015 |
| Semaglutide (administered by PDS290 pen) | Other | Phase PHASE2 | Healthy Volunteers Diabetes Mellitus, Type 2 | COMPLETED | NCT04143945 |
| Semaglutide (administered by DV3396 pen) | Other | Phase PHASE2 | Healthy Volunteers Diabetes Mellitus, Type 2 | COMPLETED | NCT04143945 |
| Together on Diabetes | Other | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT04722289 |
| NNC0174-0833 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04209049 |
| Standard of care | Other | Preclinical | Severe Postpartum Haemorrhage | COMPLETED | NCT04444856 |
| Eptacog alfa (activated) | Other | Preclinical | Severe Postpartum Haemorrhage | COMPLETED | NCT04444856 |
| Forxiga | Other | Phase PHASE4 | Nephropathy | COMPLETED | NCT04193566 |
| Oral semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04109508 |
| Promestriene Vaginal | Other | Phase PHASE3 | Vulvovaginal Atrophy | COMPLETED | NCT04232813 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] | Other | Phase PHASE3 | Vulvovaginal Atrophy | COMPLETED | NCT04232813 |
| Placebo (semaglutide 1.0 mg) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Semaglutide 1.0 mg | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Placebo (semaglutide 0.5 mg) | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Semaglutide 0.5 mg | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Aspart | Other | Phase PHASE4 | Type1 Diabetes Mellitus | COMPLETED | NCT04409587 |
| placebo | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT02889510 |
| liraglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT02889510 |
| Semaglutide placebo 1.0 mg | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Semaglutide placebo 0.5 mg | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Sitagliptin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Sitagliptin placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Semaglutide 1.0 mg | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Semaglutide 0.5 mg | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Dulaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03015220 |
| Semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03015220 |
| Insulin glargine U100 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03766854 |
| insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03766854 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02148861 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02148861 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02148861 |
| Exercise | Other | Approved | Physical Exercise Behavior (Liking/Aversion) | COMPLETED | NCT02615756 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes | WITHDRAWN | NCT04057261 |
| Liraglutide Pen Injector [Victoza] | Other | Phase PHASE3 | Type 2 Diabetes | WITHDRAWN | NCT04057261 |
| Placebo (insulin glargine) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Insulin glargine | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Dipeptidyl peptidase-4 inhibitors | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Metformin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Placebo (insulin 287) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Insulin icodec | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Insulin Glargine | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03951805 |
| Insulin icodec | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03951805 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02911948 |
| Insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02911948 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02607306 |
| insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02607306 |
| insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02607306 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02443155 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02443155 |
| NNC0114-0006 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT02443155 |
| Insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03785522 |
| Placebo Liraglutide Pen Injector | Other | Phase PHASE3 | Pre Diabetes | COMPLETED | NCT03480022 |
| Liraglutide Pen Injector [Saxenda] | Other | Phase PHASE3 | Pre Diabetes | COMPLETED | NCT03480022 |
| Placebo | Other | Phase PHASE2 | Anorexia Nervosa | COMPLETED | NCT01626833 |
| SOMATROPINE* : Norditropine® simplexx® | Other | Phase PHASE2 | Anorexia Nervosa | COMPLETED | NCT01626833 |
| Aerobic exercise training | Other | Approved | Diabetes Mellitus, Type 2 | UNKNOWN | NCT04945551 |
| Placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03086330 |
| Semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03086330 |
| Low carbohydrate diet high in monounsaturated fats | Other | Approved | Type2 Diabetes | COMPLETED | NCT03068078 |
| metformin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01541215 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01541215 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT01541215 |
| Liraglutide | Other | Preclinical | Obesity | COMPLETED | NCT03560336 |
| Liraglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03888157 |
| Cilofexor | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03987074 |
| Firsocostat | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03987074 |
| Semaglutide | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03987074 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03631186 |
| Placebo | Other | Phase PHASE1 | Anemia | COMPLETED | NCT02868229 |
| COR-001 | Other | Phase PHASE1 | Anemia | COMPLETED | NCT02868229 |
| Liraglutide treatment | Drug | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02138045 |
| Placebo treatment | Drug | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02138045 |
| insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04315688 |
| insulin degludec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02964104 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02964104 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT02964104 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03457012 |
| Insulin degludec/liraglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03823339 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04067999 |
| Ryzodeg® | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04656106 |
| Trial product 12 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 10 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 9 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 8 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 7 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 6 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 5 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 4 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 3 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 2 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 1 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Eptacog alfa | Other | Phase PHASE2 | Congenital Bleeding Disorder | COMPLETED | NCT03196284 |
| Concizumab | Other | Phase PHASE2 | Congenital Bleeding Disorder | COMPLETED | NCT03196284 |
| Placebo (ziltivekimab) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Glargine + OADs | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01919489 |
| Liraglutide + OADs | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01919489 |
| Placebo II (Semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Placebo I (Semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Semaglutide 2.4 mg | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Semaglutide 1.0 mg | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04152915 |
| Insulin degludec /insulin aspart | Other | Preclinical | Diabetes | COMPLETED | NCT03416855 |
| Semaglutide | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04187300 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03611582 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03611582 |
| turoctocog alfa | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT03179748 |
| turoctocog alfa | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT02207218 |
| Turoctocog alfa | Other | Phase PHASE2 | Haemostasis | COMPLETED | NCT03196297 |
| Concizumab | Other | Phase PHASE2 | Haemostasis | COMPLETED | NCT03196297 |
| Placebo | Other | Phase PHASE2 | Hepatobiliary Disorders | COMPLETED | NCT02970942 |
| Semaglutide | Other | Phase PHASE2 | Hepatobiliary Disorders | COMPLETED | NCT02970942 |
| Placebo (NNC0174-0833) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03600480 |
| Semaglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03600480 |
| NNC0174-0833 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT03600480 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT03548935 |
| Semaglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT03548935 |
| Placebo | Other | Phase PHASE1 | Hepatobiliary Disorders | COMPLETED | NCT03357380 |
| Semaglutide | Other | Phase PHASE1 | Hepatobiliary Disorders | COMPLETED | NCT03357380 |
| No treatment given | Drug | Preclinical | Haemophilia A | COMPLETED | NCT03741881 |
| Detemir | Other | Approved | Diabetes | COMPLETED | NCT01186003 |
| PLACEBO | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03308721 |
| NNC9204-1177 A 1.0 mg/mL | Other | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03308721 |
| Placebo (NNC0385-0434) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04058834 |
| NNC0385-0434 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04058834 |
| Semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04228354 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04074174 |
| Oral contraceptive (OC) tablets | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04074174 |
| NNC0174-0833 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04074174 |
| Metformin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03268005 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03268005 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03268005 |
| Faster-acting insulin aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03268005 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03078478 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03078478 |
| Insulin glargine U100 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03922750 |
| Insulin icodec | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03922750 |
| Placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT03548987 |
| Semaglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT03548987 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05013359 |
| Beetroot Juice | Other | Approved | Preeclampsia | UNKNOWN | NCT05241327 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03811574 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03811574 |
| Aspart | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03336528 |
| Glargine | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03336528 |
| Degludec | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03336528 |
| Placebo (NNC0194-0499 ) | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT04722653 |
| NNC0194-0499 | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT04722653 |
| Clinical and demographic data | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Blood samples | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Dual Energy X-ray Absorptiometry (DEXA) scan | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Intra venous glucose infusion (IIGI) | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Oral glucose tolerance test (OGTT) | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Continuous glucose monitoring (CGM) for four days. | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Fibroscan of the liver | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| MR spectroscopy of the liver | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Clinical and demographic data | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Blood samples | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Dual Energy X-ray Absorptiometry (DEXA) scan | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Intra venous glucose infusion (IIGI) | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Oral glucose tolerance test (OGTT) | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Continuous glucose monitoring (CGM) for four days. | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Fibroscan of the liver | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| MR spectroscopy of the liver | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Standard of care | Other | Preclinical | Post Partum Hemorrhage | COMPLETED | NCT04723979 |
| Eptacog alfa | Other | Preclinical | Post Partum Hemorrhage | COMPLETED | NCT04723979 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02415556 |
| Regular Human Insulin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02415556 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05250427 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT03523273 |
| Liraglutide | Other | Phase PHASE2 | Obesity | COMPLETED | NCT03523273 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02906930 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02906930 |
| placebo | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02863419 |
| liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02863419 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02863419 |
| empagliflozin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02863328 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02863328 |
| sitagliptin | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02849080 |
| semaglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT02849080 |
| BPD-DS as a revisional procedure | Procedure | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| SADI-S as a revisional procedure | Procedure | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Biliopancreatic diversion with duodenal switch | Other | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Single anastomosis duodeno-ileal bypass | Other | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| BPD-DS as a revisional procedure | Procedure | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| SADI-S as a revisional procedure | Procedure | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Biliopancreatic diversion with duodenal switch | Other | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Single anastomosis duodeno-ileal bypass | Other | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Insulin aspart (standard of care insulin) + closed loop device | Device | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT03579615 |
| FIASP + closed loop device | Device | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT03579615 |
| SOS-PD | Other | Preclinical | Pediatric Delirium | COMPLETED | NCT04774211 |
| Omics markers | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| Cytokeratin 18 | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| LiverTRAIL | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| Direct serum markers of liver fibrosis | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| Indirect serum markers of liver fibrosis | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| Enhanced liver fibrosis test | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| transient elastography | Other | Approved | Liver Diseases, Alcoholic | RECRUITING | NCT03308916 |
| insulin glargine | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04136067 |
| NNC0268-0965 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04136067 |
| Oral semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04097600 |
| Placebo (NNC0472-0147) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04262661 |
| insulin glargine | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04262661 |
| NNC0472-0147 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04262661 |
| Oral Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT05473286 |
| Standardised meals | Other | Approved | Type 2 Diabetes | COMPLETED | NCT01053234 |
| somatropin | Other | Preclinical | Growth Disorder | COMPLETED | NCT01578135 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05232786 |
| IDegLira | Other | Preclinical | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT05479591 |
| Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization | Other | Preclinical | Heart Failure With Reduced Ejection Fraction | UNKNOWN | NCT05299879 |
| Insulin detemir | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05134987 |
| NNC0363-0845 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05134987 |
| Dulaglutide | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT04189848 |
| Semaglutide | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT04189848 |
| Physical activity | Other | Approved | Intellectual Disability | UNKNOWN | NCT05336487 |
| IDegLira | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05324462 |
| Empagliflozin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT05444153 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT05444153 |
| Insulin Degludec/Insulin Aspart | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04892069 |
| Medication for chronic weight management (Rx) | Drug | Phase PHASE4 | Obesity | COMPLETED | NCT03799198 |
| Weight Management Program (WMP) | Other | Phase PHASE4 | Obesity | COMPLETED | NCT03799198 |
| Insulin glargine U100 | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03689374 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03689374 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03689374 |
| Somatropin | Other | Preclinical | Genetic Disorder | COMPLETED | NCT03435627 |
| Saxenda® | Other | Preclinical | Obesity or Overweight | COMPLETED | NCT05153590 |
| Continuous Glucose Monitor (CGM) alone | Other | Approved | Type1 Diabetes Mellitus | COMPLETED | NCT03093636 |
| Continuous Glucose Monitor (CGM)+Decision Support System (DSS) | Other | Approved | Type1 Diabetes Mellitus | COMPLETED | NCT03093636 |
| Liraglutide | Other | Preclinical | Obesity | COMPLETED | NCT03479762 |
| Placebo | Other | Phase PHASE4 | Obesity | COMPLETED | NCT03048578 |
| Saxenda | Other | Phase PHASE4 | Obesity | COMPLETED | NCT03048578 |
| Liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03172494 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03172494 |
| Insulin degludec/liraglutide | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03172494 |
| Turoctocog alfa pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT03528551 |
| Non-Vagifem® LDVE, Estradiol | Other | Preclinical | Postmenopausal Vaginal Atrophy | COMPLETED | NCT05243823 |
| Vagifem® | Other | Preclinical | Postmenopausal Vaginal Atrophy | COMPLETED | NCT05243823 |
| Fast-acting insulin aspart | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04655690 |
| NNC0471-0119 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04655690 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04582448 |
| semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03929679 |
| Insulin detemir | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03377699 |
| Insulin Aspart | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03377699 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes | COMPLETED | NCT03377699 |
| liraglutide | Other | Preclinical | Metabolism and Nutrition Disorder | COMPLETED | NCT02967757 |
| Liraglutide | Other | Preclinical | Obesity | WITHDRAWN | NCT05438186 |
| Biopsy | Other | Preclinical | Diabetes | UNKNOWN | NCT05209061 |
| Biopsy | Other | Preclinical | Diabetes | UNKNOWN | NCT05209061 |
| Biopsy | Other | Preclinical | Diabetes | UNKNOWN | NCT05195502 |
| Biopsy | Other | Preclinical | Diabetes | UNKNOWN | NCT05195502 |
| Placebo | Other | Phase PHASE2 | TBI (Traumatic Brain Injury) | RECRUITING | NCT04121780 |
| Growth Hormone | Other | Phase PHASE2 | TBI (Traumatic Brain Injury) | RECRUITING | NCT04121780 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03989232 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03989232 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05468632 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04094415 |
| Standard heart failure medical therapy | Drug | Phase PHASE4 | Advanced Heart Failure | UNKNOWN | NCT05284955 |
| CardioMEMS HF System | Other | Phase PHASE4 | Advanced Heart Failure | UNKNOWN | NCT05284955 |
| semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04261933 |
| semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04083820 |
| Omron Walking Style pro. 20 | Other | Approved | Colorectal Cancer | COMPLETED | NCT02522520 |
| Pedometer + hospital based intervention | Other | Approved | Colorectal Cancer | COMPLETED | NCT02522520 |
| Pedometer intervention | Other | Approved | Colorectal Cancer | COMPLETED | NCT02522520 |
| NNC0113-6891 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04676906 |
| NNC0113-6860 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04676906 |
| NNC0113-6861 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04676906 |
| Nutritional Psycho-Behavioral Reeducation Program | Other | Preclinical | Overweight and Obesity | NOT_YET_RECRUITING | NCT05857319 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05736120 |
| Primed tracer infusion | Other | Approved | Chronic Kidney Diseases | COMPLETED | NCT05056584 |
| Glucagon infusion | Other | Approved | Chronic Kidney Diseases | COMPLETED | NCT05056584 |
| Primed tracer infusion | Other | Approved | Chronic Kidney Diseases | COMPLETED | NCT05056584 |
| Glucagon infusion | Other | Approved | Chronic Kidney Diseases | COMPLETED | NCT05056584 |
| Oral Semaglutide | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT04513704 |
| No treatment given | Drug | Preclinical | Type 2 Diabetes | COMPLETED | NCT05737810 |
| Placebo (Semaglutide) | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT04878406 |
| Semaglutide | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT04878406 |
| Placebo (NNC0480-0389) | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT04878406 |
| NNC0480-0389 | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT04878406 |
| insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04857398 |
| Vira mobile app intervention + coaching | Other | Approved | Mental Health Disorder | COMPLETED | NCT05638516 |
| Vira mobile app intervention | Other | Approved | Mental Health Disorder | COMPLETED | NCT05638516 |
| Placebo (liraglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04074161 |
| Liraglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04074161 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04074161 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04074161 |
| Heparin | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT05178550 |
| Fresh organic vegetables | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT04938388 |
| Semaglutide Pill | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT04938388 |
| ALPROLIX® | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT03075670 |
| N9-GP | Other | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT03075670 |
| No treatment given | Drug | Preclinical | Atherosclerotic Cardiovascular Disease (ASCVD) | COMPLETED | NCT05755373 |
| No treatment given | Drug | Preclinical | Diabetes | ENROLLING_BY_INVITATION | NCT01511393 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05690789 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03786406 |
| Insulin degludec | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04569994 |
| Placebo (NNC0363-0845) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04569994 |
| NNC0363-0845 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04569994 |
| NNC0480-0389 A 10 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| Semaglutide 1.34 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| semaglutide 1.34 mg/mL (placebo) | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| Placebo (Semaglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03693430 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03693430 |
| placebo | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02527200 |
| liraglutide | Other | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02527200 |
| Chronic care multidisciplinary intervention of childhood obesity | Other | Preclinical | Childhood Obesity | COMPLETED | NCT00823277 |
| FT-7051 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04575766 |
| somatropin | Other | Phase PHASE3 | Genetic Disorder | COMPLETED | NCT01529944 |
| Insulin glargine | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03945656 |
| insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03945656 |
| Insulin Aspart | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT03737240 |
| Insulin Degludec (U-100) | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT03737240 |
| IDegLira | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT03737240 |
| Insulin Icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04582435 |
| Smoking Cessation Counseling | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03712098 |
| Placebo | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03712098 |
| Liraglutide | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03712098 |
| Oral semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04524832 |
| No treatment given | Drug | Preclinical | Non-alcoholic Steatohepatitis (MASH) | COMPLETED | NCT05765890 |
| NO intervention - observational study | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT04304963 |
| Faster aspart | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| NNC0471-0119 D | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| NNC0471-0119 B | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| NNC0471-0119 A | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| Lifestyle Therapy | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT03862716 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT03862716 |
| insulin degludec | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT03862716 |
| IDegLira | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT03862716 |
| Mim8 B, placebo | Other | Phase PHASE1 | Healthy Volunteers - Haemophilia A | COMPLETED | NCT05127473 |
| Mim8 B, 100 mg/mL | Other | Phase PHASE1 | Healthy Volunteers - Haemophilia A | COMPLETED | NCT05127473 |
| Mim8 B, 10 mg/mL | Other | Phase PHASE1 | Healthy Volunteers - Haemophilia A | COMPLETED | NCT05127473 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01508949 |
| liraglutide | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01508949 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507285 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01507285 |
| biphasic insulin aspart 30 | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT01486862 |
| NNC0174 0833 | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05254158 |
| Microgynon® | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| NNC0480-0389 30 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| NNC0480-0389 10 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| Semaglutide 3.0 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| Semaglutide 1.34 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| NNC0480-0389 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05015894 |
| Placebo (semaglutide) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04259801 |
| Placebo (NNC0480-0389) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04259801 |
| Semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04259801 |
| NNC0480-0389 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04259801 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT04624672 |
| Semaglutide (1 Mg Dose) | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT04624672 |
| Lee Symptom Scala | Other | Approved | GVHD, Chronic | COMPLETED | NCT04884204 |
| Turoctocog alfa | Other | Preclinical | Haemophilia A | COMPLETED | NCT04584892 |
| Sooma Oy (Sham), Helsinki, Finland | Other | Approved | Diabetic Neuropathy, Painful | UNKNOWN | NCT06152887 |
| Sooma Oy (tDCS), Helsinki, Finland | Other | Approved | Diabetic Neuropathy, Painful | UNKNOWN | NCT06152887 |
| Placebo | Other | Approved | Obesity | COMPLETED | NCT03795701 |
| Saxenda® | Other | Approved | Obesity | COMPLETED | NCT03795701 |
| NNC0194-0499 | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05727644 |
| FIT FIRST | Other | Approved | Primary Prevention | UNKNOWN | NCT06180772 |
| Semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05498610 |
| NNC0480 0389 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05498610 |
| NNC0385-0434 A 100 mg | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT05094934 |
| NNC0385-0434 | Other | Phase PHASE1 | Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk | COMPLETED | NCT05091073 |
| eptacog alfa (activated) | Other | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01830712 |
| factor VIII | Other | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT01561391 |
| factor IX | Other | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT01561391 |
| activated recombinant human factor VII | Other | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT01561391 |
| Rybelsus® | Other | Preclinical | Diabetes Mellitus, Type 2 | UNKNOWN | NCT04572165 |
| Active Comparator | Other | Preclinical | Diabetes Mellitus, Type 2 | UNKNOWN | NCT04572165 |
| Ozempic® | Other | Preclinical | Diabetes Mellitus, Type 2 | UNKNOWN | NCT04572165 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01508897 |
| Placebo | Other | Phase PHASE3 | Type 1 Diabetes | COMPLETED | NCT01722266 |
| Liraglutide | Other | Phase PHASE3 | Type 1 Diabetes | COMPLETED | NCT01722266 |
| Placebo (insulin glargine) | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| Placebo (NNC0268-0965) | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| Insulin glargine | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| NNC0268-0965 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05716724 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05003440 |
| NNC0385-0434 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05003440 |
| Placebo (NNC0247-0829) | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04010786 |
| NNC0247-0829 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT04010786 |
| Semaglutide D, 1.0 mg/mL | Other | Phase PHASE1 | Healthy Volunteers (Diabetes Mellitus, Type 2) | COMPLETED | NCT05232708 |
| Semaglutide B, 1.34 mg/mL | Other | Phase PHASE1 | Healthy Volunteers (Diabetes Mellitus, Type 2) | COMPLETED | NCT05232708 |
| Telemonitoring | Other | Approved | Type 2 Diabetes Treated With Insulin | COMPLETED | NCT04981808 |
| basal insulin | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| GLP-1 receptor agonist | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| basal insulin | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| GLP-1 receptor agonist | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| basal insulin | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| GLP-1 receptor agonist | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| Adhera® Caring digital intervention for Type 1 Diabetes | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT05483803 |
| School-based extracurricular intervention focusing on screen media use and time spent with friends | Other | Approved | Screen Media Use | COMPLETED | NCT05480085 |
| placebo | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01509742 |
| liraglutide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT01509742 |
| No treatment is given | Drug | Preclinical | Overweight | COMPLETED | NCT06260696 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT06083675 |
| Empagliflozin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT06083675 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT06083675 |
| placebo | Other | Phase PHASE4 | Growth Hormone Disorder | COMPLETED | NCT01562834 |
| somatropin | Other | Phase PHASE4 | Growth Hormone Disorder | COMPLETED | NCT01562834 |
| NNC0194-0499/Semaglutide A (40/0.33mg/mL) | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05766709 |
| NNC0194-0499/Semaglutide A (40/3.20 mg/mL) | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05766709 |
| Semaglutide | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05766709 |
| NNC0194-0499 | Other | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05766709 |
| Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT02953665 |
| Liraglutide | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT02953665 |
| Insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04227431 |
| Insulin degludec and liraglutide (IDegLira) | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04666987 |
| Control group | Other | Approved | Postoperative Pain, Acute | RECRUITING | NCT06222151 |
| Intervention 2: Mobilization the first 4 postoperative weeks | Other | Approved | Postoperative Pain, Acute | RECRUITING | NCT06222151 |
| Intervention 1: Mobilization during hospitalization | Other | Approved | Postoperative Pain, Acute | RECRUITING | NCT06222151 |
| Placebo oral tablet | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05441267 |
| Semaglutide Oral Tablet | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05441267 |
| Amino acid bolus infusion | Other | Approved | Healthy | COMPLETED | NCT05954923 |
| Amino acid bolus infusion | Other | Approved | Healthy | COMPLETED | NCT05954923 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE2 | Primary Hyperoxaluria Type 1 (PH1) | COMPLETED | NCT03847909 |
| DCR-PHXC | Other | Phase PHASE2 | Primary Hyperoxaluria Type 1 (PH1) | COMPLETED | NCT03847909 |
| NNC0385-0434 E | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| NNC0385-0434 D | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| NNC0385-0434 C | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| NNC0385-0434 B | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide I | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide H | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide G | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide D | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Placebo (semaglutide) | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT03987451 |
| Semaglutide | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT03987451 |
| Live music in the intensive care unit | Other | Approved | Stress | NOT_YET_RECRUITING | NCT06442644 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05780905 |
| Semaglutide Auto-Injector | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05780905 |
| Placebo | Other | Phase PHASE2 | Intestinal Mucositis | NOT_YET_RECRUITING | NCT06449625 |
| Semaglutide Pen Injector [Ozempic] | Other | Phase PHASE2 | Intestinal Mucositis | NOT_YET_RECRUITING | NCT06449625 |
| NC0194-0499 | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT05742919 |
| NNC0194-0499 | Other | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT05742919 |
| Ryzodeg® | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05221580 |
| Standard of care | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03596450 |
| Semaglutide | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03596450 |
| Placebo (Liraglutide 3.0 mg) | Other | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| Liraglutide 3.0 mg | Other | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| Placebo (NNC0174-0833) | Other | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| NNC0174-0833 | Other | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05873660 |
| Placebo | Other | Phase PHASE1 | Primary Hyperoxaluria Type 1 | TERMINATED | NCT02795325 |
| DCR-PH1 | Other | Phase PHASE1 | Primary Hyperoxaluria Type 1 | TERMINATED | NCT02795325 |
| Placebo | Other | Phase PHASE1 | Primary Hyperoxaluria Type 1 | TERMINATED | NCT02795325 |
| DCR-PH1 | Other | Phase PHASE1 | Primary Hyperoxaluria Type 1 | TERMINATED | NCT02795325 |
| DCR-MYC | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02314052 |
| DCR-MYC | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02314052 |
| DCR-MYC | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02110563 |
| DCR-MYC | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02110563 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04597697 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04016974 |
| Oral semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04016974 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03723785 |
| Sugar Pill | Other | Phase PHASE4 | Insulin Resistance | COMPLETED | NCT02403284 |
| Liraglutide | Other | Phase PHASE4 | Insulin Resistance | COMPLETED | NCT02403284 |
| Placebo Pen Injector | Other | Phase PHASE2 | Pouchitis | TERMINATED | NCT04763564 |
| Liraglutide Pen Injector | Other | Phase PHASE2 | Pouchitis | TERMINATED | NCT04763564 |
| No treatment given | Drug | Preclinical | Atherosclerotic Cardiovascular Disease (ASCVD) | COMPLETED | NCT06322641 |
| Standard face-to-face patient education | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04669340 |
| E-learning patient education | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04669340 |
| Semaglutide/dapagliflozin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05429593 |
| Dapagliflozin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05429593 |
| Semaglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05429593 |
| Specialist Obesity Management Services | Other | Phase PHASE4 | Obesity | COMPLETED | NCT03036800 |
| Saxenda | Other | Phase PHASE4 | Obesity | COMPLETED | NCT03036800 |
| CT-guided radiotherapy | Drug | Preclinical | Prostate Cancer | COMPLETED | NCT05615909 |
| Online MR-guided radiotherapy | Drug | Preclinical | Prostate Cancer | COMPLETED | NCT05615909 |
| No treatment given | Drug | Preclinical | Type 2 Diabetes | COMPLETED | NCT06517784 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03574597 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT03574597 |
| No treatment given | Drug | Preclinical | Type-2 Diabetes Mellitus (T2DM) | COMPLETED | NCT06592950 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05795166 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05542420 |
| Oral semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05502562 |
| no treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT05428501 |
| Placebo ( Semaglutide D) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Placebo (Semaglutide C) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide C Dose 5 (50 mg) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide C Dose 4 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide D Dose 3 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide D Dose 2 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide D Dose 1 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide Dose 6 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide Dose 5 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide Dose 4 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide D Dose 3 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide D Dose 2 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide D Dose 1 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Belcesiran | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | WITHDRAWN | NCT05146882 |
| Belcesiran | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | WITHDRAWN | NCT05146882 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Primary Hyperoxaluria Type 3 | COMPLETED | NCT04555486 |
| DCR-PHXC | Other | Phase PHASE1 | Primary Hyperoxaluria Type 3 | COMPLETED | NCT04555486 |
| Oral Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04537624 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04109547 |
| Oral semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04109547 |
| Insulin Degludec/Insulin Aspart | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04042441 |
| Placebo for DCR-HBVS | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT03772249 |
| DCR-HBVS | Other | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT03772249 |
| Placebo | Other | Phase PHASE1 | Primary Hyperoxaluria | COMPLETED | NCT03392896 |
| DCR-PHXC | Other | Phase PHASE1 | Primary Hyperoxaluria | COMPLETED | NCT03392896 |
| Placebo | Other | Phase PHASE1 | Primary Hyperoxaluria | COMPLETED | NCT03392896 |
| DCR-PHXC | Other | Phase PHASE1 | Primary Hyperoxaluria | COMPLETED | NCT03392896 |
| RYGB | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03115424 |
| Placebos | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03115424 |
| Saxenda | Other | Phase PHASE3 | Obesity | COMPLETED | NCT03115424 |
| IDegLira | Other | Preclinical | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT06113341 |
| Placebo (sitagliptin) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| Placebo (oral semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| Sitagliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| Oral semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| Semaglutide B, 0.68 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05689099 |
| Semaglutide B, 1.34 mg/mL | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05689099 |
| Education-First | Other | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT06046560 |
| SGLT2 inhibitor, GLP-1 RA | Other | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT06046560 |
| VIA Family 2.0 | Other | Approved | Child | RECRUITING | NCT06312410 |
| Placebo | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT04174118 |
| belcesiran | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT04174118 |
| Placebo | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT04174118 |
| belcesiran | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT04174118 |
| Placebo insulin degludec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04795531 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04795531 |
| Placebo insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04795531 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04795531 |
| CCK | Other | Approved | Gallbladder | COMPLETED | NCT04651868 |
| Placebo | Other | Approved | Gallbladder | COMPLETED | NCT04651868 |
| GLP-2 | Other | Approved | Gallbladder | COMPLETED | NCT04651868 |
| CCK | Other | Approved | Gallbladder | COMPLETED | NCT04651868 |
| Placebo | Other | Approved | Gallbladder | COMPLETED | NCT04651868 |
| GLP-2 | Other | Approved | Gallbladder | COMPLETED | NCT04651868 |
| Placebo infusion (saline) | Other | Approved | Fibroblast Growth Factor 21 | COMPLETED | NCT04232033 |
| Fibroblast growth factor 21 infusion | Other | Approved | Fibroblast Growth Factor 21 | COMPLETED | NCT04232033 |
| Infusion of either NST or placebo at different blood glucose levels | Other | Approved | Type 1 Diabetes | COMPLETED | NCT06143267 |
| Infusion of GIP[1-42], GIP[1-30] or placebo | Other | Approved | Type1diabetes | COMPLETED | NCT06137586 |
| Infusion of GIP[1-42], GIP[1-30] or placebo | Other | Approved | Type1diabetes | COMPLETED | NCT06137586 |
| Placebo for DCR-AUD | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT05021640 |
| DCR-AUD | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT05021640 |
| Placebo for DCR-AUD | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT05021640 |
| DCR-AUD | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT05021640 |
| ethinylestradiol/levonorgestrel | Other | Phase PHASE1 | Healthy Volunteers (Non-alcoholic Steatohepatitis) | COMPLETED | NCT06188026 |
| NNC0194-0499 | Other | Phase PHASE1 | Healthy Volunteers (Non-alcoholic Steatohepatitis) | COMPLETED | NCT06188026 |
| Insulin aspart | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT04538352 |
| Insulin Degludec | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT04538352 |
| Semaglutide | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT04538352 |
| point-of-care ultrasound | Other | Preclinical | Point-of-care Ultrasound | COMPLETED | NCT05523882 |
| point-of-care ultrasound | Other | Preclinical | Point-of-care Ultrasound | COMPLETED | NCT05523882 |
| point-of-care ultrasound | Other | Preclinical | Point-of-care Ultrasound | COMPLETED | NCT05523882 |
| Motivational enhancement therapy | Drug | Approved | Alcoholic Hepatitis (AH) | RECRUITING | NCT06740318 |
| Placebo (NNC0487-0111) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06049329 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06049329 |
| Oral semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04817644 |
| IGlar U100 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723772 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723772 |
| Placebo semaglutide pen injector | Other | Phase PHASE4 | Pre Diabetes | RECRUITING | NCT04873050 |
| Semaglutide Pen Injector [Ozempic] | Other | Phase PHASE4 | Pre Diabetes | RECRUITING | NCT04873050 |
| Estradiol Vaginal Insert | Other | Phase PHASE4 | HIV Infection | COMPLETED | NCT04079218 |
| Placebo | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT04979130 |
| Semaglutide | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT04979130 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03819153 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03819153 |
| semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05435677 |
| insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05435677 |
| IcoSema | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05435677 |
| Glucagon-like peptide-1 (GLP-1) | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04809311 |
| Basal insulin | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04809311 |
| Oral antidiabetetic drugs | Drug | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04809311 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06559527 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT06351748 |
| Placebo (NNC6022-0001) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06336005 |
| NNC6022-0001 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06336005 |
| Placebo (semaglutide) | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04032197 |
| Semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04032197 |
| Placebo | Other | Phase PHASE2 | Diabetes type1 | RECRUITING | NCT06411210 |
| Semaglutide Pen Injector | Other | Phase PHASE2 | Diabetes type1 | RECRUITING | NCT06411210 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05979428 |
| NNC0491-6075 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05979428 |
| Acetaminophen - 500 mg/15 ml | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| NNC0487-0111 C | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| NNC0487-0111 A | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| No treatment given | Drug | Preclinical | Cardiovascular Risk | COMPLETED | NCT06122961 |
| Warfarin | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06289504 |
| Atorvastatin | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06289504 |
| Semaglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06289504 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06289504 |
| Growth hormone | Other | Preclinical | Growth Hormone Deficiency | COMPLETED | NCT03225755 |
| Placebo | Other | Phase PHASE1 | Type I Diabetes | COMPLETED | NCT04279613 |
| NNC0361-0041 | Other | Phase PHASE1 | Type I Diabetes | COMPLETED | NCT04279613 |
| Insulin degludec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06288412 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06288412 |
| Control | Other | Approved | Overweight and Obesity | ACTIVE_NOT_RECRUITING | NCT05768958 |
| Exercise | Other | Approved | Overweight and Obesity | ACTIVE_NOT_RECRUITING | NCT05768958 |
| DCR-PHXC | Other | Phase PHASE3 | Primary Hyperoxaluria Type 1 (PH1) | ACTIVE_NOT_RECRUITING | NCT04042402 |
| DCR-PHXC | Other | Phase PHASE3 | Primary Hyperoxaluria Type 1 (PH1) | ACTIVE_NOT_RECRUITING | NCT04042402 |
| DCR-PHXC | Other | Phase PHASE3 | Primary Hyperoxaluria Type 1 (PH1) | ACTIVE_NOT_RECRUITING | NCT04042402 |
| Esperoct | Other | Preclinical | Haemophilia A | RECRUITING | NCT05621746 |
| Nonacog beta pegol | Other | Preclinical | Haemophilia B | ENROLLING_BY_INVITATION | NCT03690336 |
| placebo (semaglutide) | Other | Phase PHASE3 | Overweight and Obesity | COMPLETED | NCT05132088 |
| semaglutide 50 mg | Other | Phase PHASE3 | Overweight and Obesity | COMPLETED | NCT05132088 |
| Evolocumab 140 mg/mL, Repatha® | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| Placebo II A (for NNC0385-0434 A 100 mg) | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| Placebo I A (for NNC0385-0434 A 40 mg) | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| NNC0385-0434 A 100 mg | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| Placebo I A (for NNC0385-0434 A 15 mg) | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| NNC0385-0434 A 40 mg | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| NNC0385-0434 A 15 mg | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| semaglutide | Other | Preclinical | Obesity and Overweight | ENROLLING_BY_INVITATION | NCT07018544 |
| Placebo A (NNC0487-0111 A) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| Placebo B (NNC0487-0111 B) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| NNC0487-0111 B | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| NNC0487-0111 A | Other | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06069895 |
| NNC0113-6856 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06069895 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05870670 |
| NNC0519-0130 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05870670 |
| No treatment given | Drug | Preclinical | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH) | COMPLETED | NCT06741111 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06625307 |
| NNC0537-1482 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06625307 |
| Placebo | Other | Phase PHASE2 | NAFLD | RECRUITING | NCT05424003 |
| Semaglutide Pen Injector | Other | Phase PHASE2 | NAFLD | RECRUITING | NCT05424003 |
| matching liraglutide-placebo pre-filled pens | Other | Phase PHASE4 | Type2 Diabetes | COMPLETED | NCT03260881 |
| Liraglutide Pen Injector [Victoza] | Other | Phase PHASE4 | Type2 Diabetes | COMPLETED | NCT03260881 |
| Semaglutide 1 mg | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05259033 |
| IcoSema | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05259033 |
| Multi-level, Multi-component Intervention Package | Other | Approved | Quality of Life (QOL) | NOT_YET_RECRUITING | NCT07061665 |
| NaCl 0.9% | Other | Phase PHASE2 | Acute Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT05350592 |
| Dobutamine | Other | Phase PHASE2 | Acute Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT05350592 |
| Tocilizumab | Other | Phase PHASE2 | Acute Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT05350592 |
| Dasiglucagon | Other | Phase PHASE3 | Hypoglycemia | COMPLETED | NCT05378672 |
| Nedosiran | Other | Preclinical | Primary Hyperoxaluria Type 1 (PH1) | NO_LONGER_AVAILABLE | NCT05993416 |
| Nedosiran | Other | Preclinical | Primary Hyperoxaluria Type 1 (PH1) | NO_LONGER_AVAILABLE | NCT05993416 |
| Placebo semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07010432 |
| Placebo cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07010432 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07010432 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07010432 |
| Preventive treatment with oral hydration | Drug | Approved | Contrast-induced Nephropathy | RECRUITING | NCT05283512 |
| Preventive treatment with IV-hydration | Drug | Approved | Contrast-induced Nephropathy | RECRUITING | NCT05283512 |
| NNC0487-0111 (formulation C) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06478563 |
| NNC0487-0111 (formulation D) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06478563 |
| No treatment given | Drug | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT07121114 |
| Placebo (NNC0487-0111) | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06820476 |
| NNC0487-0111 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06820476 |
| CagriSema A | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06716307 |
| CagriSema (cagrilintide B and semaglutide I) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06716307 |
| Placebo | Other | Approved | Obesity | COMPLETED | NCT05917873 |
| LaKe Ester | Other | Approved | Obesity | COMPLETED | NCT05917873 |
| Concizumab | Other | Preclinical | Haemophilia A, Haemophilia B | ENROLLING_BY_INVITATION | NCT06831734 |
| Concizumab | Other | Preclinical | Haemophilia A | ENROLLING_BY_INVITATION | NCT06285071 |
| Turoctocog alfa pegol | Other | Preclinical | Haemophilia A | COMPLETED | NCT04334057 |
| Insulin aspart | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06809621 |
| NNC0471-0119 H | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06809621 |
| Insulin Glargine 300U/mL | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| Insulin Degludec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| Insulin Glargine 100U/mL | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05548647 |
| Placebo | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05548647 |
| Behavioral Treatment | Drug | Phase PHASE4 | Obesity | COMPLETED | NCT05548647 |
| Placebo (NNC0662-0419) | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06737536 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06737536 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06859073 |
| NNC4004-0002 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06859073 |
| Semaglutide | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05996874 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05316662 |
| Oral semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05230615 |
| Oral semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05230589 |
| Oral semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04878393 |
| Oral semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04862923 |
| NNC0365-3769 (Mim8) | Other | Phase PHASE1 | Haemophilia A | COMPLETED | NCT05681845 |
| DCR-PDL1 | Other | Phase PHASE1 | Solid Tumors, Adult | RECRUITING | NCT06504368 |
| DCR-PDL1 | Other | Phase PHASE1 | Solid Tumors, Adult | RECRUITING | NCT06504368 |
| NNC0519-0130 C | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06642571 |
| NNC0519-0130 B | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06642571 |
| NNC6019-0001 | Other | Phase PHASE2 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | ACTIVE_NOT_RECRUITING | NCT06260709 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04560998 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04560998 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT07101783 |
| No treatment given | Drug | Preclinical | Parkinson Disease | ENROLLING_BY_INVITATION | NCT05779475 |
| Kidney Biopsy | Other | Preclinical | Chronic Kidney Diseases | RECRUITING | NCT04916132 |
| IDegLira | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04838743 |
| No Intervention | Other | Preclinical | Pregnancy | ENROLLING_BY_INVITATION | NCT05872022 |
| Placebo | Other | Phase PHASE1 | Alcohol Use Disorder | COMPLETED | NCT05845398 |
| DCR-AUD | Other | Phase PHASE1 | Alcohol Use Disorder | COMPLETED | NCT05845398 |
| Placebo | Other | Phase PHASE1 | Alcohol Use Disorder | COMPLETED | NCT05845398 |
| DCR-AUD | Other | Phase PHASE1 | Alcohol Use Disorder | COMPLETED | NCT05845398 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT07358052 |
| No treatment given | Drug | Preclinical | Overweight | COMPLETED | NCT07141914 |
| Telemonitoring | Other | Approved | Type 2 Diabetes Treated With Insulin | RECRUITING | NCT06185296 |
| Intelligent telemonitoring | Other | Approved | Type 2 Diabetes Treated With Insulin | RECRUITING | NCT06185296 |
| Placebo (NNC6019-0001) | Other | Phase PHASE2 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | COMPLETED | NCT05442047 |
| NNC6019-0001 | Other | Phase PHASE2 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | COMPLETED | NCT05442047 |
| Placebo semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05564117 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05564117 |
| Eptacog alfa (NovoSeven) | Other | Phase PHASE4 | Severe Postpartum Haemorrhage | RECRUITING | NCT07157423 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Early Alzheimer´s Disease | COMPLETED | NCT04777409 |
| Semaglutide | Other | Phase PHASE3 | Early Alzheimer´s Disease | COMPLETED | NCT04777409 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07503210 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07503210 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07509307 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07509307 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency | ENROLLING_BY_INVITATION | NCT06709040 |
| Football Fitness Concept | Other | Phase PHASE2 | Postmenopausal Women | ACTIVE_NOT_RECRUITING | NCT06789900 |
| Everolimus (Afinitor®) | Other | Phase PHASE2 | Postmenopausal Women | ACTIVE_NOT_RECRUITING | NCT06789900 |
| Metformin Hydrochloride | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03514108 |
| Placebo Oral Tablet | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03514108 |
| Hydralazine Isosorbide Dinitrate | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03514108 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Early Alzheimer's Disease | COMPLETED | NCT04777396 |
| Semagludtide | Other | Phase PHASE3 | Early Alzheimer's Disease | COMPLETED | NCT04777396 |
| Placebo | Other | Phase PHASE3 | Non-alcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT04822181 |
| Semaglutide | Other | Phase PHASE3 | Non-alcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT04822181 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Oral Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04601753 |
| Oral Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04601740 |
| Oral Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04537637 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Metformin | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Pitavastatin | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Etavopivat | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Norditropin | Other | Preclinical | Noonan Syndrome | ENROLLING_BY_INVITATION | NCT05308927 |
| Turoctocog alfa pegol | Other | Preclinical | Haemophilia A | ENROLLING_BY_INVITATION | NCT04682145 |
| Norditropin® FlexPro® | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT03972345 |
| DCR-STAT3 | Other | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT06098651 |
| No treatment given | Drug | Preclinical | Overweight, Obesity | ACTIVE_NOT_RECRUITING | NCT06805539 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05755360 |
| Oral semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05443568 |
| Low Energy Diet | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07184086 |
| CagriSema (Cagrilintide B + semaglutide I) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07184086 |
| Placebo (NNC0581-0001) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05599945 |
| NNC0581-0001 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05599945 |
| Etavopivat | Other | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06433661 |
| Etavopivat | Other | Phase PHASE1 | Liver Diseases | COMPLETED | NCT06336018 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT06288399 |
| Semaglutide N | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide M | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide L | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide J | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide B | Other | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| No treatment given | Drug | Preclinical | Systemic Inflammation (hsCRP) | COMPLETED | NCT06655493 |
| No treatment given | Drug | Preclinical | Haemophilia | ENROLLING_BY_INVITATION | NCT07163260 |
| Somatropin injection | Other | Preclinical | Growth Hormone Deficiency | COMPLETED | NCT04020913 |
| DCR-PDL1 | Other | Phase PHASE1 | Solid Tumors, Adult | RECRUITING | NCT06504368 |
| Mim8 | Other | Phase PHASE3 | Haemophilia A With or Without Inhibitors | COMPLETED | NCT05306418 |
| semaglutide 2.4 mg (placebo) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05064735 |
| semaglutide 2.4 mg | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05064735 |
| Placebo (monlunabant) | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06542536 |
| Monlunabant | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06542536 |
| Placebo (NNC0487-0111) | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06064006 |
| NNC0487-0111 | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06064006 |
| NNC0174 0833 placebo | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| NNC0174 0833 10 mg/mL | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Semaglutide placebo | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Semaglutide 3 mg/mL | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Placebo (NNC0194-0499) | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| NNC0194 0499 50 mg/mL | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Community Co-designed Physical Activity and Diet Intervention Package | Other | Approved | Quality of Life (QOL) | ACTIVE_NOT_RECRUITING | NCT07191925 |
| Somapacitan | Other | Phase PHASE3 | SGA | ACTIVE_NOT_RECRUITING | NCT05723835 |
| No treatment given | Drug | Preclinical | Obesity | ENROLLING_BY_INVITATION | NCT07154238 |
| Sleep extension | Other | Approved | Sleep Duration | RECRUITING | NCT06341179 |
| Sleep extension | Other | Approved | Sleep Duration | RECRUITING | NCT06341179 |
| Insuline glargine U100 (titrated) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| oral glucose-lowering medications (commercially available) | Drug | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05035082 |
| semaglutide | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05035082 |
| Community capacity building | Other | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| Sleep and screen media | Other | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| Physical Activity (FitFirst) | Other | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| Food and Nutrition | Other | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| PTM CILO/FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| PTM SEMA | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| Cilofexor (CILO)/Firsocostat (FIR) | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| Semaglutide (SEMA) | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| Placebo (Semaglutide) | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | COMPLETED | NCT04916470 |
| Semaglutide | Other | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | COMPLETED | NCT04916470 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06323161 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06323161 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06323161 |
| Hypercaloric High-Fat Diet | Other | Approved | Metabolic Health | NOT_YET_RECRUITING | NCT07255807 |
| Physical Inactivity | Other | Approved | Metabolic Health | NOT_YET_RECRUITING | NCT07255807 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Semaglutide C | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05784402 |
| Semaglutide J | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05784402 |
| insulin aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05013229 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05013229 |
| IcoSema | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05013229 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05352815 |
| IcoSema | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05352815 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Oral semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05035095 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04880850 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04880850 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04880850 |
| insulin aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04848480 |
| insulin degludec | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04848480 |
| insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04848480 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT04775082 |
| Liraglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT04775082 |
| Novo Rapid | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04698018 |
| Faster Aspart | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04698018 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04588259 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04588259 |
| Faster aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04588259 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04460885 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04460885 |
| Placebo | Other | Phase PHASE1 | Heart Failure | RECRUITING | NCT07218627 |
| NNC0537-1482 | Other | Phase PHASE1 | Heart Failure | RECRUITING | NCT07218627 |
| Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06797869 |
| CagriSema (Cagrilintide B and Semaglutide I) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06797869 |
| No treatment given | Drug | Preclinical | Atherosclerotic Cardiovascular Disease (ASCVD) | COMPLETED | NCT06589791 |
| Glucagon | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06588504 |
| Dasiglucagon | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06588504 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06284798 |
| NNC0650-0013 A | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06284798 |
| Oral Semaglutide | Other | Preclinical | Type 2 Diabetes | RECRUITING | NCT06269120 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT05714683 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT05689372 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT04788511 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT04788511 |
| Oral Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04559815 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07270731 |
| NNC9733-0001 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07270731 |
| NNC0365-3769 (Mim8) PPX | Other | Phase PHASE3 | Haemophilia A | COMPLETED | NCT05878938 |
| NNC0365-3769 (Mim8) | Other | Phase PHASE3 | Haemophilia A | COMPLETED | NCT05053139 |
| Oral semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04707469 |
| Placebo | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04102189 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04102189 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03914326 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03914326 |
| Semaglutide | Other | Preclinical | Obesity | ENROLLING_BY_INVITATION | NCT07280221 |
| Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT07011667 |
| CagriSema (Cagrilintide B and Semaglutide I) | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT07011667 |
| No treatment is given | Drug | Preclinical | Idiopathic Short Stature | TERMINATED | NCT05894876 |
| Cagrilintide | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05564104 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05486065 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05486065 |
| Semaglutide B | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05478252 |
| Semaglutide J | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05478252 |
| Cagrilintide and semaglutide | Other | Phase PHASE1 | Obesity & Overweight | COMPLETED | NCT04940078 |
| semaglutide | Other | Phase PHASE1 | Obesity & Overweight | COMPLETED | NCT04940078 |
| Cagrilintide | Other | Phase PHASE1 | Obesity & Overweight | COMPLETED | NCT04940078 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04770532 |
| Insulin degludec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04770532 |
| Semaglutide | Other | Phase PHASE4 | Obesity | ACTIVE_NOT_RECRUITING | NCT06571383 |
| Community-based intervention packages | Other | Approved | Obesity | ENROLLING_BY_INVITATION | NCT06855563 |
| Placebo (Mim8) | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT04204408 |
| NNC0365-3769 (Mim8) | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT04204408 |
| Turoctocog alfa pegol (N8-GP) | Other | Preclinical | Haemophilia A | ENROLLING_BY_INVITATION | NCT04574076 |
| Nonacog beta pegol | Other | Preclinical | Haemophilia B | ENROLLING_BY_INVITATION | NCT03745924 |
| Placebo (cagrilintide) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04982575 |
| Placebo (semaglutide) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04982575 |
| Cagrilintide 2.4 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04982575 |
| Semaglutide 2.4 mg | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04982575 |
| Norditropin® | Other | Phase PHASE2 | Short Stature Children Born Small for Gestational Age (SGA) | ACTIVE_NOT_RECRUITING | NCT03878446 |
| Somapacitan | Other | Phase PHASE2 | Short Stature Children Born Small for Gestational Age (SGA) | ACTIVE_NOT_RECRUITING | NCT03878446 |
| nonacog beta pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT02141074 |
| turoctocog alfa pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT02137850 |
| nonacog beta pegol | Other | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01467427 |
| Group visits (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioral support (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioural support (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits PHD | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes PHD | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioural support PHD | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (PHD) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioral support (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioural support (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits PHD | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes PHD | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioural support PHD | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (control) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (Ovo-lacto-vegetarian diet) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (PHD) | Other | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05624580 |
| NNC0582-0001 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05624580 |
| DCR-PHXC | Other | Phase PHASE2 | Primary Hyperoxaluria Type 1 | RECRUITING | NCT04580420 |
| Etavopivat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06581627 |
| Placebo (NNC0487-0111 oral) | Other | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| NNC0487-0111 oral | Other | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| Placebo (NNC0487-0111 subcutanous) | Other | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| NNC0487-0111 subcutanous | Other | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| Decitabine-THU | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06291285 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT06507475 |
| Ziltivekimab C | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05721989 |
| Ziltivekimab D | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05721989 |
| Ziltivekimab B | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05721989 |
| No treatment given | Drug | Preclinical | Obesity and Cardiovascular Risk | COMPLETED | NCT05642533 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05443191 |
| Placebo | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05405114 |
| HU - Hydroxyurea | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05405114 |
| NDec - oral decitabine-tetrahydrouridine | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05405114 |
| Concizumab | Other | Phase PHASE3 | Haemophilia A and B With and Without Inhibitors | ACTIVE_NOT_RECRUITING | NCT05135559 |
| Placebo (semaglutide 2.4 mg) | Other | Phase PHASE3 | Obesity | COMPLETED | NCT04998136 |
| Semaglutide 2.4 mg | Other | Phase PHASE3 | Obesity | COMPLETED | NCT04998136 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07238816 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06567041 |
| NNC0519-0130 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06567041 |
| Trizepatide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06326047 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06326047 |
| NNC0519-0130 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06326047 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05521256 |
| NNC0113-6856 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05521256 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Disease and Systemic Inflammation | COMPLETED | NCT05379829 |
| Ziltivekimab | Other | Phase PHASE1 | Chronic Kidney Disease and Systemic Inflammation | COMPLETED | NCT05379829 |
| Placebo (NNC0519-0130) | Other | Phase PHASE1 | Healthy Volunteers (Diabetes Mellitus, Type 2) | COMPLETED | NCT05363774 |
| NNC0519-0130 | Other | Phase PHASE1 | Healthy Volunteers (Diabetes Mellitus, Type 2) | COMPLETED | NCT05363774 |
| Fast-acting insulin aspart | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT05069545 |
| Insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT05069545 |
| Xultophy® (insulin degludec/liraglutide) | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04952779 |
| semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04469855 |
| Ziltivekimab | Other | Phase PHASE2 | Chronic Kidney Diseases | COMPLETED | NCT03926117 |
| NNC0363-1063 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07305805 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07023029 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07023029 |
| Etavopivat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07023029 |
| turoctocog alfa pegol (N8-GP) | Other | Phase PHASE3 | Haemophilia A | COMPLETED | NCT05082116 |
| Norditropin® | Other | Phase PHASE3 | Growth Hormone Deficiency in Children | COMPLETED | NCT04970654 |
| somapacitan | Other | Phase PHASE3 | Growth Hormone Deficiency in Children | COMPLETED | NCT04970654 |
| Norditropin® | Other | Phase PHASE3 | Growth Hormone Deficiency in Children | COMPLETED | NCT03811535 |
| Somapacitan | Other | Phase PHASE3 | Growth Hormone Deficiency in Children | COMPLETED | NCT03811535 |
| Semaglutide (administered by PDS290 pen-injector) | Other | Preclinical | Monogenic Obesity | RECRUITING | NCT07302802 |
| Placebo | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06267092 |
| Cagrilintide and Semaglutide | Other | Phase PHASE1 | Overweight | COMPLETED | NCT06267092 |
| No treatment given | Drug | Phase PHASE1 | Overweight | COMPLETED | NCT06267092 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06207877 |
| Semaglutide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06207877 |
| Cagrilintide | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06207877 |
| Semaglutide 2.4 mg and placebo 1.0 mg | Other | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Semaglutide 2.4 mg and NNC0165-1875 1.0 mg | Other | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Semaglutide 2.4 mg and placebo 2.0 mg | Other | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | Other | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Liraglutide | Other | Preclinical | Obesity | COMPLETED | NCT06283641 |
| Insulin degludec | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT06153537 |
| Placebo Cagrilintide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05996848 |
| Placebo Semaglutide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05996848 |
| Semaglutide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05996848 |
| Cagrilintide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05996848 |
| Telemedicine behavioral weight program | Other | Phase PHASE2 | Endometrial Hyperplasia | WITHDRAWN | NCT05829460 |
| LNG-IUD (Progestin) | Other | Phase PHASE2 | Endometrial Hyperplasia | WITHDRAWN | NCT05829460 |
| Placebo | Other | Phase PHASE2 | Endometrial Hyperplasia | WITHDRAWN | NCT05829460 |
| Semaglutide | Other | Phase PHASE2 | Endometrial Hyperplasia | WITHDRAWN | NCT05829460 |
| Nonacog beta pegol | Other | Phase PHASE3 | Haemophilia B | COMPLETED | NCT05365217 |
| Placebo | Other | Phase PHASE3 | Overweight | COMPLETED | NCT06041217 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT06041217 |
| Liraglutide | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Naltrexone/Bupropion | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Phentermine/Topiramate | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Orlistat | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Semaglutide | Other | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| No Intervention | Other | Preclinical | Pregnancy | ENROLLING_BY_INVITATION | NCT05503927 |
| Conventional TURB | Other | Approved | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05223491 |
| En Bloc resection | Other | Approved | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05223491 |
| Norditropin® FlexPro® pen | Other | Phase PHASE2 | Growth Hormone Disorder | COMPLETED | NCT02616562 |
| somapacitan | Other | Phase PHASE2 | Growth Hormone Disorder | COMPLETED | NCT02616562 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06780449 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06780449 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06780449 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06780449 |
| Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | ACTIVE_NOT_RECRUITING | NCT03496883 |
| Recombinant Activated Factor VII (rFVIIa) | Other | Phase PHASE3 | Intracerebral Hemorrhage | ACTIVE_NOT_RECRUITING | NCT03496883 |
| Placebo semaglutide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT06065540 |
| Placebo cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT06065540 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT06065540 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT06065540 |
| Semaglutide Placebo | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05890976 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05890976 |
| Placebo Semaglutide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05813925 |
| Semaglutide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05813925 |
| Cagrilintide | Other | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05813925 |
| Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07225816 |
| Oral Semaglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07225816 |
| Liraglutide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07225816 |
| Detemir | Other | Approved | Diabetes | ACTIVE_NOT_RECRUITING | NCT01239550 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Nicotinamide Riboside 1g (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Quercetin 1.250 mg (oral) | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Dasatinib 100 Mg Oral Tablet | Other | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Placebo semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05394519 |
| Placebo cagrilintide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05394519 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05394519 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT05394519 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05040971 |
| Semaglutide 2.4 mg | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05040971 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04251156 |
| Semaglutide | Other | Phase PHASE3 | Overweight | COMPLETED | NCT04251156 |
| Glugagon | Other | Approved | Metabolic Associated Fatty Liver Disease | RECRUITING | NCT07246421 |
| Tirzepatide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06131437 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06131437 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT06131437 |
| Placebo (Semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04865770 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04865770 |
| Placebo | Other | Phase PHASE1 | Fatty Liver Disease | RECRUITING | NCT07214870 |
| NNC4005-001 | Other | Phase PHASE1 | Fatty Liver Disease | RECRUITING | NCT07214870 |
| No treatment given | Drug | Preclinical | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT07160829 |
| Semaglutide | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT06478550 |
| NNC0194-0499 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05917938 |
| No treatment given | Drug | Preclinical | Overweight | COMPLETED | NCT04972721 |
| Beta-blocker treatment group | Drug | Phase PHASE4 | Idiopathic Ventricular Fibrillation | RECRUITING | NCT07405229 |
| Turoctocog alfa | Other | Preclinical | Congenital Bleeding Disorder | RECRUITING | NCT06574984 |
| Concizumab | Other | Preclinical | Congenital Haemophilia | AVAILABLE | NCT04921956 |
| Placebo A | Other | Phase PHASE1 | Overweight | COMPLETED | NCT07121153 |
| NNC0487-0111 A | Other | Phase PHASE1 | Overweight | COMPLETED | NCT07121153 |
| Placebo | Other | Phase PHASE3 | Alzheimers Disease | COMPLETED | NCT05891496 |
| Semaglutide | Other | Phase PHASE3 | Alzheimers Disease | COMPLETED | NCT05891496 |
| Placebo (NNC6989-0001 A) | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07437079 |
| NNC6989-0001 A | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07437079 |
| Placebo cagrilintide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06403761 |
| Placebo semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06403761 |
| Cagrilintide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06403761 |
| Semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06403761 |
| There is no intervention | Other | Preclinical | Diabetic Nephropathies | RECRUITING | NCT02986984 |
| Mineralocorticoid Receptor Antagonists(MRAs) | Other | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Glucagon-like peptide-1 receptor agonists (GLP 1 RA) | Other | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Renin-angiotensin-aldosterone system blockade | Other | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Sodium-glucose cotransporter 2 inhibitors (SGLT2i) | Other | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| CH-reduced diet with exercise | Other | Approved | Type 2 Diabetes | RECRUITING | NCT07262788 |
| CH-rich diet with exercise | Other | Approved | Type 2 Diabetes | RECRUITING | NCT07262788 |
| Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs | Other | Approved | Type 2 Diabetes | COMPLETED | NCT06111508 |
| Semaglutide | Other | Preclinical | Obesity | ENROLLING_BY_INVITATION | NCT07055607 |
| INV-347 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07153172 |
| D-β-hydroxybutyrate/D 1,3 butanediol monoester | Other | Approved | Aging | COMPLETED | NCT05732909 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07415954 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07415954 |
| NNC0662-0419 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07415954 |
| Ziltivekimab Placebo | Other | Phase PHASE3 | Myocardial Infarction | RECRUITING | NCT07301034 |
| Ziltivekimab | Other | Phase PHASE3 | Myocardial Infarction | RECRUITING | NCT07301034 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07029568 |
| NNC0705-0001 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07029568 |
| Placebo | Other | Phase PHASE2 | Heart Failure | RECRUITING | NCT06979375 |
| CDR132L | Other | Phase PHASE2 | Heart Failure | RECRUITING | NCT06979375 |
| Placebo | Other | Phase PHASE2 | Heart Failure | RECRUITING | NCT06979362 |
| CDR132L | Other | Phase PHASE2 | Heart Failure | RECRUITING | NCT06979362 |
| Semaglutide | Other | Phase PHASE2 | Chronic Kidney Disease | RECRUITING | NCT06717698 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | RECRUITING | NCT06717698 |
| NNC0519-0130 | Other | Phase PHASE2 | Chronic Kidney Disease | RECRUITING | NCT06717698 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT05636176 |
| Ziltivekimab | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT05636176 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04596631 |
| Oral semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04596631 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| No treatment given | Drug | Preclinical | Metabolic Dysfunction-associated Steatohepatitis (MASH) | COMPLETED | NCT07201831 |
| Paracetamol | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06513104 |
| Levonorgestrel + Ethinylestradiol | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06513104 |
| NNC0519-0130 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06513104 |
| Semaglutide placebo (Group B) | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Cagrilintide placebo | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Cagrilintide | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Cagrilintide + semaglutide | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Semaglutide placebo (Group A) | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| NNC0194-0499 placebo | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Semaglutide | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| NNC0194-0499 | Other | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05669755 |
| Semaglutide | Other | Phase PHASE3 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05669755 |
| Cagrilintide | Other | Phase PHASE3 | Cardiovascular Disease | ACTIVE_NOT_RECRUITING | NCT05669755 |
| Placebo (NNC0638-0355) | Other | Phase PHASE1 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577766 |
| NNC0638-0355 | Other | Phase PHASE1 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577766 |
| Placebo | Other | Phase PHASE3 | Coronary Artery Disease | RECRUITING | NCT07276282 |
| Ziltivekimab | Other | Phase PHASE3 | Coronary Artery Disease | RECRUITING | NCT07276282 |
| Etavopivat C | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06609226 |
| Etavopivat B | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06609226 |
| Etavopivat A | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06609226 |
| Concizumab | Other | Phase PHASE3 | Haemophilia A With Inhibitors | ACTIVE_NOT_RECRUITING | NCT04083781 |
| Concizumab | Other | Phase PHASE3 | Haemophilia A Without Inhibitors | ACTIVE_NOT_RECRUITING | NCT04082429 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06388187 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06388187 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT06388187 |
| Inactivity | Other | Approved | Overweight | RECRUITING | NCT06240208 |
| Placebo semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Placebo cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05567796 |
| Oral semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT07271251 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT07004322 |
| NNC0519-0130 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT07004322 |
| Placebo | Other | Phase PHASE1 | Haemophilia A | COMPLETED | NCT06649630 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | COMPLETED | NCT06649630 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06131372 |
| Semaglutide | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06131372 |
| Cagrilintide | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06131372 |
| Placebo semaglutide | Other | Phase PHASE3 | Overweight | RECRUITING | NCT07253285 |
| Placebo cagrilintide | Other | Phase PHASE3 | Overweight | RECRUITING | NCT07253285 |
| Semaglutide | Other | Phase PHASE3 | Overweight | RECRUITING | NCT07253285 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | RECRUITING | NCT07253285 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06323174 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06323174 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06323174 |
| Semaglutide | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | ACTIVE_NOT_RECRUITING | NCT07087795 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | ACTIVE_NOT_RECRUITING | NCT07087795 |
| NNC0194-0499 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | ACTIVE_NOT_RECRUITING | NCT07087795 |
| NNC0519-0130 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT06718998 |
| lifestyle change program | Other | Preclinical | Obesity and Cardiovascular Risk | ENROLLING_BY_INVITATION | NCT07404150 |
| Insulin icodec | Other | Preclinical | Diabetes Mellitus, Type 1 | RECRUITING | NCT07160816 |
| Basal insulin analogues | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07112339 |
| Insulin icodec | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07112339 |
| Insulin aspart | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07076199 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07076199 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07076199 |
| Sitagliptin 100mg | Other | Phase PHASE4 | Liver Transplant; Complications | ENROLLING_BY_INVITATION | NCT05195944 |
| Semaglutide Treatment | Drug | Phase PHASE4 | Liver Transplant; Complications | ENROLLING_BY_INVITATION | NCT05195944 |
| Etavopivat Tablets | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Placebo Tablets | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets High dose | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets Low dose | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Placebo Tablets | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets High dose | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets Low dose | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07339423 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07339423 |
| Insulin Aspart | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT07068295 |
| NNC0471-0119 H | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT07068295 |
| Placebo (NNC0581-0001) | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06891365 |
| NNC0581-0001 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06891365 |
| NNC0519-0130 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06370819 |
| Placebo | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06200207 |
| Ziltivekimab | Other | Phase PHASE3 | Heart Failure | RECRUITING | NCT06200207 |
| Mim8 | Other | Phase PHASE3 | Haemophilia A | ACTIVE_NOT_RECRUITING | NCT05685238 |
| Placebo | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04764448 |
| Belcesiran | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04764448 |
| Placebo | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04764448 |
| Belcesiran | Other | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04764448 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT07220642 |
| Cagrilintide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT07220642 |
| No treatment given | Drug | Preclinical | Obesity | COMPLETED | NCT06843473 |
| Tirzepatide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Cagrilintide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05725902 |
| Standard of Care (SOC) | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | Other | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| DuraTouch® | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT07052292 |
| Insulin Icodec | Other | Preclinical | Diabetes Mellitus, Type 1 | RECRUITING | NCT06807190 |
| Insulin detemir | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06685185 |
| Insulin degludec | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06685185 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06685185 |
| NNC0363-1063 | Other | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06685185 |
| Insulin glargine | Other | Phase PHASE3 | Diabetes, Type 2 | COMPLETED | NCT06340854 |
| Insulin icodec | Other | Phase PHASE3 | Diabetes, Type 2 | COMPLETED | NCT06340854 |
| Insulin glargine | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06269107 |
| IcoSema | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06269107 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05813912 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05813912 |
| Insulin icodec | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05790681 |
| Somapacitan | Other | Preclinical | Adult Growth Hormone Deficiency | ENROLLING_BY_INVITATION | NCT05718570 |
| Placebo (semaglutide) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| Placebo (NNC080-0389) | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| Semaglutide | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| NNC0480-0389 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| Faster-acting insulin aspart | Other | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT03987802 |
| Coramitug | Other | Phase PHASE1 | Transthyretin Amyloid Cardiomyopathy | RECRUITING | NCT07448623 |
| Somapacitan | Other | Preclinical | Adult Growth Hormone Deficiency | ACTIVE_NOT_RECRUITING | NCT05230550 |
| Placebo (Ziltivekimab C) | Other | Phase PHASE3 | Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT05021835 |
| Placebo (Ziltivekimab B) | Other | Phase PHASE3 | Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT05021835 |
| Ziltivekimab C | Other | Phase PHASE3 | Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT05021835 |
| Ziltivekimab B | Other | Phase PHASE3 | Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT05021835 |
| liraglutide 3.0 mg | Other | Preclinical | Obesity | COMPLETED | NCT02773355 |
| Placebo | Other | Phase PHASE3 | Cardiovascular Risk | RECRUITING | NCT06118281 |
| Ziltivekimab | Other | Phase PHASE3 | Cardiovascular Risk | RECRUITING | NCT06118281 |
| Tirzepatide | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06326060 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06326060 |
| NNC0519-0130 | Other | Phase PHASE2 | Obesity | COMPLETED | NCT06326060 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | RECRUITING | NCT07532863 |
| nedosiran | Other | Phase PHASE2 | Primary Hyperoxaluria | COMPLETED | NCT05001269 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo (semaglutide) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Semaglutide | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT03811561 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Placebo Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| Cagrilintide | Other | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07557953 |
| No intervention (observational study) | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT07560059 |
| Insulin Icodec | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05823948 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Physical activity monitoring and recommendations | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | Other | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Somapacitan | Other | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT06109935 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo (matched to NNC0487-0111 ) | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| NNC0487-0111 | Other | Phase PHASE3 | Obesity | RECRUITING | NCT07481630 |
| Placebo | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| NNC0662-0419 | Other | Phase PHASE2 | Overweight | ACTIVE_NOT_RECRUITING | NCT07184632 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| NNC0487-0111 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07508020 |
| Semaglutide | Other | Preclinical | Obesity | TERMINATED | NCT07081178 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05649137 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | RECRUITING | NCT07533175 |
| Placebo (NNC6019-0001) | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Etavopivat | Other | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06612268 |
| Refixia® | Other | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Etavopivat | Other | Phase PHASE2 | Sickle Cell Disease | RECRUITING | NCT06198712 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| NNC0442-0344 A | Other | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07220564 |
| Acetaminophen | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Oral contraceptive | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| NNC0662-0419 | Other | Phase PHASE1 | Overweight | RECRUITING | NCT07525791 |
| Norditropin® | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Somapacitan | Other | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT07535307 |
| High carbohydrate liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | Other | Approved | Obesity | RECRUITING | NCT06752967 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Placebo | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Semaglutide | Other | Phase PHASE3 | Obesity | COMPLETED | NCT05646706 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Semaglutide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05726227 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Tirzepatide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Semaglutide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Cagrilintide | Other | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06221969 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Biological/Vaccine: Placebo | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Semaglutide | Other | Preclinical | Obesity | ACTIVE_NOT_RECRUITING | NCT06283667 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Placebo (matched to Cagrilintide) | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Cagrilintide | Other | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07535307 |
| NNC0487-0111 | Other | Phase PHASE1 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07535307 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| UBT251 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | RECRUITING | NCT07532863 |
| nedosiran | Other | Phase PHASE2 | Primary Hyperoxaluria | COMPLETED | NCT05001269 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| Placebo | Other | Phase PHASE3 | Non-alcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT04822181 |
| Semaglutide | Other | Phase PHASE3 | Non-alcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT04822181 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | RECRUITING | NCT07532863 |
| nedosiran | Other | Phase PHASE2 | Primary Hyperoxaluria | COMPLETED | NCT05001269 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | RECRUITING | NCT07532863 |
| nedosiran | Other | Phase PHASE2 | Primary Hyperoxaluria | COMPLETED | NCT05001269 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| No treatment given | Drug | Preclinical | Diabetes Mellitus, Type 2 | RECRUITING | NCT07532863 |
| nedosiran | Other | Phase PHASE2 | Primary Hyperoxaluria | COMPLETED | NCT05001269 |
| Placebo (matched to NNC0487-0111) | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| NNC0487-0111 | Other | Phase PHASE3 | Diabetes Mellitus | NOT_YET_RECRUITING | NCT07533175 |
| Placebo (matched to NNC0487-0111 ) | DRUG | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07481630 |
| Radiologic Surveillance (MRI and Transvaginal Ultrasound) | PROCEDURE | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| Endometrial Biopsy With or Without Hysteroscopy | PROCEDURE | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| Structured Exercise and Prehabilitation Program | BEHAVIORAL | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| Dietetic-Nutritional intervention | BEHAVIORAL | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| Oral Progestins | DRUG | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| Levonorgestrel IUD (Lng-IUD) | DEVICE | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| Coramitug | DRUG | Phase PHASE1 | Transthyretin Amyloid Cardiomyopathy | NOT_YET_RECRUITING | NCT07448623 |
| Mineralocorticoid Receptor Antagonists(MRAs) | DRUG | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Glucagon-like peptide-1 receptor agonists (GLP 1 RA) | DRUG | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Renin-angiotensin-aldosterone system blockade | DRUG | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Sodium-glucose cotransporter 2 inhibitors (SGLT2i) | DRUG | Preclinical | Diabetic Nephropathies | RECRUITING | NCT07444203 |
| Placebo (NNC6989-0001 A) | DRUG | Phase PHASE1 | Overweight | RECRUITING | NCT07437079 |
| NNC6989-0001 A | DRUG | Phase PHASE1 | Overweight | RECRUITING | NCT07437079 |
| SEMAFOLLOW questionnaire | OTHER | Preclinical | Obesity & Overweight | NOT_YET_RECRUITING | NCT07423481 |
| Placebo GIP | DRUG | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07411560 |
| Glucose-dependent Insulinotropic Polypeptide (GIP) | DRUG | Phase PHASE1 | Overweight | NOT_YET_RECRUITING | NCT07411560 |
| Beta-blocker treatment group | DRUG | Phase PHASE4 | Idiopathic Ventricular Fibrillation | RECRUITING | NCT07405229 |
| lifestyle change program | OTHER | Preclinical | Obesity and Cardiovascular Risk | ENROLLING_BY_INVITATION | NCT07404150 |
| Placebo (matched to semaglutide) | DRUG | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07400107 |
| UBT251 | DRUG | Phase PHASE2 | Overweight | RECRUITING | NCT07395687 |
| Standard of Care (SOC) | DRUG | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 50 mL | DRUG | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Amicidin-β topical solution - 15 mL | DRUG | Phase PHASE1 | Surgical Wound Infection | RECRUITING | NCT07379684 |
| Cagrisema | DRUG | Phase PHASE3 | Overweight | NOT_YET_RECRUITING | NCT07357766 |
| Placebo CagriSema | DRUG | Phase PHASE3 | Overweight | NOT_YET_RECRUITING | NCT07357766 |
| CagriSema | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07357740 |
| Placebo (matched to NNC0487-0111) | DRUG | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07509307 |
| Ziltivekimab Placebo | DRUG | Phase PHASE3 | Myocardial Infarction | RECRUITING | NCT07301034 |
| NNC9733-0001 | DRUG | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07270731 |
| CH-reduced diet with exercise | OTHER | Approved | Type 2 Diabetes | RECRUITING | NCT07262788 |
| CH-rich diet with exercise | OTHER | Approved | Type 2 Diabetes | RECRUITING | NCT07262788 |
| Hypercaloric High-Fat Diet | BEHAVIORAL | Approved | Metabolic Health | NOT_YET_RECRUITING | NCT07255807 |
| Physical Inactivity | BEHAVIORAL | Approved | Metabolic Health | NOT_YET_RECRUITING | NCT07255807 |
| Glugagon | OTHER | Approved | Metabolic Associated Fatty Liver Disease | RECRUITING | NCT07246421 |
| Biological/Vaccine: Placebo | BIOLOGICAL | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Recombinant Factor VIIa | BIOLOGICAL | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT07227246 |
| Placebo (matched to Cagrilintide) | DRUG | Phase PHASE3 | Overweight | ACTIVE_NOT_RECRUITING | NCT07220759 |
| NNC4005-001 | DRUG | Phase PHASE1 | Fatty Liver Disease | RECRUITING | NCT07214870 |
| Community Co-designed Physical Activity and Diet Intervention Package | BEHAVIORAL | Approved | Quality of Life (QOL) | ACTIVE_NOT_RECRUITING | NCT07191925 |
| Group visits (control) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes (control) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioral support (control) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits (Ovo-lacto-vegetarian diet) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes (Ovo-lacto-vegetarian diet) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioural support (Ovo-lacto-vegetarian diet) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Group visits PHD | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Food boxes PHD | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Behavioural support PHD | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (control) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (Ovo-lacto-vegetarian diet) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Dietary advice (PHD) | BEHAVIORAL | Approved | Cardiometabolic Diseases | RECRUITING | NCT07189676 |
| Low Energy Diet | BEHAVIORAL | Phase PHASE1 | Obesity | RECRUITING | NCT07184086 |
| CagriSema (Cagrilintide B + semaglutide I) | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07184086 |
| Eptacog alfa (NovoSeven) | DRUG | Phase PHASE4 | Severe Postpartum Haemorrhage | RECRUITING | NCT07157423 |
| INV-347 | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07153172 |
| Placebo A | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT07121153 |
| Basal insulin analogues | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07112339 |
| Multi-level, Multi-component Intervention Package | BEHAVIORAL | Approved | Quality of Life (QOL) | NOT_YET_RECRUITING | NCT07061665 |
| DuraTouch® | DEVICE | Preclinical | Diabetes Mellitus, Type 1 | ACTIVE_NOT_RECRUITING | NCT07052292 |
| Debio 1453P | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07035769 |
| NNC0705-0001 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07029568 |
| CDR132L | DRUG | Phase PHASE2 | Heart Failure | RECRUITING | NCT06979375 |
| NNC4004-0002 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06859073 |
| B-COMPASS implementation | BEHAVIORAL | Approved | Cardiovascular Diseases | RECRUITING | NCT06856902 |
| Community-based intervention packages | BEHAVIORAL | Approved | Obesity | ENROLLING_BY_INVITATION | NCT06855563 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Pitavastatin | DRUG | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Digoxin | DRUG | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| NNC0471-0119 H | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07068295 |
| Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07282613 |
| CagriSema (Cagrilintide B and Semaglutide I) | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07282613 |
| Football Fitness Concept | OTHER | Phase PHASE2 | Postmenopausal Women | ACTIVE_NOT_RECRUITING | NCT06789900 |
| Everolimus (Afinitor®) | DRUG | Phase PHASE2 | Postmenopausal Women | ACTIVE_NOT_RECRUITING | NCT06789900 |
| No tretament given | OTHER | Preclinical | Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD) | COMPLETED | NCT06769646 |
| High carbohydrate liquid test meal | OTHER | Approved | Obesity | RECRUITING | NCT06752967 |
| High protein liquid test meal | OTHER | Approved | Obesity | RECRUITING | NCT06752967 |
| Motivational enhancement therapy | OTHER | Approved | Alcoholic Hepatitis (AH) | RECRUITING | NCT06740318 |
| Placebo (NNC0662-0419) | OTHER | Phase PHASE1 | Overweight | COMPLETED | NCT06737536 |
| NNC0662-0419 | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | NOT_YET_RECRUITING | NCT07415954 |
| Placebo A (NNC0174 1213 A) | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT06719011 |
| Cagrilintide B | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT06719011 |
| NNC0174-1213 A | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT06719011 |
| CagriSema A | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06716307 |
| CagriSema (cagrilintide B and semaglutide I) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06716307 |
| NNC0363-1063 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07305805 |
| NNC0442-0344 A | DRUG | Phase PHASE1 | Haemophilia A | RECRUITING | NCT07238816 |
| Semaglutide N | DRUG | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide M | DRUG | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide L | DRUG | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| NNC0519-0130 C | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06642571 |
| NNC0519-0130 B | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06642571 |
| NNC0537-1482 | DRUG | Phase PHASE1 | Heart Failure | RECRUITING | NCT07218627 |
| Etavopivat C | DRUG | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06609226 |
| Etavopivat B | DRUG | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06609226 |
| Etavopivat A | DRUG | Phase PHASE3 | Sickle Cell Disease | RECRUITING | NCT06609226 |
| Placebo (NNC0638-0355) | DRUG | Phase PHASE1 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577766 |
| NNC0638-0355 | DRUG | Phase PHASE1 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577766 |
| Placebo (NNC0487-0111 oral) | DRUG | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| NNC0487-0111 oral | DRUG | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| Placebo (NNC0487-0111 subcutanous) | DRUG | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| NNC0487-0111 subcutanous | DRUG | Phase PHASE2 | Type 2 Diabetes (T2D) | COMPLETED | NCT06542874 |
| Placebo (monlunabant) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06542536 |
| Monlunabant | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06542536 |
| Paracetamol | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06513104 |
| Levonorgestrel + Ethinylestradiol | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06513104 |
| DCR-PDL1 | DRUG | Phase PHASE1 | Solid Tumors, Adult | RECRUITING | NCT06504368 |
| NNC0487-0111 (formulation C) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06478563 |
| NNC0487-0111 (formulation D) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06478563 |
| Acetaminophen - 500 mg/15 ml | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| NNC0487-0111 C | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06461039 |
| Live music in the intensive care unit | OTHER | Approved | Stress | NOT_YET_RECRUITING | NCT06442644 |
| Semaglutide placebo (Group B) | DRUG | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Cagrilintide placebo | DRUG | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Cagrilintide + semaglutide | DRUG | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Semaglutide placebo (Group A) | DRUG | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| NNC0194-0499 placebo | DRUG | Phase PHASE2 | Alcohol-related Liver Disease | COMPLETED | NCT06409130 |
| Sleep extension | BEHAVIORAL | Approved | Sleep Duration | RECRUITING | NCT06341179 |
| Placebo (NNC6022-0001) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06336005 |
| NNC6022-0001 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06336005 |
| Trizepatide | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06326047 |
| VIA Family 2.0 | OTHER | Approved | Child | RECRUITING | NCT06312410 |
| Decitabine-THU | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06291285 |
| Warfarin | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06289504 |
| Atorvastatin | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT06289504 |
| NNC0650-0013 A | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06284798 |
| Cagrilintide and Semaglutide | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT06267092 |
| Inactivity | BEHAVIORAL | Approved | Overweight | RECRUITING | NCT06240208 |
| GLP-1 receptor agonist | DRUG | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| Control group | OTHER | Approved | Postoperative Pain, Acute | RECRUITING | NCT06222151 |
| Intervention 2: Mobilization the first 4 postoperative weeks | OTHER | Approved | Postoperative Pain, Acute | RECRUITING | NCT06222151 |
| Intervention 1: Mobilization during hospitalization | OTHER | Approved | Postoperative Pain, Acute | RECRUITING | NCT06222151 |
| ethinylestradiol/levonorgestrel | DRUG | Phase PHASE1 | Healthy Volunteers (Non-alcoholic Steatohepatitis) | COMPLETED | NCT06188026 |
| Intelligent telemonitoring | DEVICE | Approved | Type 2 Diabetes Treated With Insulin | RECRUITING | NCT06185296 |
| FIT FIRST | BEHAVIORAL | Approved | Primary Prevention | ENROLLING_BY_INVITATION | NCT06180772 |
| Sooma Oy (Sham), Helsinki, Finland | DEVICE | Approved | Diabetic Neuropathy, Painful | RECRUITING | NCT06152887 |
| Sooma Oy (tDCS), Helsinki, Finland | DEVICE | Approved | Diabetic Neuropathy, Painful | RECRUITING | NCT06152887 |
| Infusion of either NST or placebo at different blood glucose levels | OTHER | Approved | Type 1 Diabetes | COMPLETED | NCT06143267 |
| Infusion of GIP[1-42], GIP[1-30] or placebo | OTHER | Approved | Type1diabetes | COMPLETED | NCT06137586 |
| Placebo (NNC0560-0004) | DRUG | Phase PHASE1 | Healthy Volunteers - Liver Diseases | COMPLETED | NCT06133270 |
| NNC0560-0004 | DRUG | Phase PHASE1 | Healthy Volunteers - Liver Diseases | COMPLETED | NCT06133270 |
| Tirzepatide | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Physical activity monitoring and recommendations | BEHAVIORAL | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Complex lifestyle intervention | BEHAVIORAL | Approved | Lifestyle, Healthy | ACTIVE_NOT_RECRUITING | NCT06122441 |
| Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs | DEVICE | Approved | Type 2 Diabetes | COMPLETED | NCT06111508 |
| DCR-STAT3 | DRUG | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT06098651 |
| Placebo (NNC0487-0111) | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT06820476 |
| NNC0487-0111 | DRUG | Phase PHASE3 | Obesity | NOT_YET_RECRUITING | NCT07509307 |
| Education-First | BEHAVIORAL | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT06046560 |
| SGLT2 inhibitor, GLP-1 RA | DRUG | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT06046560 |
| Dasatinib 100 Mg Oral Tablet | DRUG | Phase PHASE2 | Osteopenia, Osteoporosis | ACTIVE_NOT_RECRUITING | NCT06018467 |
| Placebo Cagrilintide | DRUG | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05996848 |
| Nedosiran | DRUG | Preclinical | Primary Hyperoxaluria Type 1 (PH1) | NO_LONGER_AVAILABLE | NCT05993416 |
| NNC0491-6075 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05979428 |
| Amino acid bolus infusion | OTHER | Approved | Healthy | COMPLETED | NCT05954923 |
| Facilitated referral to a cardiometabolic team-based center | OTHER | Approved | Type 2 Diabetes | UNKNOWN | NCT05948969 |
| Decision support | OTHER | Approved | Type 2 Diabetes | UNKNOWN | NCT05948969 |
| Community capacity building | BEHAVIORAL | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| Sleep and screen media | BEHAVIORAL | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| Physical Activity (FitFirst) | BEHAVIORAL | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| Food and Nutrition | BEHAVIORAL | Approved | Childhood Obesity | COMPLETED | NCT05940675 |
| No treatment is given | OTHER | Preclinical | Overweight | COMPLETED | NCT06260696 |
| Semaglutide Placebo | DRUG | Phase PHASE3 | Overweight | COMPLETED | NCT05890976 |
| NNC0365-3769 (Mim8) PPX | DRUG | Phase PHASE3 | Haemophilia A | COMPLETED | NCT05878938 |
| Nutritional Psycho-Behavioral Reeducation Program | BEHAVIORAL | Preclinical | Overweight and Obesity | NOT_YET_RECRUITING | NCT05857319 |
| Telemedicine behavioral weight program | BEHAVIORAL | Phase PHASE2 | Endometrial Hyperplasia | WITHDRAWN | NCT05829460 |
| LNG-IUD (Progestin) | DRUG | Phase PHASE2 | Endometrial Hyperplasia | WITHDRAWN | NCT05829460 |
| Placebo Semaglutide | DRUG | Phase PHASE3 | Obesity or Overweight | COMPLETED | NCT05996848 |
| Moxifloxacin Placebo | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05804162 |
| Cagrilintide Placebo | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05804162 |
| Semaglutide C | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05784402 |
| Semaglutide Auto-Injector | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05780905 |
| Control | OTHER | Approved | Overweight and Obesity | ACTIVE_NOT_RECRUITING | NCT05768958 |
| NNC0194-0499/Semaglutide A (40/0.33mg/mL) | DRUG | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05766709 |
| NNC0194-0499/Semaglutide A (40/3.20 mg/mL) | DRUG | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05766709 |
| NC0194-0499 | DRUG | Phase PHASE1 | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT05742919 |
| Etavopivat | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07023029 |
| Ziltivekimab D | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05721989 |
| Semaglutide B, 0.68 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05689099 |
| Vira mobile app intervention + coaching | BEHAVIORAL | Approved | Mental Health Disorder | COMPLETED | NCT05638516 |
| Vira mobile app intervention | BEHAVIORAL | Approved | Mental Health Disorder | COMPLETED | NCT05638516 |
| NNC0582-0001 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05624580 |
| Esperoct | DRUG | Preclinical | Haemophilia A | RECRUITING | NCT05621746 |
| CT-guided radiotherapy | RADIATION | Preclinical | Prostate Cancer | COMPLETED | NCT05615909 |
| Online MR-guided radiotherapy | RADIATION | Preclinical | Prostate Cancer | COMPLETED | NCT05615909 |
| Placebo (NNC0581-0001) | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06891365 |
| NNC0581-0001 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT06891365 |
| Naltrexone/Bupropion | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Phentermine/Topiramate | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Orlistat | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT05579249 |
| Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT05548647 |
| Behavioral Treatment | BEHAVIORAL | Phase PHASE4 | Obesity | COMPLETED | NCT05548647 |
| NNC0113-6856 | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06069895 |
| Insuline glargine U100 (titrated) | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| Insuline glargine U100 (reduced) | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05514535 |
| No Intervention | OTHER | Preclinical | Pregnancy | ENROLLING_BY_INVITATION | NCT05872022 |
| NNC0480 0389 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05498610 |
| Adhera® Caring digital intervention for Type 1 Diabetes | BEHAVIORAL | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT05483803 |
| School-based extracurricular intervention focusing on screen media use and time spent with friends | BEHAVIORAL | Approved | Screen Media Use | COMPLETED | NCT05480085 |
| Semaglutide B | DRUG | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Semaglutide J | DRUG | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT06642584 |
| Empagliflozin | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT06083675 |
| Placebo (NNC6019-0001) | DRUG | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| NNC6019-0001 | DRUG | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | RECRUITING | NCT07207811 |
| Placebo oral tablet | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05441267 |
| Semaglutide Oral Tablet | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | RECRUITING | NCT05441267 |
| Semaglutide/dapagliflozin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05429593 |
| Dapagliflozin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05429593 |
| no treatment given | OTHER | Preclinical | Obesity | COMPLETED | NCT05428501 |
| Semaglutide Pen Injector | DRUG | Phase PHASE2 | Diabetes type1 | RECRUITING | NCT06411210 |
| HU - Hydroxyurea | DRUG | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05405114 |
| NDec - oral decitabine-tetrahydrouridine | DRUG | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT05405114 |
| Placebo semaglutide | DRUG | Phase PHASE3 | Overweight | RECRUITING | NCT07253285 |
| Placebo cagrilintide | DRUG | Phase PHASE3 | Overweight | RECRUITING | NCT07253285 |
| Dasiglucagon | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06588504 |
| Placebo A (NNC0487-0111 A) | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| Placebo B (NNC0487-0111 B) | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| NNC0487-0111 B | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05369390 |
| NNC0487-0111 A | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT07121153 |
| Placebo (NNC0519-0130) | DRUG | Phase PHASE1 | Healthy Volunteers (Diabetes Mellitus, Type 2) | COMPLETED | NCT05363774 |
| NNC0519-0130 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT06370819 |
| NaCl 0.9% | DRUG | Phase PHASE2 | Acute Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT05350592 |
| Dobutamine | DRUG | Phase PHASE2 | Acute Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT05350592 |
| Tocilizumab | DRUG | Phase PHASE2 | Acute Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT05350592 |
| Physical activity | OTHER | Approved | Intellectual Disability | UNKNOWN | NCT05336487 |
| NNC0385-0434 F | DRUG | Phase PHASE1 | Healthy Volunteers; High Cholesterol | COMPLETED | NCT05333107 |
| NNC0385-0434 G | DRUG | Phase PHASE1 | Healthy Volunteers; High Cholesterol | COMPLETED | NCT05333107 |
| DV3395 C1 | DEVICE | Phase PHASE1 | Healthy Volunteers, Medical Device | COMPLETED | NCT05314283 |
| Mim8 | DRUG | Phase PHASE3 | Haemophilia A | ACTIVE_NOT_RECRUITING | NCT05685238 |
| Standard heart failure medical therapy | DRUG | Phase PHASE4 | Advanced Heart Failure | RECRUITING | NCT05284955 |
| CardioMEMS HF System | DEVICE | Phase PHASE4 | Advanced Heart Failure | RECRUITING | NCT05284955 |
| Preventive treatment with oral hydration | OTHER | Approved | Contrast-induced Nephropathy | RECRUITING | NCT05283512 |
| Preventive treatment with IV-hydration | OTHER | Approved | Contrast-induced Nephropathy | RECRUITING | NCT05283512 |
| NNC0471-0119 D | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| NNC0471-0119 B | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| NNC0471-0119 A | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| Semaglutide 1 mg | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05259033 |
| NNC0174 0833 | DRUG | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05254158 |
| Non-Vagifem® LDVE, Estradiol | DRUG | Preclinical | Postmenopausal Vaginal Atrophy | COMPLETED | NCT05243823 |
| Vagifem® | DRUG | Preclinical | Postmenopausal Vaginal Atrophy | COMPLETED | NCT05243823 |
| Placebo ( Semaglutide D) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Placebo (Semaglutide C) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide C Dose 5 (50 mg) | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide C Dose 4 | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide D, 1.0 mg/mL | DRUG | Phase PHASE1 | Healthy Volunteers (Diabetes Mellitus, Type 2) | COMPLETED | NCT05232708 |
| Semaglutide B, 1.34 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05689099 |
| Semaglutide Dose 6 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide Dose 5 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide Dose 4 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05227196 |
| Semaglutide D Dose 3 | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide D Dose 2 | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Semaglutide D Dose 1 | DRUG | Phase PHASE1 | Obesity | COMPLETED | NCT05236517 |
| Conventional TURB | PROCEDURE | Approved | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05223491 |
| En Bloc resection | PROCEDURE | Approved | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05223491 |
| Biopsy | OTHER | Preclinical | Diabetes | UNKNOWN | NCT05209061 |
| Sitagliptin 100mg | DRUG | Phase PHASE4 | Liver Transplant; Complications | ENROLLING_BY_INVITATION | NCT05195944 |
| Semaglutide Treatment | DRUG | Phase PHASE4 | Liver Transplant; Complications | ENROLLING_BY_INVITATION | NCT05195944 |
| Heparin | DRUG | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT05178550 |
| NNC0480-0389 30 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| NNC0480-0389 10 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| Semaglutide 3.0 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| Placebo (NNC080-0389) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| placebo (semaglutide) | DRUG | Phase PHASE3 | Overweight and Obesity | COMPLETED | NCT05132088 |
| semaglutide 50 mg | DRUG | Phase PHASE3 | Overweight and Obesity | COMPLETED | NCT05132088 |
| NNC0385-0434 E | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| NNC0385-0434 D | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| NNC0385-0434 C | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| NNC0385-0434 B | DRUG | Phase PHASE1 | Healthy Volunteers; High Cholesterol | COMPLETED | NCT05333107 |
| Semaglutide I | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide H | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide G | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Semaglutide D | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05129891 |
| Mim8 B, placebo | DRUG | Phase PHASE1 | Healthy Volunteers - Haemophilia A | COMPLETED | NCT05127473 |
| Mim8 B, 100 mg/mL | DRUG | Phase PHASE1 | Healthy Volunteers - Haemophilia A | COMPLETED | NCT05127473 |
| Mim8 B, 10 mg/mL | DRUG | Phase PHASE1 | Healthy Volunteers - Haemophilia A | COMPLETED | NCT05127473 |
| Semaglutide 2.4mg | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT05087342 |
| turoctocog alfa pegol (N8-GP) | DRUG | Phase PHASE3 | Haemophilia A | COMPLETED | NCT05082116 |
| semaglutide 2.4 mg (placebo) | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT05064735 |
| semaglutide 2.4 mg | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT05064735 |
| Primed tracer infusion | BIOLOGICAL | Approved | Chronic Kidney Diseases | COMPLETED | NCT05056584 |
| Glucagon infusion | BIOLOGICAL | Approved | Chronic Kidney Diseases | COMPLETED | NCT05056584 |
| NNC0480-0389 A 10 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| Semaglutide 1.34 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| semaglutide 1.34 mg/mL (placebo) | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05046873 |
| oral glucose-lowering medications (commercially available) | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05035082 |
| Placebo (Ziltivekimab C) | DRUG | Phase PHASE3 | Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT05021835 |
| Placebo (Ziltivekimab B) | DRUG | Phase PHASE3 | Cardiovascular Risk | ACTIVE_NOT_RECRUITING | NCT05021835 |
| Ziltivekimab C | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05721989 |
| Ziltivekimab B | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05721989 |
| Placebo for DCR-AUD | DRUG | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT05021640 |
| DCR-AUD | DRUG | Phase PHASE1 | Alcohol Use Disorder | COMPLETED | NCT05845398 |
| NNC0174 0833 placebo | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| NNC0174 0833 10 mg/mL | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Semaglutide placebo | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Semaglutide 3 mg/mL | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| Placebo (NNC0194-0499) | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| NNC0194 0499 50 mg/mL | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT05016882 |
| IcoSema | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT06269107 |
| nedosiran | DRUG | Phase PHASE2 | Primary Hyperoxaluria | COMPLETED | NCT05001269 |
| Placebo (semaglutide 2.4 mg) | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT04998136 |
| Evolocumab 140 mg/mL, Repatha® | DRUG | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| Placebo II A (for NNC0385-0434 A 100 mg) | OTHER | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| Placebo I A (for NNC0385-0434 A 40 mg) | OTHER | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| NNC0385-0434 A 100 mg | DRUG | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT05094934 |
| Placebo I A (for NNC0385-0434 A 15 mg) | OTHER | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| NNC0385-0434 A 40 mg | DRUG | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| NNC0385-0434 A 15 mg | DRUG | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT04992065 |
| Placebo (cagrilintide) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04982575 |
| Cagrilintide 2.4 mg | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04982575 |
| Telemonitoring | DEVICE | Approved | Type 2 Diabetes Treated With Insulin | RECRUITING | NCT06185296 |
| PTM CILO/FIR | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| PTM SEMA | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| Cilofexor (CILO)/Firsocostat (FIR) | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| Semaglutide (SEMA) | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT04971785 |
| Semaglutide 2.4 mg and placebo 1.0 mg | DRUG | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Semaglutide 2.4 mg and NNC0165-1875 1.0 mg | DRUG | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Semaglutide 2.4 mg and placebo 2.0 mg | DRUG | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | DRUG | Phase PHASE2 | Obesity | COMPLETED | NCT04969939 |
| Xultophy® (insulin degludec/liraglutide) | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04952779 |
| Aerobic exercise training | BEHAVIORAL | Approved | Diabetes Mellitus, Type 2 | UNKNOWN | NCT04945551 |
| Cagrilintide and semaglutide | DRUG | Phase PHASE1 | Obesity & Overweight | COMPLETED | NCT04940078 |
| Cagrilintide | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | ACTIVE_NOT_RECRUITING | NCT06534411 |
| Semaglutide Pill | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT04938388 |
| Kidney Biopsy | PROCEDURE | Preclinical | Chronic Kidney Diseases | RECRUITING | NCT04916132 |
| Lee Symptom Scala | BEHAVIORAL | Approved | GVHD, Chronic | COMPLETED | NCT04884204 |
| Placebo semaglutide pen injector | DRUG | Phase PHASE4 | Pre Diabetes | RECRUITING | NCT04873050 |
| Semaglutide Pen Injector [Ozempic] | DRUG | Phase PHASE2 | Intestinal Mucositis | NOT_YET_RECRUITING | NCT06449625 |
| Glucagon-like peptide-1 (GLP-1) | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04809311 |
| Basal insulin | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04809311 |
| Oral antidiabetetic drugs | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04809311 |
| Placebo insulin degludec | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04795531 |
| Placebo insulin icodec | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04795531 |
| Semagludtide | DRUG | Phase PHASE3 | Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT04777396 |
| Belcesiran | DRUG | Phase PHASE2 | Alpha 1-Antitrypsin Deficiency | TERMINATED | NCT04764448 |
| Placebo Pen Injector | DRUG | Phase PHASE2 | Pouchitis | TERMINATED | NCT04763564 |
| Liraglutide Pen Injector | DRUG | Phase PHASE2 | Pouchitis | TERMINATED | NCT04763564 |
| Insulin Glargine 300U/mL | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| Insulin Glargine 100U/mL | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| HM-PRO | OTHER | Approved | Hematologic Malignancy | COMPLETED | NCT04757545 |
| Placebo (NNC0194-0499 ) | DRUG | Phase PHASE1 | Non-alcoholic Steatohepatitis | COMPLETED | NCT04722653 |
| Together on Diabetes | BEHAVIORAL | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT04722289 |
| BPD-DS as a revisional procedure | PROCEDURE | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| SADI-S as a revisional procedure | PROCEDURE | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Biliopancreatic diversion with duodenal switch | PROCEDURE | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Single anastomosis duodeno-ileal bypass | PROCEDURE | Approved | Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures | UNKNOWN | NCT04712409 |
| Novo Rapid | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04698018 |
| Faster Aspart | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04698018 |
| NNC0113-6891 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04676906 |
| NNC0113-6860 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04676906 |
| NNC0113-6861 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04676906 |
| Standard face-to-face patient education | OTHER | Approved | Rheumatoid Arthritis | COMPLETED | NCT04669340 |
| E-learning patient education | OTHER | Approved | Rheumatoid Arthritis | COMPLETED | NCT04669340 |
| Insulin degludec and liraglutide (IDegLira) | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04666987 |
| Ryzodeg® | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT05221580 |
| NNC0471-0119 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04655690 |
| CCK | OTHER | Approved | Gallbladder | COMPLETED | NCT04651868 |
| GLP-2 | OTHER | Approved | Gallbladder | COMPLETED | NCT04651868 |
| Placebo matching empagliflozin and placebo pen injector matching semaglutide | DRUG | Phase PHASE4 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT04639414 |
| Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide | DRUG | Phase PHASE4 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT04639414 |
| Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector | DRUG | Phase PHASE4 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT04639414 |
| Placebo (ziltivekimab) | DRUG | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04626505 |
| Semaglutide (1 Mg Dose) | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT04624672 |
| Etavopivat Tablets | DRUG | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Placebo Tablets | DRUG | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets High dose | DRUG | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Etavopivat Tablets Low dose | DRUG | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04624659 |
| Insulin Icodec | DRUG | Preclinical | Diabetes Mellitus, Type 1 | RECRUITING | NCT06807190 |
| FT-7051 | DRUG | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT04575766 |
| Placebo (NNC0268-0965) | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| Turoctocog alfa pegol (N8-GP) | DRUG | Preclinical | Haemophilia A | ENROLLING_BY_INVITATION | NCT04574076 |
| Rybelsus® | DRUG | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT04572165 |
| Active Comparator | DRUG | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT04572165 |
| Ozempic® | DRUG | Preclinical | Diabetes Mellitus, Type 2 | ENROLLING_BY_INVITATION | NCT04572165 |
| Placebo (NNC0363-0845) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04569994 |
| NNC0363-0845 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05134987 |
| Oral Semaglutide | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07225816 |
| Trial product 12 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 10 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 9 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 8 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 7 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 6 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 5 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 4 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 3 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 2 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Trial product 1 | OTHER | Phase PHASE1 | Obesity | COMPLETED | NCT04482725 |
| Eptacog alfa (activated) | DRUG | Preclinical | Severe Postpartum Haemorrhage | COMPLETED | NCT04444856 |
| NO intervention - observational study | OTHER | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT04304963 |
| NNC0361-0041 | DRUG | Phase PHASE1 | Type I Diabetes | COMPLETED | NCT04279613 |
| Placebo (NNC0472-0147) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04262661 |
| NNC0472-0147 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04262661 |
| Placebo (NNC0480-0389) | DRUG | Phase PHASE1 | Healthy Volunteers Type 2 Diabetes | COMPLETED | NCT04878406 |
| NNC0480-0389 | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| Semaglutide (administered by PDS290 pen-injector) | DRUG | Preclinical | Monogenic Obesity | RECRUITING | NCT07302802 |
| Semaglutide (administered by DV3396 pen-injector) | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT04238962 |
| Promestriene Vaginal | DRUG | Phase PHASE3 | Vulvovaginal Atrophy | COMPLETED | NCT04232813 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] | DRUG | Phase PHASE3 | Vulvovaginal Atrophy | COMPLETED | NCT04232813 |
| Placebo infusion (saline) | OTHER | Approved | Fibroblast Growth Factor 21 | COMPLETED | NCT04232033 |
| Fibroblast growth factor 21 infusion | OTHER | Approved | Fibroblast Growth Factor 21 | COMPLETED | NCT04232033 |
| Placebo (Mim8) | DRUG | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT04204408 |
| NNC0365-3769 (Mim8) | DRUG | Phase PHASE1 | Haemophilia A | COMPLETED | NCT05681845 |
| Long BPL RYGB | PROCEDURE | Approved | Obesity | UNKNOWN | NCT04196348 |
| Short BPL RYGB | PROCEDURE | Approved | Obesity | UNKNOWN | NCT04196348 |
| Forxiga | DRUG | Phase PHASE4 | Nephropathy | COMPLETED | NCT04193566 |
| belcesiran | DRUG | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | COMPLETED | NCT04174118 |
| Growth Hormone | BIOLOGICAL | Phase PHASE2 | TBI (Traumatic Brain Injury) | RECRUITING | NCT04121780 |
| Estradiol Vaginal Insert | DRUG | Phase PHASE4 | HIV Infection | COMPLETED | NCT04079218 |
| Acetaminophen | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT04074174 |
| Oral contraceptive (OC) tablets | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT04074174 |
| Placebo (liraglutide) | DRUG | Phase PHASE3 | Overweight | COMPLETED | NCT04074161 |
| Empagliflozin 25 MG | DRUG | Phase PHASE4 | Type 2 Diabetes With Renal Manifestations | UNKNOWN | NCT04061200 |
| Placebo, 1,34 mg/mL | OTHER | Phase PHASE4 | Type 2 Diabetes With Renal Manifestations | UNKNOWN | NCT04061200 |
| Cocktail of 5 already approved drugs | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04059367 |
| Placebo (NNC0385-0434) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04058834 |
| NNC0385-0434 | DRUG | Phase PHASE1 | Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk | COMPLETED | NCT05091073 |
| Somatropin injection | DRUG | Preclinical | Growth Hormone Deficiency | COMPLETED | NCT04020913 |
| Placebo (sitagliptin) | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| Placebo (oral semaglutide) | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| Oral semaglutide | DRUG | Phase PHASE3 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT07271251 |
| Cross-over study | OTHER | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT05375656 |
| Placebo (NNC0247-0829) | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT04010786 |
| NNC0247-0829 | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT04010786 |
| Semaglutide (administered by PDS290 pen) | DRUG | Phase PHASE2 | Healthy Volunteers Diabetes Mellitus, Type 2 | COMPLETED | NCT04143945 |
| Semaglutide (administered by DV3396 pen) | DRUG | Phase PHASE2 | Healthy Volunteers Diabetes Mellitus, Type 2 | COMPLETED | NCT04143945 |
| Cilofexor | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03987074 |
| Firsocostat | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03987074 |
| Norditropin® FlexPro® | DRUG | Preclinical | Growth Hormone Deficiency in Children | ENROLLING_BY_INVITATION | NCT03972345 |
| NNC0268-0965 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| Ziltivekimab | DRUG | Phase PHASE3 | Heart Failure | RECRUITING | NCT06200207 |
| Fiasp® | DRUG | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT03895515 |
| Refixia® | DRUG | Preclinical | Haemophilia B | COMPLETED | NCT03875547 |
| Clinical and demographic data | OTHER | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Blood samples | BIOLOGICAL | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Dual Energy X-ray Absorptiometry (DEXA) scan | RADIATION | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Continuous glucose monitoring (CGM) for four days. | DEVICE | Preclinical | Non-Alcoholic Fatty Liver Disease | TERMINATED | NCT03866421 |
| Lifestyle Therapy | BEHAVIORAL | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT03862716 |
| Placebo (Liraglutide 3.0 mg) | DRUG | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Phase PHASE1 | Primary Hyperoxaluria Type 3 | COMPLETED | NCT04555486 |
| iLet™ | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03816761 |
| Norditropin® | DRUG | Phase PHASE3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | ACTIVE_NOT_RECRUITING | NCT05330325 |
| Medication for chronic weight management (Rx) | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT03799198 |
| Weight Management Program (WMP) | OTHER | Phase PHASE4 | Obesity | COMPLETED | NCT03799198 |
| Saxenda® | DRUG | Preclinical | Obesity or Overweight | COMPLETED | NCT05153590 |
| NNC0148-0287 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03789578 |
| NNC0148-0287sema | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03789578 |
| Placebo for DCR-HBVS | DRUG | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT03772249 |
| DCR-HBVS | DRUG | Phase PHASE1 | Hepatitis B, Chronic | COMPLETED | NCT03772249 |
| insulin icodec | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05435677 |
| Placebo (insulin glargine) | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04575181 |
| Dipeptidyl peptidase-4 inhibitors | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Placebo (insulin 287) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03751657 |
| Insulin Degludec/Insulin Aspart | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT04892069 |
| Insulin Degludec (U-100) | DRUG | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT03737240 |
| IDegLira | DRUG | Preclinical | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT06113341 |
| IGlar U100 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723772 |
| Faster aspart 100 U/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723759 |
| Faster Aspart 200 U/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03723759 |
| Smoking Cessation Counseling | BEHAVIORAL | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03712098 |
| Placebo (NNC0165-1875) | DRUG | Phase PHASE1 | Obesity and Overweight | COMPLETED | NCT03707990 |
| NNC0165-1875 | DRUG | Phase PHASE1 | Obesity and Overweight | COMPLETED | NCT03707990 |
| Placebo (Semaglutide) | DRUG | Phase PHASE3 | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | COMPLETED | NCT04916470 |
| Nonacog beta pegol | DRUG | Phase PHASE3 | Haemophilia B | COMPLETED | NCT05365217 |
| Insulin glargine U100 | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03922750 |
| N-acetylcysteine | DRUG | Phase PHASE1 | Drug-Induced Acute Liver Injury | COMPLETED | NCT03679442 |
| LANTUS® SOLOSTAR® INSULIN PEN | DEVICE | Phase PHASE4 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03668808 |
| TRESIBA® FLEXTOUCH® | DEVICE | Phase PHASE4 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03668808 |
| Placebo (NNC9204-1706) | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03661879 |
| NNC9204-1706 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03661879 |
| Semaglutide D 7 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide D 3 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide C 7 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide C 3 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide B 7 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide B 3 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide 7 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Semaglutide 3 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03638778 |
| Placebo (NNC0113-2023) | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03617081 |
| NNC0113-2023 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03617081 |
| PDS290 pen-injector | DEVICE | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| DV3372 | DEVICE | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Semaglutide, 1.0 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Semaglutide, 0.5 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Semaglutide, 0.25 mg | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03611322 |
| Placebo (NNC0174-0833) | DRUG | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| NovoPen®4 | DEVICE | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| PDS290 | DEVICE | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| DV3372, 1.0 mg/mL | DEVICE | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| DV3372, 0.5 mg/mL | DEVICE | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 2.0 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 1.34 mg/mL | DRUG | Phase PHASE4 | Type 2 Diabetes With Renal Manifestations | UNKNOWN | NCT04061200 |
| Semaglutide, 1.0 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Semaglutide, 0.5 mg/mL | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03598621 |
| Standard of care | OTHER | Preclinical | Post Partum Hemorrhage | COMPLETED | NCT04723979 |
| Insulin aspart (standard of care insulin) + closed loop device | DEVICE | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT03579615 |
| FIASP + closed loop device | DEVICE | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT03579615 |
| Placebo (NNC0165-1562) | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorders | COMPLETED | NCT03574584 |
| Indocyanine Green (ICG) | DRUG | Approved | Secondary Lymphedema | UNKNOWN | NCT03572998 |
| Placebo II (Semaglutide) | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Placebo I (Semaglutide) | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Semaglutide 2.4 mg | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT05040971 |
| Turoctocog alfa pegol | DRUG | Preclinical | Haemophilia A | ENROLLING_BY_INVITATION | NCT04682145 |
| Metformin Hydrochloride | DRUG | Phase PHASE4 | Heart Failure | COMPLETED | NCT03514108 |
| Hydralazine Isosorbide Dinitrate | DRUG | Phase PHASE4 | Heart Failure | COMPLETED | NCT03514108 |
| Recombinant Activated Factor VII (rFVIIa) | BIOLOGICAL | Phase PHASE3 | Intracerebral Hemorrhage | ACTIVE_NOT_RECRUITING | NCT03496883 |
| Placebo Liraglutide Pen Injector | DRUG | Phase PHASE3 | Pre Diabetes | COMPLETED | NCT03480022 |
| Liraglutide Pen Injector [Saxenda] | DRUG | Phase PHASE3 | Pre Diabetes | COMPLETED | NCT03480022 |
| Ciclosporin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03466567 |
| Probenecid | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03466567 |
| Fast-acting insulin aspart | DRUG | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT05069545 |
| NNC9204-1513 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03444467 |
| Needs assesment tool integrated in nursing consultation. | OTHER | Approved | Head and Neck Neoplasms | COMPLETED | NCT03443258 |
| Somatropin | DRUG | Preclinical | Genetic Disorder | COMPLETED | NCT03435627 |
| Insulin degludec /insulin aspart | DRUG | Preclinical | Diabetes | COMPLETED | NCT03416855 |
| Insulin aspart (NovoRapid®) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03407599 |
| Faster aspart | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT05262595 |
| DCR-PHXC | DRUG | Phase PHASE2 | Primary Hyperoxaluria Type 1 | RECRUITING | NCT04580420 |
| BIAsp 30 | DRUG | Preclinical | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT03862690 |
| Starter Kit Algorithm | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03365180 |
| Insulin Degludec U100 | DRUG | Phase PHASE4 | Type2 Diabetes | TERMINATED | NCT03349840 |
| Aspart | DRUG | Phase PHASE4 | Type1 Diabetes Mellitus | COMPLETED | NCT04409587 |
| Degludec | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03336528 |
| PLACEBO | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03308721 |
| NNC9204-1177 A 1.0 mg/mL | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03308721 |
| Placebo (semaglutide 1.0 mg) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Placebo (semaglutide 0.5 mg) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml | DRUG | Phase PHASE3 | Binge-Eating Disorder | TERMINATED | NCT03279731 |
| matching liraglutide-placebo pre-filled pens | DRUG | Phase PHASE4 | Type2 Diabetes | COMPLETED | NCT03260881 |
| Liraglutide Pen Injector [Victoza] | DRUG | Phase PHASE3 | Type 2 Diabetes | WITHDRAWN | NCT04057261 |
| Insulin Degludec 100 UNT/ML [Tresiba] | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT03244241 |
| Cornerstones4Care Powered by Glooko App | DEVICE | Approved | Diabetes Mellitus, Type 2 | UNKNOWN | NCT03222284 |
| Turoctocog alfa | DRUG | Preclinical | Congenital Bleeding Disorder | RECRUITING | NCT06574984 |
| Eptacog alfa | DRUG | Preclinical | Post Partum Hemorrhage | COMPLETED | NCT04723979 |
| Somapacitan | DRUG | Preclinical | Growth Hormone Deficiency | ENROLLING_BY_INVITATION | NCT06709040 |
| Placebo (semaglutide) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05144984 |
| Placebo (canagliflozin) | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT03136484 |
| Canagliflozin | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT03136484 |
| RYGB | PROCEDURE | Phase PHASE3 | Obesity | COMPLETED | NCT03115424 |
| NNC9204-1706 A | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT03095807 |
| Continuous Glucose Monitor (CGM) alone | OTHER | Approved | Type1 Diabetes Mellitus | COMPLETED | NCT03093636 |
| Continuous Glucose Monitor (CGM)+Decision Support System (DSS) | DEVICE | Approved | Type1 Diabetes Mellitus | COMPLETED | NCT03093636 |
| ALPROLIX® | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT03075670 |
| N9-GP | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT03075670 |
| Norditropin | DRUG | Preclinical | Noonan Syndrome | ENROLLING_BY_INVITATION | NCT05308927 |
| Semaglutide placebo 1.0 mg | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Semaglutide placebo 0.5 mg | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Sitagliptin placebo | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT03061214 |
| Semaglutide 1.0 mg | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT03552757 |
| Semaglutide 0.5 mg | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03288740 |
| Specialist Obesity Management Services | OTHER | Phase PHASE4 | Obesity | COMPLETED | NCT03036800 |
| Saxenda | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT03115424 |
| Cardiac CT | RADIATION | Approved | Diabetes | UNKNOWN | NCT03022344 |
| NNC0194-0499 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | ACTIVE_NOT_RECRUITING | NCT07087795 |
| Rosuvastatin | DRUG | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Furosemide | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03010475 |
| There is no intervention | OTHER | Preclinical | Diabetic Nephropathies | RECRUITING | NCT02986984 |
| Normal physical activity | BEHAVIORAL | Approved | Type 2 Diabetes Mellitus | COMPLETED | NCT02982408 |
| no treatment | OTHER | Preclinical | Quality of Life | COMPLETED | NCT02965144 |
| CMS Intensive Behavior Therapy | BEHAVIORAL | Phase PHASE3 | Metabolism and Nutrition Disorder | COMPLETED | NCT02963935 |
| Liraglutide 3.0 mg | DRUG | Phase PHASE2 | Overweight | COMPLETED | NCT03856047 |
| NNC9204-1177 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04059367 |
| Levothyroxine | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02920385 |
| Semaglutide | DRUG | Preclinical | Obesity | ENROLLING_BY_INVITATION | NCT07081178 |
| Neutral drinking-water | OTHER | Approved | Healthy Participants | COMPLETED | NCT02917616 |
| Alkaline drinking-water | OTHER | Approved | Healthy Participants | COMPLETED | NCT02917616 |
| Insulin degludec | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | RECRUITING | NCT06685185 |
| Insulin degludec/liraglutide | DRUG | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03823339 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07023029 |
| Extension Study CMS-recommended lifestyle counseling | BEHAVIORAL | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Phentermine 15 MG | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Placebo Oral Tablet | DRUG | Phase PHASE4 | Heart Failure | COMPLETED | NCT03514108 |
| Portion-Controlled Diet | OTHER | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Liraglutide 3.0mg | DRUG | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| CMS-recommended lifestyle counseling | BEHAVIORAL | Phase PHASE4 | Obesity | COMPLETED | NCT02911818 |
| Insulin degludec/insulin aspart | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT02906917 |
| Liraglutide 3 mg placebo | DRUG | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT02905864 |
| Liraglutide 3 mg (Saxenda) | DRUG | Phase PHASE4 | Osteoarthritis | COMPLETED | NCT02905864 |
| COR-001 | DRUG | Phase PHASE1 | Anemia | COMPLETED | NCT02868229 |
| empagliflozin | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT02863328 |
| Microgynon® | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05153564 |
| SNAC | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03010475 |
| DCR-PH1 | DRUG | Phase PHASE1 | Primary Hyperoxaluria Type 1 | TERMINATED | NCT02795325 |
| liraglutide 3.0 mg | DRUG | Preclinical | Obesity | COMPLETED | NCT02773355 |
| thiazolidinediones | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| SGLT-2 inhibitors | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| meglitinides | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| DPP-4 inhibitors | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| alpha-glucosidase inhibitors | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| Dulaglutide | DRUG | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT04189848 |
| DV3316 pen-injector | DEVICE | Phase PHASE1 | Diabetes | COMPLETED | NCT02627287 |
| standard antenatal care | OTHER | Phase PHASE4 | Diabetes | COMPLETED | NCT02617693 |
| lifestyle intervention | BEHAVIORAL | Phase PHASE4 | Diabetes | COMPLETED | NCT02617693 |
| Control Group | OTHER | Approved | Type 1 Diabetes | TERMINATED | NCT02617160 |
| MD-Logic Pump Advisor | DEVICE | Approved | Type 1 Diabetes | TERMINATED | NCT02617160 |
| NNC0143-0406 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02938572 |
| 3D-Transit after Malone appendicostomy | DEVICE | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| 3D-Transit during treatment with Pyridostigmine | DRUG | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| 3D-Transit | DEVICE | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| 11C Donepezil PET/CT scan | RADIATION | Approved | Diabetic Autonomic Neuropathy | TERMINATED | NCT02573519 |
| NNC0165-1562 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorders | COMPLETED | NCT03574584 |
| Subcutaneous insertions of needles | DEVICE | Approved | Diabetes Mellitus, Type 2 | COMPLETED | NCT02531776 |
| Omron Walking Style pro. 20 | DEVICE | Approved | Colorectal Cancer | COMPLETED | NCT02522520 |
| Pedometer + hospital based intervention | BEHAVIORAL | Approved | Colorectal Cancer | COMPLETED | NCT02522520 |
| Pedometer intervention | BEHAVIORAL | Approved | Colorectal Cancer | COMPLETED | NCT02522520 |
| Meal Test | OTHER | Preclinical | Bone Remodeling | COMPLETED | NCT02518737 |
| Concizumab | DRUG | Preclinical | Haemophilia A, Haemophilia B | ENROLLING_BY_INVITATION | NCT06831734 |
| Outdoor weather | OTHER | Preclinical | Nonshivering Thermogenisis | COMPLETED | NCT02486419 |
| None, observational study | OTHER | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT02486237 |
| Insulin 320 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02479022 |
| Regular Human Insulin | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02415556 |
| Mixed Meal Tolerance Test with paracetamol | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT02408705 |
| Sugar Pill | DRUG | Phase PHASE4 | Insulin Resistance | COMPLETED | NCT02403284 |
| Physical activity intervention | BEHAVIORAL | Approved | Type 2 Diabetes | COMPLETED | NCT02371239 |
| Pancreatic clamp | OTHER | Approved | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT02337660 |
| Liver biopsy | PROCEDURE | Approved | Non-alcoholic Fatty Liver Disease | COMPLETED | NCT02337660 |
| NNC0174-0833 | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT04209049 |
| Liraglutide or Placebo | DRUG | Phase PHASE4 | Diabetes Mellitus, Non-Insulin-Dependent | COMPLETED | NCT02299388 |
| Omeprazole | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02249871 |
| Insulin 338 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02220296 |
| Sitagliptin | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04017832 |
| survey | BEHAVIORAL | Preclinical | Diabetes | COMPLETED | NCT01950650 |
| Other: 4. Usual care | BEHAVIORAL | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| Experimental: 3. Experimental | BEHAVIORAL | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| Experimental: 2. Experimental | BEHAVIORAL | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| Experimental: 1. Experimental | BEHAVIORAL | Approved | Lung Cancer | TERMINATED | NCT01893580 |
| other injectable antidiabetic treatment regimens | DRUG | Preclinical | Diabetes Mellitus | COMPLETED | NCT01892319 |
| Insulin (glargine) | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT01794143 |
| GLP-1 receptor agonist (liraglutide) | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT01794143 |
| DPP-4 inhibitor (sitagliptin) | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT01794143 |
| Sulfonylurea (glimepiride) | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT01794143 |
| insulin degludec/insulin aspart 15 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01773798 |
| Soccer training | BEHAVIORAL | Approved | Prostatic Neoplasms | COMPLETED | NCT01711892 |
| Blast Traumatic Brain Injury | OTHER | Preclinical | Traumatic Brain Injury | UNKNOWN | NCT01666964 |
| Personal instruction | BEHAVIORAL | Approved | Musculoskeletal Disorders | COMPLETED | NCT01543893 |
| Video instruction | BEHAVIORAL | Approved | Musculoskeletal Disorders | COMPLETED | NCT01543893 |
| digoxin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02249910 |
| griseofulvin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01518166 |
| atorvastatin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02243098 |
| oestrogen | DRUG | Phase PHASE4 | Genetic Disorder | COMPLETED | NCT01518062 |
| liraglutide [3H] | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01517568 |
| paracetamol | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01517555 |
| NordiFlex PenMate™ | DEVICE | Preclinical | Growth Hormone Disorder | COMPLETED | NCT01500486 |
| NNC 0123-0000-0338 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01334034 |
| Insulin Asparte | DRUG | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00072904 |
| NNC9204-0530 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | COMPLETED | NCT02870231 |
| DPP-4 inhibitor | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT02207374 |
| NNC0090-2746 | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT02205528 |
| Metformin | DRUG | Phase PHASE1 | Healthy Volunteers Sickle Cell Disease, Thalassemia | COMPLETED | NCT06813924 |
| Insulin icodec | DRUG | Preclinical | Diabetes Mellitus, Type 1 | RECRUITING | NCT07160816 |
| Liraglutide treatment | DRUG | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02138045 |
| Placebo treatment | DRUG | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02138045 |
| Diet/exercise | BEHAVIORAL | Phase PHASE3 | Diabetes | TERMINATED | NCT02131272 |
| Insulin NPH | DRUG | Phase PHASE3 | Diabetes | TERMINATED | NCT02131272 |
| DCR-MYC | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02314052 |
| Adalimumab | DRUG | Phase PHASE2 | Inflammation | WITHDRAWN | NCT02097264 |
| Synthetic mesh | DEVICE | Approved | Abdominal Donor-site | COMPLETED | NCT02076724 |
| Biological mesh | DEVICE | Approved | Abdominal Donor-site | COMPLETED | NCT02076724 |
| lisinopril | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02070510 |
| lixisenatide | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01973231 |
| Genotropin Pen® | DRUG | Phase PHASE1 | Growth Disorder | COMPLETED | NCT01943084 |
| Norditropin® FlexPro® pen | DRUG | Phase PHASE2 | Growth Hormone Disorder | COMPLETED | NCT02616562 |
| Glargine + OADs | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01919489 |
| Liraglutide + OADs | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01919489 |
| insulin degludec/insulin aspart 55 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 45 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 50 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01865331 |
| insulin degludec/insulin aspart 40 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| insulin degludec/insulin aspart 30 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01868568 |
| basal insulin | DRUG | Preclinical | Type 2 Diabetes | COMPLETED | NCT06236672 |
| Insulin Degludec | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT04760626 |
| Basal-bolus detemir-aspart insulin regimen | DRUG | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT01828970 |
| insulin 287 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01809184 |
| Early intervention | BEHAVIORAL | Approved | Health Behavior | COMPLETED | NCT01799447 |
| insulin 338 (GIPET I) | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT02470039 |
| Atenolol | DRUG | Approved | Healthy | UNKNOWN | NCT01795235 |
| Glucagon | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | COMPLETED | NCT06588504 |
| Placebos | DRUG | Phase PHASE3 | Obesity | COMPLETED | NCT03115424 |
| glucose clamp | OTHER | Phase PHASE1 | Diabetes | COMPLETED | NCT01789593 |
| Plasma-derived FVII conc. (pdFVII PFL) | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Plasma-derived FVII conc. (pdFVII Baxter) | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Prothrombin Complex conc. (PCC) | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Plasma-derived FVII (LFB) | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Fresh frozen plasma (Source unspecified) | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT01779921 |
| Liraglutide - Placebo | DRUG | Phase PHASE4 | Diabetes Mellitus Type 2 | COMPLETED | NCT02660047 |
| sodium chloride 0.9% w/v | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01730014 |
| 148-0287-A-4.2mM-cartridge | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01730014 |
| 17-beta estradiol | DRUG | Phase PHASE3 | Genetic Disorder | COMPLETED | NCT01710696 |
| NNC0113-0987 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02094521 |
| sodium chloride 0.9% solution | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01680328 |
| 19 injections | OTHER | Phase PHASE1 | Diabetes | COMPLETED | NCT01680328 |
| Placebo-liraglutide | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT01664676 |
| biphasic human insulin 50 | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01892020 |
| NNC0109-0012 | DRUG | Phase PHASE2 | Inflammation | WITHDRAWN | NCT02097264 |
| placebo injection | DRUG | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01628445 |
| SOMATROPINE* : Norditropine® simplexx® | DRUG | Phase PHASE2 | Anorexia Nervosa | COMPLETED | NCT01626833 |
| NNC0215-0384 | DRUG | Phase PHASE1 | Inflammation | COMPLETED | NCT01955603 |
| Glimepiride | DRUG | Phase PHASE2 | Maturity-onset Diabetes of the Young | COMPLETED | NCT01610934 |
| NNC 0148-0000-0362 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01597713 |
| 2 mg estradiol / 1 mg norethisterone acetate (NETA) | DRUG | Phase PHASE1 | Menopause | COMPLETED | NCT01596010 |
| NNC0114-0006 | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT02443155 |
| standard therapy | DRUG | Phase PHASE2 | Acquired Bleeding Disorder | TERMINATED | NCT01564563 |
| clopidogrel | DRUG | Phase PHASE1 | Haemostasis | COMPLETED | NCT01603342 |
| warfarin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02070510 |
| factor VIII | DRUG | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT01561391 |
| factor IX | OTHER | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT01561391 |
| MEDI5117 Placebo | BIOLOGICAL | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT01559103 |
| MEDI5117 | BIOLOGICAL | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT01559103 |
| Health counseling and exercise | BEHAVIORAL | Phase EARLY_PHASE1 | Acute Leukemia | COMPLETED | NCT01557686 |
| NNC172-2021 | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | TERMINATED | NCT01631942 |
| observational study | OTHER | Preclinical | Hemorrhage | COMPLETED | NCT01532661 |
| electrocardiogram (ECG) | PROCEDURE | Phase PHASE1 | Diabetes | COMPLETED | NCT01516255 |
| moxifloxacin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02064348 |
| placebo (somapacitan) | DRUG | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01514500 |
| somapacitan | DRUG | Phase PHASE3 | Growth Hormone Deficiency in Children | COMPLETED | NCT04970654 |
| oral anti-diabetic drug | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT01512108 |
| levonorgestrel / ethinylestradiol | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01508858 |
| Saline | DRUG | Approved | Healthy | UNKNOWN | NCT01795235 |
| Marketed low dose hormone replacement therapy | DRUG | Preclinical | Menopause | COMPLETED | NCT01487304 |
| human soluble insulin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02162407 |
| 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) | DRUG | Phase PHASE4 | Menopause | COMPLETED | NCT01705249 |
| liraglutide-depot | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01473953 |
| gastric bypass | PROCEDURE | Preclinical | Obesity | COMPLETED | NCT01463449 |
| Open-loop control | OTHER | Approved | Type 1 Diabetes | COMPLETED | NCT01444443 |
| Closed-loop control | DEVICE | Approved | Type 1 Diabetes | COMPLETED | NCT01444443 |
| oral placebo | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT01923181 |
| I.v. NNC 0113-0987 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01405261 |
| oral NNC 0113-0987 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01405261 |
| Exercise based multimodal intervention | OTHER | Approved | Acute Leukemia | COMPLETED | NCT01404520 |
| Remote ischemic conditioning | OTHER | Approved | Kidney Transplantation | UNKNOWN | NCT01395719 |
| IVGTT | OTHER | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| OGTT | OTHER | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| TNF-alfa | DRUG | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| Placebo (Saline) | DRUG | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| GLP-1 | DRUG | Approved | Hypoglycaemia | COMPLETED | NCT01347801 |
| Isotone NaCl | BIOLOGICAL | Approved | Kidney Functional | COMPLETED | NCT01333163 |
| Human GLP-1 (7-36) amide | BIOLOGICAL | Approved | Kidney Functional | COMPLETED | NCT01333163 |
| Microgyn® | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01324505 |
| counseling and behavioral therapy for weight loss | BEHAVIORAL | Approved | Obesity | COMPLETED | NCT01312090 |
| Whole body cryotherapy | BIOLOGICAL | Approved | Obesity | COMPLETED | NCT01312090 |
| neutral protamine insulin | DRUG | Approved | Type 2 Diabetes Mellitus | UNKNOWN | NCT01310452 |
| NNC109-0012 | DRUG | Phase PHASE2 | Inflammation | COMPLETED | NCT01282255 |
| NNC 0128-0000-2021 | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01272206 |
| NNC 0128-0000-2011 | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01288391 |
| Exercise | OTHER | Approved | Overweight and Obesity | ACTIVE_NOT_RECRUITING | NCT05768958 |
| Education | OTHER | Approved | Type 1 Diabetes | COMPLETED | NCT01223547 |
| Victoza® | DRUG | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01208012 |
| NN1218 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01121289 |
| Faster-acting insulin aspart | DRUG | Preclinical | Diabetes Mellitus, Type 1 | COMPLETED | NCT03987802 |
| NN9924 (i.v.) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| NN9924 (s.c.) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| NN9924 (oral) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01037582 |
| NN1952 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01028404 |
| insulin degludec/liraglutide | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03292185 |
| PDAphone | DEVICE | Approved | TYPE 2 DIABETES | COMPLETED | NCT00937703 |
| IVS | DEVICE | Approved | TYPE 2 DIABETES | COMPLETED | NCT00937703 |
| Novofine needle | DEVICE | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00894270 |
| Placebo injection | PROCEDURE | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00894270 |
| Sterile air injection | PROCEDURE | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00894270 |
| Chronic care multidisciplinary intervention of childhood obesity | OTHER | Preclinical | Childhood Obesity | COMPLETED | NCT00823277 |
| insulin aspart protamine/insulin aspart 70/30 mix | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00821795 |
| NPH/Regular 70/30 mix | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00821795 |
| biphasic insulin aspart 70 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01620333 |
| placebo+placebo | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00699426 |
| nexium | DRUG | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00699426 |
| short-acting Insulin (Actrapid) | DRUG | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00662714 |
| Repaglinide | DRUG | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00662714 |
| NovoPen® 3 | DEVICE | Preclinical | Diabetes | COMPLETED | NCT01454024 |
| NovoPen™ 4 | DEVICE | Phase PHASE3 | Diabetes | COMPLETED | NCT00569998 |
| rehabilitation | OTHER | Phase PHASE2 | Quality of Life | COMPLETED | NCT00569478 |
| somatotropin | DRUG | Phase PHASE2 | Muscular Atrophy, Spinal | COMPLETED | NCT00533221 |
| NPH insulin | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT03220425 |
| detemir | DRUG | Approved | Type 2 Diabetes | COMPLETED | NCT00457093 |
| glargine | DRUG | Approved | Type 2 Diabetes | COMPLETED | NCT00457093 |
| Subjects without diabetes will have their blood glucose levels monitored while in the hospital | BEHAVIORAL | Approved | Type 2 Diabetes | TERMINATED | NCT00456105 |
| Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team | BEHAVIORAL | Approved | Type 2 Diabetes | TERMINATED | NCT00456105 |
| Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician | BEHAVIORAL | Approved | Type 2 Diabetes | TERMINATED | NCT00456105 |
| Rosiglitazone | DRUG | Phase PHASE4 | Type 1 Diabetes | COMPLETED | NCT00372086 |
| dual-action insulin analog | DRUG | Approved | Diabetes Mellitus, Type 2 | UNKNOWN | NCT00348231 |
| Hormone replacement therapy | DRUG | Phase PHASE4 | Osteoporosis | COMPLETED | NCT00252408 |
| Actrapid® (Insulin) | DRUG | Phase PHASE3 | Severe Sepsis | COMPLETED | NCT00135473 |
| Sterofundin® (Ringer lactate solution) | DRUG | Phase PHASE3 | Severe Sepsis | COMPLETED | NCT00135473 |
| 10% Hemohes® (10% Hydroxyethyl starch) | DRUG | Phase PHASE3 | Severe Sepsis | COMPLETED | NCT00135473 |
| administration of autologous stored platelets | OTHER | Phase PHASE2 | Bleeding | COMPLETED | NCT01248351 |
| autologous stored platelets | BIOLOGICAL | Phase PHASE2 | Bleeding | COMPLETED | NCT01248351 |
| Norditropin NordiFlex® | DRUG | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01706783 |
| Liraglutide-placebo | OTHER | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT01237119 |
| Liraglutide | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07225816 |
| Metformin XR plus liraglutide | DRUG | Phase PHASE3 | Gestational Diabetes Mellitus | COMPLETED | NCT01234649 |
| Metformin XR plus placebo | DRUG | Phase PHASE3 | Gestational Diabetes Mellitus | COMPLETED | NCT01234649 |
| liraglutide plus insulin detemir | DRUG | Approved | Type 2 Diabetes | COMPLETED | NCT01232946 |
| NNC 0172-0000-2021 | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT01228669 |
| NNC0114-0000-0005 | DRUG | Phase PHASE1 | Inflammation | COMPLETED | NCT01208506 |
| turoctocog alfa pegol | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT02994407 |
| NovoPen Echo® | DEVICE | Preclinical | Diabetes | COMPLETED | NCT01180530 |
| Epidemiological intervention | OTHER | Preclinical | Diabetes Mellitus | COMPLETED | NCT01117831 |
| Aspart flexible dose | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01101867 |
| Aspart fixed dose | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01101867 |
| Norditropin SimpleXx (growth hormone) | DRUG | Phase PHASE2 | Growth Hormone Deficiency | COMPLETED | NCT01090778 |
| Placebo | DRUG | Phase PHASE3 | Non-alcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT04822181 |
| Hydrocortisone | DRUG | Phase PHASE4 | Partial Corticotrope Insufficiency | TERMINATED | NCT01089075 |
| NN9925 (i.v.) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01087645 |
| NN9925 (oral) | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01087645 |
| recombinant factor XIII | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT02670213 |
| DexCom CGM | DEVICE | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| SenseWear Pro3® armband | DEVICE | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Insulin-Levemir and Exenatide-Bayetta | DRUG | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Exenatide-Bayetta | DRUG | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| Insulin-Levemir | DRUG | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01076842 |
| '2-0453 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | TERMINATED | NCT01044108 |
| NNC 0070-0002-0453 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | TERMINATED | NCT01044108 |
| Norditropin® SimpleXx® | DRUG | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01034202 |
| gliclazide | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01022762 |
| NNC 0151-0000-0000 | DRUG | Phase PHASE1 | Inflammation | COMPLETED | NCT02151409 |
| Insulin detemir and pre-meal insulin aspart. | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00998335 |
| Long-acting bedtime insulin detemir (Levemir) | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00998335 |
| nonacog beta pegol | DRUG | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT02141074 |
| activated recombinant human factor VII, long acting | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT00951873 |
| Insulin (Aspart Insulin [Novolog], Regular Insulin) | DRUG | Approved | Diabetic Ketoacidosis | COMPLETED | NCT00920725 |
| Erythropoietin | DRUG | Phase PHASE2 | Mood Disorders | COMPLETED | NCT00916552 |
| gastric bypass surgery and testing | PROCEDURE | Preclinical | Gastric Bypass | COMPLETED | NCT00915980 |
| Levemir (Detemir) and Novolog (Aspart) Insulin | DRUG | Phase PHASE4 | Type 2 Diabetes | WITHDRAWN | NCT00906529 |
| Euglycaemic hyperinsulinaemic clamp | OTHER | Phase PHASE1 | Diabetes | COMPLETED | NCT00897169 |
| Oral Glucose Tolerance Test (OGTT) | OTHER | Phase PHASE1 | Diabetes | COMPLETED | NCT00897169 |
| Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00888732 |
| NovoFine® needle 8 mm | DEVICE | Phase PHASE4 | Diabetes | COMPLETED | NCT01024218 |
| NovoFine® needle 12 mm | DEVICE | Phase PHASE3 | Diabetes | COMPLETED | NCT00871416 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | DRUG | Phase PHASE1 | Turner's Syndrome | TERMINATED | NCT00870220 |
| Detemir or Glargine | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00862875 |
| Nurse case management | OTHER | Approved | Colonic Neoplasms | COMPLETED | NCT00845247 |
| turoctocog alfa | DRUG | Phase PHASE4 | Congenital Bleeding Disorder | COMPLETED | NCT03449342 |
| Advate® | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | COMPLETED | NCT00837356 |
| insulin glulisine | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT00824668 |
| anti-IL-20 | DRUG | Phase PHASE1 | Inflammation | TERMINATED | NCT01261767 |
| insulin analogue | DRUG | Preclinical | Diabetes | COMPLETED | NCT00806936 |
| NovoPen® 4 | DEVICE | Preclinical | Diabetes | COMPLETED | NCT00806858 |
| No treatment given | OTHER | Preclinical | Obesity | COMPLETED | NCT06843473 |
| biphasic human insulin 30 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01707160 |
| sulphonylurea | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02730377 |
| Tablet treatment | DRUG | Approved | Latent Autoimmune Diabetes in Adults LADA | UNKNOWN | NCT00776607 |
| NovoMix 30 | DRUG | Approved | Latent Autoimmune Diabetes in Adults LADA | UNKNOWN | NCT00776607 |
| FlexTouch® | DEVICE | Phase PHASE3 | Diabetes | COMPLETED | NCT00773279 |
| human regular insulin and NPH insulin (Actrapid, Protaphne) | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT00747409 |
| insulin aspart and detemir (NovoRapid, Levemir) | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT00747409 |
| NNC 0070-0002-0349 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | WITHDRAWN | NCT00728455 |
| Detemir | DRUG | Approved | Diabetes | ACTIVE_NOT_RECRUITING | NCT01239550 |
| NNC126-0083 | DRUG | Phase PHASE1 | Growth Hormone Disorder | COMPLETED | NCT01034202 |
| insulin | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01720303 |
| automated telephone intervention vs. usual care | BEHAVIORAL | Approved | Type 2 Diabetes | COMPLETED | NCT00700908 |
| sitagliptin | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT02849080 |
| semaglutide | DRUG | Preclinical | Endometrial Cancer | NOT_YET_RECRUITING | NCT07462663 |
| NNC 0070-0002-0182 | DRUG | Phase PHASE1 | Metabolism and Nutrition Disorder | TERMINATED | NCT00665665 |
| Usual care as prescribed by the ED physicians. | DRUG | Phase PHASE4 | Diabetes | WITHDRAWN | NCT00663624 |
| aspart insulin | DRUG | Phase PHASE4 | Diabetes | WITHDRAWN | NCT00663624 |
| EX1000 | DRUG | Phase PHASE2 | Diabetes | COMPLETED | NCT00698802 |
| Insulin aspart | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07076199 |
| insulin aspart + insulin aspart protamin | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00657943 |
| insulin detemir [rDNA origin] injection | DRUG | Phase PHASE2 | Cystic Fibrosis Related Diabetes | TERMINATED | NCT00639626 |
| biphasic insulin aspart 50 | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01892020 |
| biphasic insulin aspart 30 | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT02582242 |
| Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate | OTHER | Preclinical | Obesity | TERMINATED | NCT00625040 |
| sunitinib | DRUG | Phase PHASE2 | Cancer | COMPLETED | NCT00617253 |
| insulin degludec/insulin aspart | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02844790 |
| insulin degludec | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 1 | COMPLETED | NCT04848480 |
| saline | DRUG | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00607737 |
| NPH insulin + regular insulin | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00590226 |
| Detemir + aspart insulin before meals | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT00590226 |
| Ultra-Fine needle 12.7 mm | DEVICE | Phase PHASE4 | Diabetes | COMPLETED | NCT00572052 |
| glicazide | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT00568984 |
| Glucobay® | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT00568074 |
| Glurenorm® | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT00568074 |
| Insulatard | DRUG | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00788840 |
| Insulin glargine | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 1 | RECRUITING | NCT07076199 |
| NPH | DRUG | Approved | Type 1 Diabetes | TERMINATED | NCT00564018 |
| Glargine | DRUG | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03336528 |
| Insulin detemir | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 1 | RECRUITING | NCT06685185 |
| estradiol, 25 mcg | DRUG | Preclinical | Menopause | COMPLETED | NCT01507454 |
| caelyx (pegylated liposomal doxorubicin) | DRUG | Phase PHASE2 | Cancer | COMPLETED | NCT00523380 |
| paroxetine | DRUG | Phase PHASE4 | Premenstrual Dysphoric Disorder | COMPLETED | NCT00516113 |
| human regular insulin | DRUG | Phase PHASE1 | Diabetes Mellitus | COMPLETED | NCT00513643 |
| Insulin Aspart | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | RECRUITING | NCT07068295 |
| Insulin Glargine | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03951805 |
| repaglinide | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01720303 |
| vatreptacog alfa (activated) | DRUG | Phase PHASE3 | Congenital Bleeding Disorder | COMPLETED | NCT01392547 |
| biphasic human insulin | DRUG | Preclinical | Diabetes | COMPLETED | NCT01492153 |
| GlucoNorm | DRUG | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00451620 |
| glyburide | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01698931 |
| Insulin Lispro versus Insulin Aspart | DRUG | Approved | Type 1 Diabetes Mellitus | TERMINATED | NCT00428207 |
| Insulin Aspart versus Insulin Lispro | DRUG | Approved | Type 1 Diabetes Mellitus | TERMINATED | NCT00428207 |
| orlistat | DRUG | Phase PHASE2 | Metabolism and Nutrition Disorder | COMPLETED | NCT00422058 |
| UNITED Planned Care | BEHAVIORAL | Approved | Diabetes Mellitus | COMPLETED | NCT00421850 |
| isophane human insulin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01865279 |
| soluble human insulin | DRUG | Preclinical | Diabetes | COMPLETED | NCT00715780 |
| NNC 55-0414 | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT00400283 |
| rosiglitazone and metformin combination tablet | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT00399711 |
| repaglinide and metformin combination tablet | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01490658 |
| sulfonylurea | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT00395746 |
| NIDCAP | BEHAVIORAL | Phase EARLY_PHASE1 | Infant Growth | COMPLETED | NCT00388141 |
| Metformin on top of intensive insulin therapy | DRUG | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00375388 |
| Norditropin SimpleXx | DRUG | Approved | Prader-Willi Syndrome | COMPLETED | NCT00372125 |
| human insulin /insulin isophane | DRUG | Phase PHASE4 | Type 1 Diabetes | COMPLETED | NCT00346996 |
| insulin levemir / aspart | DRUG | Phase PHASE4 | Type 1 Diabetes | COMPLETED | NCT00346996 |
| NovoFine® needle 4 mm | DEVICE | Phase PHASE2 | Diabetes | COMPLETED | NCT00343343 |
| NovoFine® needle 6 mm | DEVICE | Phase PHASE3 | Diabetes | COMPLETED | NCT00872560 |
| recombinant interleukin-21 | DRUG | Phase PHASE2 | Cancer | COMPLETED | NCT00617253 |
| inhaled human insulin | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT00725036 |
| rosiglitazone | DRUG | Phase PHASE3 | Diabetes | TERMINATED | NCT00427154 |
| exenatide | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT01885208 |
| glimepiride | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT01511692 |
| NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70 | DRUG | Approved | Type 1 Diabetes | COMPLETED | NCT00283218 |
| Insulin infusion with a goal | DRUG | Phase PHASE3 | Cardiac Surgical Procedures | COMPLETED | NCT00282698 |
| Novolin R (human recombinant Insulin) | DRUG | Approved | Sepsis | COMPLETED | NCT00282594 |
| Order Set, Education, Feedback | BEHAVIORAL | Approved | Diabetes Mellitus | COMPLETED | NCT00271700 |
| glibenclamide | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT00393718 |
| Growth hormone | DRUG | Preclinical | Growth Hormone Deficiency | COMPLETED | NCT03225755 |
| 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) | DRUG | Phase PHASE1 | Menopause | COMPLETED | NCT01477632 |
| 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) | DRUG | Phase PHASE1 | Menopause | COMPLETED | NCT01477632 |
| placebo | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT03021187 |
| Measles vaccine | BIOLOGICAL | Phase PHASE4 | Measles | COMPLETED | NCT00168571 |
| liraglutide | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT03292185 |
| estradiol | DRUG | Phase PHASE4 | Turner Syndrome | COMPLETED | NCT00134745 |
| vial and syringe | DEVICE | Phase PHASE1 | Diabetes | COMPLETED | NCT00127296 |
| FlexPen® | DEVICE | Phase PHASE1 | Diabetes | COMPLETED | NCT02627287 |
| autocover needle | DEVICE | Phase PHASE4 | Diabetes | COMPLETED | NCT01024218 |
| safety glide | DEVICE | Phase PHASE4 | Diabetes | COMPLETED | NCT00121355 |
| pump | DEVICE | Phase PHASE1 | Diabetes | COMPLETED | NCT00184613 |
| intensive insulin therapy to maintain normoglycemia | DRUG | Phase PHASE2 | Critical Illness | COMPLETED | NCT00115479 |
| estradiol, 10 mcg | DRUG | Phase PHASE1 | Menopause | COMPLETED | NCT01486979 |
| Feiba VH | DRUG | Preclinical | Congenital Bleeding Disorder | COMPLETED | NCT00710619 |
| activated recombinant human factor VII | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | WITHDRAWN | NCT02084810 |
| somatropin | DRUG | Phase PHASE3 | Adult Growth Hormone Deficiency | COMPLETED | NCT02382939 |
| eptacog alfa (activated) | DRUG | Phase PHASE1 | Congenital Bleeding Disorder | WITHDRAWN | NCT02084810 |
| dietary regimen | BEHAVIORAL | Phase PHASE4 | Diabetes | COMPLETED | NCT00101751 |
| metformin | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02249910 |
| pioglitazone | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT00598793 |
| biphasic insulin aspart | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT02762578 |
| insulin glargine | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04262661 |
| insulin detemir | DRUG | Phase PHASE1 | Diabetes | COMPLETED | NCT02162407 |
| insulin lispro | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT00097071 |
| insulin human | DRUG | Preclinical | Diabetes | TERMINATED | NCT02382757 |
| insulin aspart | DRUG | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT05013229 |
| insulin NPH | DRUG | Phase PHASE3 | Diabetes | COMPLETED | NCT01707134 |
| human insulin | DRUG | Phase PHASE4 | Diabetes | COMPLETED | NCT01467141 |
| catridecacog | DRUG | Phase PHASE1 | Acquired Bleeding Disorder | COMPLETED | NCT02239146 |